Inhaled mannitol for cystic fibrosis by Nevitt, Sarah J et al.
Cochrane Database of Systematic Reviews
Inhaled mannitol for cystic fibrosis (Review)
Nevitt SJ, Thornton J, Murray CS, Dwyer T
Nevitt SJ, Thornton J, Murray CS, Dwyer T.
Inhaledmannitol for cystic fibrosis.
Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD008649.
DOI: 10.1002/14651858.CD008649.pub3.
www.cochranelibrary.com
Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
32ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
43DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
47AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
47ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
48REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 1 HRQoL
- respiratory (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Analysis 1.2. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 2 HRQoL
- vitality (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
Analysis 1.3. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 3 HRQoL
- physical (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
Analysis 1.4. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 4 HRQoL
- emotion (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Analysis 1.5. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 5 HRQoL
- eating (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Analysis 1.6. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 6 HRQoL
- health (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Analysis 1.7. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 7 HRQoL
- social (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Analysis 1.8. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 8 HRQoL
- body (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Analysis 1.9. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 9 HRQoL
- role (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Analysis 1.10. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 10
HRQoL - weight (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . 85
Analysis 1.11. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 11
HRQoL - digestion (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . 86
Analysis 1.12. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 12
FEV1 ml (repeated measures, change from baseline). . . . . . . . . . . . . . . . . . . . . 87
Analysis 1.13. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 13
FEV1 % predicted (repeated measures, change from baseline). . . . . . . . . . . . . . . . . . 88
Analysis 1.14. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 14 FVC
mL (repeated measures, change from baseline). . . . . . . . . . . . . . . . . . . . . . . 89
Analysis 1.15. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 15
FEF25-75 mL/s (repeated measures, change from baseline). . . . . . . . . . . . . . . . . . . 90
Analysis 1.16. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 16
Adverse events at up to 6 months(mild). . . . . . . . . . . . . . . . . . . . . . . . . . 91
Analysis 1.17. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 17
Adverse events at up to 6 months (moderate). . . . . . . . . . . . . . . . . . . . . . . . 95
iInhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.18. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 18
Adverse events at up to 6 months (severe). . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 1.19. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 19
Adverse events at up to 6 months (total). . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 1.20. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 20
Participants with treatment-related respiratory and thoracic adverse events leading to study discontinuation. . 107
Analysis 1.21. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 21
Number of patients with protocol defined pulmonary exacerbations. . . . . . . . . . . . . . . . 109
Analysis 1.22. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 22 Time
to first protocol defined pulmonary exacerbation (PDPE). . . . . . . . . . . . . . . . . . . 110
Analysis 1.23. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 23
Number of patients needing additional antibiotics. . . . . . . . . . . . . . . . . . . . . . 110
Analysis 1.24. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 24
Number of participants requiring hospitalisation. . . . . . . . . . . . . . . . . . . . . . 111
Analysis 1.25. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 25
Duration of hospitalisation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Analysis 1.26. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 26
Sputum weight (g). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Analysis 1.27. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 27
Sputum weight (g) (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . 113
Analysis 1.28. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 28
Microbiology: pathogens present at end of study. . . . . . . . . . . . . . . . . . . . . . . 114
Analysis 1.29. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 29
Burden of treatment (change from baseline). . . . . . . . . . . . . . . . . . . . . . . . 116
Analysis 1.30. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis, Outcome 30
Adherence ≥ 60%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 2.1. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 1
FEV1 % predicted (absolute change from baseline). . . . . . . . . . . . . . . . . . . . . . 117
Analysis 2.2. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 2
FEV1 % predicted (absolute change from baseline - subgroup analysis by age). . . . . . . . . . . . 118
Analysis 2.3. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 3
FEV1 % predicted (absolute change from baseline - subgroup analysis by dornase alfa use. . . . . . . . 119
Analysis 2.4. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 4
FEV1 % predicted (relative change from baseline). . . . . . . . . . . . . . . . . . . . . . 120
Analysis 2.5. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 5 FVC
% predicted (absolute change from baseline). . . . . . . . . . . . . . . . . . . . . . . . 120
Analysis 2.6. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 6 FVC
% predicted (relative change from baseline). . . . . . . . . . . . . . . . . . . . . . . . 121
Analysis 2.7. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 7
FEF25-75 % predicted (absolute change from baseline). . . . . . . . . . . . . . . . . . . . 121
Analysis 2.8. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 8
FEF25-75 % predicted (relative change from baseline). . . . . . . . . . . . . . . . . . . . 122
Analysis 2.9. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis, Outcome 9
Sputum weight (grams) (post-initial treatment). . . . . . . . . . . . . . . . . . . . . . . 122
Analysis 3.1. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to
pulmonary exacerbations, Outcome 1 HRQoL - change from baseline in CFCS total score. . . . . . . . 123
Analysis 3.2. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to
pulmonary exacerbations, Outcome 2 HRQoL - change from baseline in CFQ-R respiratory domain. . . . 124
Analysis 3.3. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to
pulmonary exacerbations, Outcome 3 FEV1 % predicted (change from baseline). . . . . . . . . . . 125
Analysis 3.4. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to
pulmonary exacerbations, Outcome 4 FVC % predicted (change from baseline). . . . . . . . . . . . 126
iiInhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.5. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to
pulmonary exacerbations, Outcome 5 FEF25-75 % predicted (change from baseline). . . . . . . . . . 127
Analysis 4.1. Comparison 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis, Outcome 1
FEV1 (% change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Analysis 4.2. Comparison 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis, Outcome 2
FVC (% change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Analysis 4.3. Comparison 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis, Outcome 3
FEF25-75 (% change from baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Analysis 5.1. Comparison 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals with cystic
fibrosis, Outcome 1 FEV1 (% change from baseline). . . . . . . . . . . . . . . . . . . . . 129
Analysis 5.2. Comparison 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals with cystic
fibrosis, Outcome 2 FVC (% change from baseline). . . . . . . . . . . . . . . . . . . . . 130
Analysis 5.3. Comparison 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals with cystic
fibrosis, Outcome 3 FEF25-75 (% change from baseline). . . . . . . . . . . . . . . . . . . 130
130ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
142APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
143WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
143CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
144DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
144SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
145DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
145NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
145INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiiInhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Inhaled mannitol for cystic fibrosis
Sarah J Nevitt1, Judith Thornton2 , Clare S Murray3, Tiffany Dwyer4,5
1Department of Biostatistics, University of Liverpool, Liverpool, UK. 2Centre for Clinical Practice, National Institute for Health and
Care Excellence, Manchester, UK. 3Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of
Manchester and University Hospital of South Manchester, Manchester, UK. 4Discipline of Physiotherapy, Faculty of Health Sciences,
University of Sydney, Sydney, Australia. 5Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia
Contact address: Sarah J Nevitt, Department of Biostatistics, University of Liverpool, Block F, Waterhouse Building, 1-5 Brownlow
Hill, Liverpool, L69 3GL, UK. sjn16@liverpool.ac.uk.
Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 2, 2018.
Citation: Nevitt SJ, Thornton J, Murray CS, Dwyer T. Inhaled mannitol for cystic fibrosis. Cochrane Database of Systematic Reviews
2018, Issue 2. Art. No.: CD008649. DOI: 10.1002/14651858.CD008649.pub3.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Several agents are used to clear secretions from the airways of people with cystic fibrosis. Mannitol increases mucociliary clearance, but its
exact mechanism of action is unknown. The dry powder formulation of mannitol may be more convenient and easier to use compared
with established agents which require delivery via a nebuliser. Phase III trials of inhaled dry powder mannitol for the treatment of cystic
fibrosis have been completed and it is now available in Australia and some countries in Europe. This is an update of a previous review.
Objectives
To assess whether inhaled dry powder mannitol is well tolerated, whether it improves the quality of life and respiratory function in
people with cystic fibrosis and which adverse events are associated with the treatment.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from
comprehensive electronic databases, handsearching relevant journals and abstracts from conferences.
Date of last search: 28 September 2017.
Selection criteria
All randomised controlled studies comparing mannitol with placebo, active inhaled comparators (for example, hypertonic saline or
dornase alfa) or with no treatment.
Data collection and analysis
Authors independently assessed studies for inclusion, carried out data extraction and assessed the risk of bias in included studies. The
quality of the evidence was assessed using GRADE.
Main results
Six studies (reported in 50 publications) were included with a total of 784 participants.
Duration of treatment in the included studies ranged from 12 days to six months, with open-label treatment for an additional six
months in two of the studies. Five studies compared mannitol with control (a very low dose of mannitol or non-respirable mannitol)
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and the final study compared mannitol to dornase alfa alone and to mannitol plus dornase alfa. Two large studies had a similar parallel
design and provided data for 600 participants, which could be pooled where data for a particular outcome and time point were available.
The remaining studies had much smaller sample sizes (ranging from 22 to 95) and data could not be pooled due to differences in
design, interventions and population.
Pooled evidence from the two large parallel studies was judged to be of low to moderate quality and from the smaller studies was judged
to be of low to very low quality. In all studies, there was an initial test to see if participants tolerated mannitol, with only those who
could tolerate the drug being randomised; therefore, the study results are not applicable to the cystic fibrosis population as a whole.
While the published papers did not provide all the data required for our analysis, additional unpublished data were provided by the
drug’s manufacturer and the author of one of the studies.
Pooling the large parallel studies comparing mannitol to control, up to and including six months, lung function (forced expiratory
volume at one second) measured in both mL and% predicted was significantly improved in themannitol group compared to the control
group (moderate-quality evidence). Beneficial results were observed in these studies in adults and in both concomitant dornase alfa
users and non-users in these studies. In the smaller studies, statistically significant improvements in lung function were also observed
in the mannitol groups compared to the non-respirable mannitol groups; however, we judged this evidence to be of low to very low
quality.
For the comparisons of mannitol and control, we found no consistent differences in health-related quality of life in any of the domains
except for burden of treatment, which was less for mannitol up to four months in the two pooled studies of a similar design; this
difference was not maintained at six months. It should be noted that the tool used to measure health-related quality of life was not
designed to assess mucolytics and pooling of the age-appropriate tools (as done in some of the included studies) may not be valid
so results were judged to be low to very low quality and should be interpreted with caution. Cough, haemoptysis, bronchospasm,
pharyngolaryngeal pain and post-tussive vomiting were the most commonly reported side effects in both treatment groups. Where rates
of adverse events could be compared, statistically no significant differences were found between mannitol and control groups; although
some of these events may have clinical relevance for people with CF.
For the comparisons of mannitol to dornase alfa alone and to mannitol plus dornase alfa, very low-quality evidence from a 12-week
cross-over study of 28 participants showed no statistically significant differences in the recorded domains of health-related quality of
life or measures of lung function. Cough was the most common side effect in the mannitol alone arm but there was no occurrence of
cough in the dornase alfa alone arm and the most commonly reported reason of withdrawal from the mannitol plus dornase alfa arm
was pulmonary exacerbations.
In terms of secondary outcomes of the review (pulmonary exacerbations, hospitalisations, symptoms, sputum microbiology), evidence
provided by the included studies was more limited. For all comparisons, no consistent statistically significant and clinically meaningful
differences were observed between mannitol and control treatments (including dornase alfa).
Authors’ conclusions
There is moderate-quality evidence to show that treatment with mannitol over a six-month period is associated with an improvement in
some measures of lung function in people with cystic fibrosis compared to control. There is low to very low-quality evidence suggesting
no difference in quality of life for participants taking mannitol compared to control. This review provides very low-quality evidence
suggesting no difference in lung function or quality of life comparing mannitol to dornase alfa alone and to mannitol plus dornase alfa.
The clinical implications from this review suggest that mannitol could be considered as a treatment in cystic fibrosis; but further research
is required in order to establish who may benefit most and whether this benefit is sustained in the longer term. Furthermore, studies
comparing its efficacy against other (established) mucolytic therapies need to be undertaken before it can be considered for mainstream
practice.
P L A I N L A N G U A G E S U M M A R Y
Mannitol, an inhaled drug, for treating lung disease in cystic fibrosis
Review question
We reviewed the evidence about the effect of inhaling mannitol to treat lung disease in people with cystic fibrosis.
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Background
Cystic fibrosis is a genetic disorder that affects the exocrine glands (sweat glands and others). Lung infections produce thick mucus
(phlegm) which can block air passages and cause more infection and repeated inflammation. In turn, this progressively damages the
lungs and can eventually cause respiratory failure. There are several drugs that are used to clear mucus from the airways of people with
cystic fibrosis and inhaled dry powder mannitol is a new one that may improve their lung function. The dry powder formulation of
mannitol may be more convenient and easier to use compared with established agents delivered by a nebuliser (e.g. hypertonic saline).
Mannitol is available in Australia and some European countries. This is an updated version of the review.
Search date
The evidence is current to: 28 September 2017.
Study characteristics
We included six studies (with a total of 784 adults and children) in this review. Five studies compared a standard dose of mannitol
with control (a very low dose of mannitol or a version of mannitol which did not allow the active drug to reach the lungs) and the
sixth study compared mannitol with nebulised recombinant human deoxyribonuclease (dornase alfa), both alone and taken together.
Participants could continue using dornase alfa and other standard therapies, but were excluded from the five of the six studies if they
were using hypertonic saline. Treatment in these studies lasted from 12 days to six months. Five studies provided the treatments to
people as outpatients and in one study, the children treated were in hospital due to pulmonary exacerbations (flare ups of disease).
Key results
It was difficult to combine evidence from the studies in this review due to differences in the designs of the studies, treatments examined
and the settings (hospital or outpatients). Some additional information was obtained from the drug manufacturer and one study author
to aid the review.
The review found low- to very low-quality evidence that there is no difference between mannitol and control treatments or mannitol
given either with or without additional dornase alfa in terms of quality of life. There was moderate-quality evidence of improvements
in some measures of lung function across the larger studies comparing mannitol to control. Beneficial effects were also seen in the
subgroup of adults and in both those who were using dornase alfa and those who were not. Cough (including coughing up blood),
contraction of the airways, pain in the pharynx or larynx and post-treatment vomiting were the most commonly reported side effects
on both treatments, but there was no evidence to suggest that these side effects occurred more on mannitol than on control treatments
or on dornase alfa.
None of the studies compared mannitol to nebulised hypertonic saline and so we can not comment on which agent is better for airway
clearance. More research is needed to answer this question.
Quality of the evidence
We judged the quality of the evidence from this review to be of very low to moderate quality, depending on the outcome measured.
We do not think that the way the studies were designed affected the results. We judged that everyone taking part had equal chances of
being in either of the treatment groups and would not have known in advance or during the study which treatment they were receiving.
However, the numbers of people who dropped out of the studies might affect how the results are interpreted, as well as how many
people were recruited into the studies and how they were selected from all people with cystic fibrosis who could have been included.
Although some of these issues were resolved when the drug’s manufacturer (who also sponsored the studies) provided some additional
information. It is important to realise that before people started the study, they took a test to see if they could tolerate mannitol and
only those who did could carry on. This means that the results of the studies only apply to those people with cystic fibrosis who can
tolerate mannitol.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
400 mg inhaled mannitol compared with 50 mg inhaled mannitol for CF
Patient or population: adults, children and young people with CF
Settings: outpat ients
Intervention: 400 mg inhaled mannitol
Comparison: 50 mg (sub-therapeut ic) inhaled mannitol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
50 mg inhaledmannitol 400 mg inhaled manni-
tol
HRQoL - all domains
(change from baseline)
Scale: age-appropriate
versions of the CFQ-R
quest ionnaire
Follow-up: up to 6
months
There were no consistent stat ist ically signif i-
cant dif f erences between treatment groups in
changes f rom baseline for any domains of the
CFQ-R at any of the t ime points for which data
were available
NA 324 - 507 part icipants
(variable by domains)
2 studies
⊕⊕©©
low1,2
Lung function: FEV1mL
(change from baseline)
Follow-up: up to 6
months, repeated mea-
sures
The mean change f rom
baseline in FEV1 mL
ranged across the 50
mg mannitol groups
f rom 26.0 to 32.5
The mean change f rom
baseline in FEV1 mL in
the 400 mg mannitol
groups was on average
86.5 higher (95% CI 45.
2 to 127.9 higher)
NA 600 part icipants
2 studies
⊕⊕⊕©
moderate1
Data provided by
mannitol manufacturer
Pharmaxis were anal-
ysed via a MMRM anal-
ysis
Lung function: FEV1
% predicted (change
from baseline)
Follow-up: up to 6
months, repeated mea-
sures
The mean change f rom
baseline in FEV1 % pre-
dicted ranged across
the 50 mg mannitol
groups f rom 0.62 to 1.
63
The mean change f rom
baseline in FEV1 % pre-
dicted in the 400 mg
mannitol groups was
on average 3.89 higher
(95% CI 1.69 to 6.08
NA 600 part icipants
2 studies
⊕⊕⊕©
moderate1
Data provided by
mannitol manufacturer
Pharmaxis were anal-
ysed via a MMRM anal-
ysis
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higher)
Lung function: FVC mL
(change from baseline)
Follow-up: up to 6
months, repeated mea-
sures
The mean change f rom
baseline in FVC mL
ranged across the 50
mg mannitol groups
f rom 15.9 to 47.5
The mean change f rom
baseline in FVC mL in
the 400 mg mannitol
groups was on average
102.2 higher (95% CI
48.4 to 155.9 higher)
NA 600 part icipants
2 studies
⊕⊕⊕©
moderate1
Data provided by
mannitol manufacturer
Pharmaxis were anal-
ysed via a MMRM anal-
ysis
Lung function:
FEF25−75 mL/s (change
from baseline)
Follow-up: up to 6
months, repeated mea-
sures
The mean change f rom
baseline in FEF25−75
mL/ s ranged across the
50 mg mannitol groups
f rom 10.87 to 46.7
The mean change f rom
baseline in FEF25−75
mL/ s in the 400 mg
mannitol groups was on
average 42.67 higher
(95% CI -28.07 lower to
113.42 higher)
NA 600 part icipants
2 studies
⊕⊕⊕©
moderate1
Data provided by
mannitol manufacturer
Pharmaxis were anal-
ysed via a MMRM anal-
ysis
Adverse events relat-
ing to treatment
Scale: m ild, moderate,
severe and total
Follow-up: up to 6
months
The most commonly
adverse events re-
ported were cough and
haemoptysis (in 5%and
2% of part icipants re-
spect ively)
The most commonly
adverse events re-
ported were cough and
haemoptysis (in 10%
and 5% of part icipants
respect ively)
See comment 600 part icipants
2 studies
⊕⊕⊕©
moderate1
We found no stat ist i-
cally signif icant dif f er-
ences in rates of ad-
verse events related to
treatment (of all sever-
it ies) between treat-
ment groups
* For lung funct ion outcomes, the basis for the assumed risk is the range of mean values in the control group and the corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
For Health related Quality of Life and Adverse events, the basis of the assumed risk and the corresponding risk is described in the comments
CF: cyst ic f ibrosis;CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised version, CI: conf idence interval; FEF25−75: m id-expiratory f low; FEV1: f orced expiratory volume at one second;
FVC: f orced vital capacity; HRQoL: health-related quality of lif e; MMRM : m ixed model repeated measures; NA: not applicable.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
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1. Evidence downgraded due to indirectness: the part icipant populat ion included only those with CF who passed the tolerance
test and not all potent ial part icipants with CF.
2. Evidence downgraded due to indirectness: the CFQ-R tool used in the studies was not designed to assess mucolyt ics. Also,
pooling of the age-appropriate tools may not be valid so results should be interpreted with caut ion.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most prevalent inherited, life-limiting
disorder in populations ofNorthernEuropeanorigin. The disorder
is caused by a gene defect on the long arm of chromosome 7
which encodes for a conductance-regulating protein called the
cystic fibrosis transmembrane conductance regulator (CFTR) (
Dinwiddie 2000). It is a relatively common autosomal recessive
disease occurring in approximately 1 in 2500 live births (Ratjen
2003) and in the USA and the UK, approximately 1 in 25 people
of Northern European origin are carriers of a CFTR abnormality
(CFF 2000;Hodson 2000). It is estimated that the present number
of CF cases is 35,000 in Europe, 30,000 in North America and
3000 in Canada (CCFF 2002; CFF 2005).
Although CFTR is primarily a chloride ion channel, it is also in-
volved in the regulationof othermembrane channels and transport
of molecules which may be important in mucociliary clearance
and innate defence mechanisms (McAuley 2000). The interaction
of CFTR with the epithelial sodium channel is also important
and it is up-regulated in CF. Thus, defective CFTR in CF causes
reduced chloride secretion and excess absorption of sodium across
the epithelia, leading to thickened secretions in organs such as the
pancreas and lung (McAuley 2000). These viscous secretions lead
to airway obstruction, infection and chronic inflammation in a
vicious cycle resulting in progressive lung damage with bronchiec-
tasis and eventual respiratory failure (Dinwiddie 2000). Although
with advances in treatment, life expectancy has increased dramat-
ically over the past six decades from a median of two years to a
projected median survival of over 50 years of age (Dodge 2007),
lung disease remains the most common cause of death in people
with CF (Accurso 2007).
Several agents are used to clear secretions from the airways of peo-
ple with CF. These agents include inhaled n-acetylcysteine, hy-
pertonic saline and recombinant human deoxyribonuclease (dor-
nase alfa) (Bye 2007; Tam 2013). A Cochrane Review demon-
strated that dornase alfa reduces pulmonary exacerbations and im-
proves lung function (Yang 2016). A second Cochrane Review
showed that although regular treatment with hypertonic saline led
to only modest improvements in lung function in adults and chil-
dren, there were substantial reductions in pulmonary exacerba-
tions (Wark 2009). Although n-acetylcysteine was used as a mu-
colytic drug in CF for many years, a Cochrane Review found little
evidence for any beneficial effect (Tam 2013). These three treat-
ments have to be given using a nebuliser, which can be time-con-
suming, inconvenient and unpopular. Sawicki noted that the level
of daily treatment activity is high for adults with CF regardless of
age or disease severity and that increasing numbers of nebulised
therapies are associated with higher perceived treatment burden
(Sawicki 2009). The authors emphasised the importance of evalu-
ating treatment burden as an outcome in the development of new
CF treatments as many of these are designed to be added to exist-
ing treatment regimens. In addition, dornase alfa is expensive; in
a study in children, treatment with daily dornase alfa significantly
increased lung function compared with hypertonic saline but sig-
nificantly increased healthcare costs (Suri 2002). In the Cochrane
Review it was noted in a cost analysis of a second study in adults
and children, that healthcare costs relating to respiratory tract in-
fections were less in the treated participants, but this cost saving
did not offset the cost of therapy itself (Yang 2016). Inhaled dry
powder mannitol is now being investigated as an alternative treat-
ment for airway clearance.
Description of the intervention
Mannitol is a dry powder contained in 40 mg capsules for inhala-
tion. It is inhaled orally via a breath-activated hand-held inhala-
tion device. Clinical studies have used varying doses of mannitol
(315 mg to 635 mg), but generally around a dose of 400 mg (10
capsules) twice daily has been administered. Since mannitol is in-
haled as a dry powder, it does not require a nebuliser. However,
it is not as quick to use as many other dry powder medications
because the dose is divided into multiple capsules which must be
loaded and inhaled individually.
How the intervention might work
Mannitol is a naturally occurring six-carbon monosaccharide
(sugar alcohol) which is not actively transported and is poorly ab-
sorbed after inhalation (Anderson 1997). It appears to act by in-
ducing an influx of water into the airway lumen and evidence from
in vitro and animal studies suggests a number of mechanisms by
which it may increase mucociliary clearance, including improv-
ing hydration of airway secretions and reducing sputum viscos-
ity (Bye 2007). However, Daviskas examined ex vivo sputum and
was only able to demonstrate an improvement in hydration with
no substantial change in viscoelasticity (Daviskas 2010). Another
suggested mechanism of action is stimulating release of media-
tors that increase ciliary beat frequency (Brannan 2003; Wanner
1983). Regardless of the exact mechanism by which it is achieved,
mannitol appears to increase mucociliary clearance in people with
CF (Robinson 1999).
Why it is important to do this review
Inhaled dry powder mannitol is available for the treatment of
CF and is licensed for use in adults in the European Union and
for adults and children over the age of six years in Australia. A
Cochrane Review of inhaled hyperosmolar agents in people with
bronchiectasis identified two randomised controlled trials (RCTs)
and demonstrated that inhaled mannitol improved airway clear-
ance (Wills 2006); these findings were supported by additional
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observational studies (Daviskas 1997; Daviskas 2001; Daviskas
2002; Daviskas 2005). A number of studies looking at mannitol
in CF have now been completed. In addition, the dry powder
formulation of mannitol may be more convenient and easier to
use compared with established agents which require delivery via a
nebuliser; anecdotal reports suggest that once individuals become
familiar with the technique, administration time for inhaled man-
nitol compares well with the time taken to administer nebulised
dornase alfa. Thus, the evidence in CF should be combined and
presented in a systematic review. The UK National Institute for
Health and Care Excellence (NICE) has made a recommendation
for the the use of mannitol in certain individuals with CF; par-
ticularly those with rapid decline in lung function and those for
which dornase alfa and other osmotic agents have failed or are not
considered appropriate (NICE 2012).
This is an update of a previously published review (Nolan 2015).
O B J E C T I V E S
To assess whether inhaled dry powder mannitol is well tolerated,
whether it improves the quality of life and respiratory function in
people with CF and which adverse events are associated with the
treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of parallel or cross-over de-
sign, blinded or open-label.
Types of participants
Adults (18 years old and over) and children (under 18 years old)
with CF (diagnosed clinically and by sweat or genetic testing and
including all degrees of disease severity).
Types of interventions
We compared orally inhaled dry powder mannitol (either alone
or with another agent) with either control, active inhaled com-
parators (for example, hypertonic saline or dornase alfa) or with
no treatment. We included all doses and regimens of mannitol
administration. We also included studies of all durations of treat-
ment and follow-up.
Types of outcome measures
Primary outcomes
1. Health-related quality of life (HRQoL) as measured by a
validated tool such as the Cystic Fibrosis Questionnaire-Revised
version (CFQ-R (Quittner 2009)) or Cystic Fibrosis Quality of
Life Questionnaire (CFQoL (Gee 2000))
2. Lung function
i) forced expiratory volume in one second (FEV1) (mL
or % predicted)
ii) forced vital capacity (FVC) (mL or % predicted)
iii) forced expiratory flow between 25% and 75% expired
volume (FEF25−75) (mL/s or % predicted)
3. Adverse events relating to treatment
i) type and number of adverse events defined as follows
according to perceived effect on the participant
a) mild (not requiring extra treatment, noted but
tolerable)
b) moderate (requiring extra treatment and
cessation of the intervention)
c) severe (life-threatening or results in death,
requiring hospitalisation, results in persistent or significant
disability)
ii) number of participants who ceased inhalations
because of poor tolerability e.g. cough or bronchoconstriction
Secondary outcomes
1. Pulmonary exacerbations
i) number of participants free of pulmonary
exacerbations
ii) time to first pulmonary exacerbation
2. Time off school or work
3. Need for additional non-routine antibiotics
i) intravenous
ii) oral
iii) nebulised
4. Hospitalisations
i) number of hospitalisations
ii) duration
5. Assessment of symptoms (including cough, sputum
volume, ease of expectoration and dyspnoea)
6. Sputum microbiology (change in numbers of pathogens,
emergence of new pathogens)
7. Burden of treatment (using a validated measure)
Search methods for identification of studies
There were no restrictions regarding language or publication sta-
tus.
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Electronic searches
We identified relevant studies from the Group’s Cystic Fibrosis
Trials Register using the terms: mannitol [bronchitol].
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cochrane Cystic
Fibrosis and Genetic Disorders Group website.
Date of last search: 28 September 2017.
We searched the trials database clinicaltrials.gov (https://
clinicaltrials.gov/) using the terms: “mannitol” AND “cystic fibro-
sis”
We also searched the WHO ICTRP (http://apps.who.int/
trialsearch/) using the terms: [“mannitol” OR “bronchitol”] AND
“cystic fibrosis”.
Date of most recent search of trial databases: 03 November 2017.
Searching other resources
We checked the reference lists of any studies identified for further
relevant studies. We also contacted primary authors of identified
studies and research institutions or biotech companies for unpub-
lished studies.
Data collection and analysis
Selection of studies
All authors independently reviewed all potential studies for inclu-
sion and examined the title and abstract of potential publications
to remove those that did not meet inclusion criteria (e.g. single
case reports, reviews, etc.). We examined the full-text publications
of the remaining studies to determine if they met the eligibility
criteria. If we were unable to reach agreement regarding the de-
termination of eligibility by discussion, we resolved this by ap-
proaching a colleague to act as arbiter. We examined publications
which were potentially eligible for inclusion to identify instances
of duplication by comparing author, institution, study detail (in-
tervention, dosing, timing, etc.) and participant demographics.
Data extraction and management
Three authors (JT, CM and TD) independently extracted study
characteristics and outcome data from the studies onto a standard
data extraction form. If there was disagreement, we resolved this by
discussion. The fourth author (SJN) checked data and extracted
additional data from the files which were provided by the manu-
facturers of mannitol.
We originally planned to report data at one month, three months
and one year; however, in a post hoc change which grouped data
into more clinically appropriate time points, we reported data at
the time points of ’up to and including one month’, ’up to and
including two months’, ’up to and including three months’, ’up to
and including fourmonths’, ’up to and including fivemonths’, ’up
to and including six months’, and then at six-monthly intervals
thereafter. If any studies had followed participants beyond this
time, we also planned to report these data.
Weplanned the following comparisons (in all casesmannitol either
alone or in combination with another agent): mannitol versus no
treatment; mannitol versus control; mannitol versus n-acetylcys-
teine; mannitol versus hypertonic saline; and mannitol versus dor-
nase alfa. We were only able to present results for the randomised
comparisons; the comparisons made within this review are listed
in Effects of interventions.
Assessment of risk of bias in included studies
We assessed the risk of bias using the ’Risk of bias’ assessment
tool as documented in section 8.5 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).We defined low
and high risk of bias as in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Sequence generation
We determined if the allocation sequence was adequately gener-
ated. An adequate generation of the allocation sequence consti-
tutes a low risk of bias, inadequate generation constitutes a high
risk of bias and if it is unclear how the sequence was generated,
this constitutes an unclear risk of bias.
Allocation concealment
We determined if the allocation sequence was adequately con-
cealed. An adequate concealment of the allocation sequence con-
stitutes a low risk of bias, inadequate concealment constitutes a
high risk of bias and if it is unclear how allocation was concealed,
this constitutes an unclear risk of bias.
Blinding (or masking) of participants, personnel and
outcome assessors
We assessed whether knowledge of the allocated intervention was
adequately prevented during the study. If knowledge of allocation
was adequately prevented, this constitutes a low risk of bias; if
knowledge of allocation was not adequately prevented, this con-
stitutes a high risk of bias; and if it is unclear whether knowledge
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of allocation was adequately concealed, this constitutes an unclear
risk of bias.
Incomplete outcome data
We assessed whether incomplete outcome data were adequately
addressed. For example, if missing data from a large proportion of
the total number of participants resulted from participants drop-
ping out of only one arm of the study (e.g. the mannitol arm), this
would constitute a high risk of bias. However, if there are small
numbers of participants with missing data spread evenly across
the study arms, then this would constitute a low risk of bias. If
it is unclear how investigators addressed the issue of incomplete
outcome data, this constitutes an unclear risk of bias.
Selective outcome reporting
We assessed whether the reports of the studies are free of sugges-
tions of selective outcome reporting. If a study appears to be free
of selective outcome reporting, this constitutes a low risk of bias;
evidence of selective outcome reporting constitutes a high risk of
bias; and if it is unclear whether there is selective outcome report-
ing, this constitutes an unclear risk of bias.
Other potential sources of bias
We assessedwhether the studies were apparently free of other prob-
lems that could put them at a high risk of bias. For example, we
planned to report on whether the investigators performed a sam-
ple size calculation, for which outcome(s) and the method used.
Measures of treatment effect
For binary (dichotomous) outcome measures (numbers of: par-
ticipants who ceased inhalations because of poor tolerability; par-
ticipants free of pulmonary exacerbations; participants requiring
additional antibiotics; and hospitalisations), we aimed to calcu-
late a pooled estimate of treatment effect for each outcome across
studies using the risk ratio (RR) where appropriate and the corre-
sponding 95% confidence intervals (CIs). In a post hoc change to
account for type I statistical errors when analysing the number of
participants with any adverse events of interest, the authors used
RRs and 99% CIs.
For continuous outcome measures (HRQoL, lung function, time
off school or work, duration of hospitalisations, assessment of
symptoms, sputum microbiology, burden of treatment), we calcu-
lated a pooled estimate of treatment effect by calculating the mean
difference (MD) and the corresponding 95% CIs. Where studies
reported standard errors (SE), we converted these to standard de-
viations (SD).
The manufacturer of mannitol, Pharmaxis, provided the us with
additional data for all included studies. In two of the included
studies, investigators analysed outcomes of lung function data via
a mixed model repeated measures analysis (MMRM) based on
the average effect across the measured time points (Aitken 2012;
Bilton 2011). Such an analysis is longitudinal and uses all available
data at every visit. The data presented within this review are the
estimates from theMMRMmodel for the effect at each time point
derived from the treatment by visit term in the model (so data
presented as ’up to six months’ are the estimates from themodel at
the six-month time point); it also allows for covariate adjustment
(age, gender, disease severity, previous dornase alfa use, country or
region, etc.). The models in the Aitken and Bilton studies were
nearly identical in terms of covariates; the only difference was that
the Bilton study also included treatment by visit and treatment
by dornase alfa use interaction terms (Aitken 2012; Bilton 2011).
We felt it was most informative and appropriate to pool the MDs
and SEs from the adjusted mixed models from the two studies via
generic inverse variance (Aitken 2012; Bilton 2011).
Currently, we have not needed to analyse any count data, but we
may undertake such an analysis in future updates. When analysing
count data, we plan to decide whether to treat this as dichotomous,
continuous, time-to-an-event or as a rate when we access the data.
Although we accept that it is preferable to decide how count data
will be analysed in advance, we believe that the choice will be
determined by the format of the available data and thus we are not
be able to decide which method to use until the relevant data have
been reviewed. We plan to analyse such data as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011).
We analysed time-to-event data (time to first pulmonary exacer-
bation) using the hazard ratio (HR) and 95% CIs.
Where studies measured data longitudinally (other than for the
Pharmaxis MMRM analysis described above), we based the anal-
ysis on the final time-point results, which is a common method
used in Cochrane Reviews (Jones 2005). We accept that this anal-
ysis treats the data as independent, although in reality they are
not. However, methods are not yet available to carry out a meta-
analysis of aggregate longitudinal data, unless we are able to obtain
individual patient data.
Unit of analysis issues
When conducting a meta-analysis combining results from cross-
over studies, we planned to use the methods recommended by El-
bourne, which take account of the correlation between measure-
ments taken from the same group of participants via paired analy-
ses (Elbourne 2002). However, if only limited data were available,
we would only be able to either use the first-period data only or to
treat the cross-over studies as if they are parallel studies. Elbourne
states that this approach will produce conservative results as it does
not take into account within-patient correlation (Elbourne 2002).
Also each participant will appear in both the treatment and con-
trol group, so the two groups will not be independent.
One cross-over study adjusted for the cross-over design via mixed
effects analysis of variance, but the paper did not present the results
in a way that allowed paired analyses in this review (Jaques 2008).
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Therefore, we have presented adjusted results from the paper nar-
ratively or in additional tables. For the remaining two cross-over
studies, continuous data (e.g. lung function and sputum weight)
were presented from adjusted paired analyses, therefore we have
used a generic inverse variance method to analyse continuous out-
comes where possible, but present the remaining data from this
study in narrative form (de Boeck 2017; Minasian 2010).
We did not plan to combine data from parallel studies with data
from cross-over studies and have analysed these separately.
Dealing with missing data
In the event of missing, incomplete, or unclear data, we contacted
the original investigators and themanufacturer of mannitol (Phar-
maxis). If we could not obtain the necessary data for analysis, we
reported the outcomes in a narrative way.
Assessment of heterogeneity
For the pooled analyses, we assessed the degree of statistical hetero-
geneity between studies using the I² statistic (Higgins 2003). This
measure describes the percentage of total variation across studies
that are caused by heterogeneity rather than by chance (Higgins
2003). The values of I² lie between 0%and 100%, and a simplified
categorisation of heterogeneity that the we used is of low (I² value
of less than 25%), moderate (I² value of between 25 and 50%),
and high (I² value of over 50%) (Higgins 2003).
We assessed clinical heterogeneity between studies by comparing
study characteristics and participant demographics and planned to
assess any differences found between studies via subgroup analyses.
Assessment of reporting biases
Themanufacturer of mannitol, Pharmaxis, sponsored all the stud-
ies included in the review. We did not assess publication bias
among the studies as there were insufficient studies (i.e. fewer
than 10). In future updates, we may do this using the funnel plot
method discussed in theCochraneHandbook for Systematic Reviews
of Interventions (Sterne 2011). If asymmetry is present, we will ex-
plore possible causes including publication bias, methodological
quality, and true heterogeneity.
Data synthesis
We entered the data extracted from included studies into the Re-
view Manager software (Review Manager 2014).
We computed pooled estimates of the treatment effect for each
outcome using a fixed-effect model. We planned to use a ran-
dom-effects model to analyse outcomes with high heterogeneity
(I² value of over 50%) in the data. We used the inverse variance
method to pool continuous data and theMantel-Haenszel method
to pool dichotomous data, unless stated above that we would use
the generic inverse variance method (see Measures of treatment
effect and Unit of analysis issues).
Subgroup analysis and investigation of heterogeneity
For the comparison of mannitol versus control (where possible),
we performed the following subgroup analyses for all primary out-
comes (and for the secondary outcome of pulmonary exacerba-
tions) in order to investigate potential differences in treatment ef-
fect across the subgroups:
• age: children (under 18 years) and adult (18 years and over);
• dornase alfa: participants using or not using dornase alfa;
In future updates of this review where there are sufficient studies
included, we plan to investigate the possible causes of heterogene-
ity further by performing the additional subgroup analyses:
• sex;
• disease severity: FEV1 % predicted over 90%, 70% and over
but less than 90%, 40% and over but less than 70%, up to 40%;
• infection with Pseudomonas aeruginosa.
Sensitivity analysis
There were insufficient data to test the robustness of the review
results through a sensitivity analysis on the basis of the risk of bias
of the included studies, e.g. unpublished studies, allocation con-
cealment, assessor blinding, and loss to follow-up on the results.
In future updates of the review, we may do this if we are able to
include sufficient studies.
Summary of findings and the quality of the evidence
(GRADE)
In a post hoc change, we have presented five summary of findings
tables, one for each comparison (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4; Summary of findings 5).
Primary outcomes at the latest-reported time point are presented
in the summary of findings tables (HRQoL, lung function (FEV1
(mL and % predicted separately), FVC (mL or % predicted),
FEF25−75 (mL/s or % predicted) and adverse events from treat-
ment).
For clarity in the tables, HRQoL and adverse events are not pre-
sented according to the sub-domains in Effects of interventions;
instead we have inserted a general statement about the summary
of findings for these outcomes and the evidence is graded based
on all of the sub-domains combined.
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. They downgraded evidence
by one level if they considered the limitation to be serious and by
two levels if very serious.
R E S U L T S
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Description of studies
Results of the search
For the original version of the review, searches identified 45
unique references to nine studies (Aitken 2012; Bilton 2011;
Jaques 2008; Middleton 2015; Minasian 2010; de Boeck 2017;
NCT02134353; Robinson 1999; Teper 2011). Nine of these pa-
pers referred to two of the included studies and are listed under
both study identifiers (Aitken 2012; Bilton 2011). Pharmaxis also
highlighted three publications relating to mannitol which were
not eligible for inclusion (and are not even listed as excluded) as
they were not randomised (Bilton 2012; Button 2013a; Button
2013b).
In the previous version of the review, four studies (36 references)
were included (Aitken 2012; Bilton 2011; Jaques 2008; Minasian
2010), two studies (four references) were excluded (Robinson
1999; Teper 2011), two studies were listed as ongoing (now re-
ferred to as de Boeck 2017; NCT02134353) and and one study
was listed as awaiting classification (Middleton 2015).
The search for the 2017 update identified five new records; one
additional reference to an excluded study in the previous version
of the review (Teper 2011), one additional reference to an in-
cluded study in the previous version of the review (Aitken 2012)
and three references to a study which was ongoing at the time of
the previous review (de Boeck 2017). A total of 14 relevant trial
registry entries were identified for the 2017 update from a search
of Clinicaltrials.gov and WHO ICTRP (see Electronic searches).
The current version of the review includes six studies (62
records, 50 published references) (Aitken 2012; Bilton 2011; de
Boeck 2017; Jaques 2008; Middleton 2015; Minasian 2010),
excludes two studies (seven records, five published references)
(Robinson 1999; Teper 2011) and one study remains ongoing
(NCT02134353). This is shown in a study flow chart in the fig-
ures (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Six studies met the review’s inclusion criteria; all were available
as full papers and related abstracts, posters and unpublished pre-
sentation slides were consulted for additional information (Aitken
2012; Bilton 2011; de Boeck 2017 Jaques 2008; Middleton 2015;
Minasian 2010). One of these included studies had 13 publica-
tions (Aitken 2012), one had 17 publications (Bilton 2011) (nine
publications discussed both the Aitken and Bilton studies and are
listed under both studies in this review), one had four publications
(de Boeck 2017), one had five publications (Jaques 2008), one
had three publications (Middleton 2015) and one had had two
publications (Minasian 2010).
Trial design
All six studies were randomised, three were of parallel design (
Aitken 2012; Bilton 2011;Middleton 2015) and three had a cross-
over design (de Boeck 2017; Jaques 2008; Minasian 2010).
The duration of the studies ranged from two weeks (Jaques 2008)
to one year (consisting of a 26-week randomised treatment period
with a further 26-week open-label follow-up period; data from the
follow-up period are not eligible for consideration in this review)
(Aitken 2012; Bilton 2011). Five studies were described as double-
blind (Aitken 2012; Bilton 2011; de Boeck 2017; Jaques 2008;
Middleton 2015) and one study was open-label (Minasian 2010)
(see Risk of bias in included studies). Five studies were described
as were multicentre and conducted in Australia, New Zealand,
Europe, andNorth andSouthAmerica (Aitken 2012; Bilton 2011;
de Boeck 2017; Jaques 2008; Minasian 2010). One study was
conducted in Australia, but it was not stated whether this study
was single or multicentre (Middleton 2015).
Participants
A total of 784 randomised participants, children, young people
and adults aged six to 56 years from CF clinics, were included
in the six studies. In three studies the mean age was late teens or
early 20s (Aitken 2012; Bilton 2011; Jaques 2008) and in three
studies themean age was between 12 and 14 years (de Boeck 2017;
Middleton 2015; Minasian 2010). Two studies had roughly equal
numbers of male and female participants (Aitken 2012; Bilton
2011) and the remaining four studies recruited more females than
males; 59% females in two studies (Jaques 2008;Middleton 2015),
60% females in one study (de Boeck 2017) and 64% females in
the final study (Minasian 2010).
In all studies, the diagnosis of CF was made by clinical assessment
and by sweat or genetic testing, or both (information available in
study publication or provided by study sponsor Pharmaxis). In
five studies the participants were described as having CF and being
clinically stable at the start of treatment (Aitken2012; Bilton2011;
de Boeck 2017; Jaques 2008; Minasian 2010); the mean baseline
FEV1 ranged from 62% (Bilton 2011) to 72.23% predicted (de
Boeck 2017). In the final study, participants within the study
were hospitalised with a pulmonary exacerbation (as defined by
Fuchs criteria (Fuchs 1994)) (Middleton 2015).Within this study,
compared to the mannitol group, the control group had lower
mean (SD) admission FEV1 (58.0 (13.0)% predicted versus 73.1
(15.6)% predicted, P < 0.05) and mean (range) FEF25−75 (25.7
(20.1 - 71.8)% predicted versus 44.1 (22.8 - 92.43)% predicted,
P < 0.05).
The following table summarises participant baseline characteristics
in the included studies.
Design /
Characteristic
Aitken 2012
(n = 305)
Bilton 2011
(n = 295)
de Boeck 2017
(n = 95)
Jaques 2008
(n = 39)
Middleton
2015
(n = 22)
Minasian 2010
(n = 28)
Design Parallel study Parallel study Cross-over study Cross-over study Parallel study Cross-over study
Interventions 400 mg manni-
tol
(n = 184) vs 50
mg mannitol
(n = 121)
400 mg manni-
tol
(n = 177) vs 50
mg mannitol
(n = 118)
400mg mannitol
vs control
Baseline charac-
teristics reported
for 92 partici-
pants
Results reported
for 87 partici-
pants
Mannitol
vs non-respirable
mannitol
Results reported
for 39 partici-
pants
400 mg manni-
tol (n = 11) vs
control (n = 11)
Man-
nitol ormannitol
plus dornase alfa
vs dornase alfa
alone
Results reported
for 20 partici-
pants who com-
pleted the study
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(Continued)
Age Mean: 20 years
Range: 6 - 53
years
Aged < 18 years:
n = 154
Mean (SD): 23
(11.3) years
Aged < 18 years:
n = 105
Mean age (SD):
12.0 (3.0) years
Range 6 to 17
years
Mean: 19.1 years
Range: 8 - 48
years
Mean age (SD):
Mannitol
group = 13.2 (3.
7) years; Control
group = 14.4 (3.
0) years
Range 8 to 18
years
.
Mean (SD) age:
13.3 (2.24) years
For 20 who com-
pleted
Mean (SD) age:
13.2 (2.4) years
Gender 51.5% male (n =
157)
48.5% female (n
= 148)
55.3% male (n =
163)
44.7% female (n
= 132)
40% male (n =
37)
60% female (n =
55)
41% male (n =
16)
59% female (n =
23)
Mannitol group =
45% male (n=5)
, 55% female (n=
6);
Control group =
36% male (n=4)
; 64% female (n=
7)
36% male (n =
10)
64% female (n =
18)
For 20 who com-
pleted
30%male (n = 6)
70% female (n =
14)
FEV1 Mean (SD) 63.
8 (15.9)% pre-
dicted
Mean (SD): 62.
0 (16.3)% pre-
dicted
Mean (SD): 72.
23 (11.6) % pre-
dicted
Mannitol group
Mean (SD) 64.
9 (13.0)% pre-
dicted
Control group
Mean (SD) 64.
4 (11.8)% pre-
dicted
Mannitol group
Mean (SD): 73.
1 (15.6)% pre-
dicted
Control group
Mean (SD): 58.
0 (13.6)% pre-
dicted
For 20 who com-
pleted
Mean (SD):
1670 (500) mL
Mean (SD): 64
(10)% predicted
Dornase alfa
use
75.1% (n = 229)
of total partici-
pants re-
ceived concomi-
tant dornase alfa
74.5% (n = 137)
of the 400 mg
mannitol group
76% (n = 92) of
the 50 mg man-
nitol group
55.3% (n = 163)
of total partici-
pants re-
ceived concomi-
tant dornase alfa
54.2% (n = 96)
of the 400 mg
mannitol group
56.8% (n = 67)
of the 50 mg
mannitol group
68.5% (n = 63)
had previously
used or were us-
ing dornase alfa
at screening
46.
2% (n = 18) re-
ceived concomi-
tant dornase alfa
Stated that
dornase alfa was
used regularly in
59% of the total
cohort
NA (dornase alfa
is an interven-
tion in the study)
FEV1: forced expiratory volume in one second; NA: not applica-
ble; SD: standard deviation; vs: versus.
Interventions
Five studies comparedmannitol to a control treatment; two studies
used low-dose mannitol 50mg as the control (Aitken 2012; Bilton
2011), one study used ’very lowdose’ (50mg) non-respirableman-
nitol (Middleton 2015), one study used non-respirable mannitol
with a fine particle fraction over 2% (Jaques 2008) and one study
used 10 mg of non-spray dried, non-respirable raw material man-
nitol (de Boeck 2017).One study comparedmannitol to mannitol
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plus dornase alfa and to dornase alfa alone (Minasian 2010).
In theAitken study, 74.5%of participants randomised tomannitol
and 76% of participants randomised to control were concomitant
dornase alfa users (Aitken 2012). In the Bilton study, 54.2% of
participants randomised to mannitol and 56.8% of participants
randomised to control were concomitant dornase alfa users (Bilton
2011). The the remaining studies 68.5% (de Boeck 2017); 64%
(Jaques 2008) and 59% (Middleton 2015) had previously used
or were concomitant dornase alfa users. In three of the studies,
randomisation was stratified according to existing dornase alfa use
and participants were instructed under protocol not to change
their dornase alfa use from baseline (Aitken 2012; Bilton 2011;
de Boeck 2017).
Five studies evaluated inhaledmannitol 400mg twice daily (Aitken
2012; Bilton 2011; de Boeck 2017; Middleton 2015; Minasian
2010) and one study evaluated mannitol 420 mg twice daily (
Jaques 2008). Treatment periods in the randomised phase were 12
days (Middleton 2015), two weeks (Jaques 2008), eight weeks (de
Boeck 2017), 12 weeks (Minasian 2010) and 26 weeks (Aitken
2012; Bilton 2011). After completion of the randomised phase of
the study, two studies had an open-label follow-up phase lasting
up to 52 weeks (Aitken 2012; Bilton 2011).
Outcomes
In terms of the Primary outcomes of this review; all six included
studies reported at least onemeasure of lung function and reported
details of adverse events; five studies reported HRQoL, but one
did not (de Boeck 2017).
For some of the included studies, additional information was pro-
vided on these outcomes by Pharmaxis (see Characteristics of
included studies for details of additional data provided).
The majority of the Secondary outcomes defined in the review
were also reported in the published papers or information was
provided by Pharmaxis, only ’Time off school or work’ was not
recorded in any included study.
Excluded studies
Two studies (five references), each published as full papers, were
excluded (Robinson 1999; Teper 2011). One was a single-dose
study which examined the effect of mannitol on bronchial mucus
clearance (Robinson 1999). The second study was a dose-response
type study, and we could not incorporate any data on a clinically-
used dose (Teper 2011).
Ongoing studies
One randomised, double-blind and parallel study run by
Pharmaxis, the manufacturer of mannitol, is ongoing (
NCT02134353). Participants over 18 years of age have been re-
cruited, and the design is multicentre across North and Central
America, Europe and South Africa. Inhaled mannitol 400 mg
twice daily is being compared to inhaled control twice daily and
the study duration is reported as 26 weeks. The primary outcome
measure is mean change in FEV1 (mL). The study commenced
in October 2014 and investigators are due to collect final data for
the primary outcome measure in March 2016 (NCT02134353).
Risk of bias in included studies
Several details relating to data and study design were not available
from the published papers so we requested this missing informa-
tion from the pharmaceutical company (Pharmaxis) or authors,
or both. Pharmaxis provided analysis results from the studies and
answered some specific follow-up queries, so we were able to com-
plete risk of bias assessments. Additional data were also received
from Dr Minasian. A visual summary of the risk of bias judge-
ments is presented as a figure (Figure 2).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Generation of sequence
We judge the risk of bias in five studies to be low (Aitken 2012;
Bilton 2011; Jaques 2008; Middleton 2015; Minasian 2010). It
was stated in one study that the randomisation code used was ex-
ternally generated in a small block design, stratified by site and
dornase alfa use (Jaques 2008). In a second study, it was stated
that randomisation was performed (1:1) ratio via random number
generation without stratification (Middleton 2015). For the re-
maining three studies, there was not sufficient information in the
original publications to allow a clear judgement. For the Aitken
and Bilton studies Pharmaxis provided additional details; in both
studies, the master randomisation lists were prepared by an exter-
nal company; randomisation numbers were generated, stratified
by country and dornase alfa use, and randomisation blocking by
country was done in paired blocks (Aitken 2012; Bilton 2011). In
the final study, DrMinasian confirmed that participants were each
allocated a unique randomisation number and treatment sched-
ule with equal probability for assignment to treatment sequences.
Randomisation was carried out in balanced blocks with separate
schedules created for each of the two recruiting centres (Minasian
2010).
One study was judged to be at unclear risk of bias (de Boeck
2017). It was stated that randomisation was conducted in a 1:1
ratio and stratified according to age (6 to 11 years or 12 to 17 years)
and dornase alfa use (user or non-user), but no information was
provided with regards to how the random sequence was generated.
Concealment of allocation
Pharmaxis provided additional information for two studies de-
scribing how an interactive voice response systemwas used toman-
age randomisation and the risk of bias for these studies was judged
to be low (Aitken 2012; Bilton 2011). No information regarding
allocation concealment was available for the remaining four stud-
ies, so these are judged to be at an unclear risk of bias (de Boeck
2017; Jaques 2008; Middleton 2015; Minasian 2010).
Blinding
The risk of bias from blinding is judged to be low for participants,
clinicians and outcome assessors in three studies (Aitken 2012;
Bilton 2011; Jaques 2008). The Aitken study was described as
double-blind and the mannitol and control capsules were iden-
tical in appearance, taste and method of administration, so the
risk of bias was judged to be low for participants and clinicians. It
was unclear from the publication whether outcome assessors were
blinded; however, Pharmaxis have confirmed that investigators
and all study staff were blinded (Aitken 2012). In the Bilton study,
participants, clinicians and outcome assessors were also blinded
(the control group received sub-therapeutic doses of mannitol);
Pharmaxis confirmed this study likewise used mannitol and con-
trol capsules which were identical in appearance, taste andmethod
of administration (Bilton 2011). In the Jaques study, participants
were blinded as mannitol and control were also identical in taste
and appearance.The study publication states that “study staff and
investigators” were blinded; Pharmaxis confirmed that the statis-
tician was part of the “study staff ” and hence also blinded, we
therefore consider the risk of bias to be low (Jaques 2008).
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In one study, the risk of bias for participants and clinicians was
judged to be low risk of bias as the double-blind was achieved with
a placebo also containing a low dose of mannitol (de Boeck 2017).
However, it was not stated if outcome assessors were blinded in
this study so the risk of bias for outcome assessors was unclear.
One study was described as ’double-blind’ but no information was
given about how the blinding was achieved or who was blinded,
therefore the risk of bias for participants, clinicians and outcome
assessors was judged to be unclear (Middleton 2015).
The final study was an open study, so we judge the risk of bias
from lack of blinding to be high for participants, clinicians and
outcome assessors (Minasian 2010).
Incomplete outcome data
Three studies were judged to have a low risk of bias (Aitken 2012;
Bilton 2011; Middleton 2015). In one study, there was higher
drop-out rate with mannitol (17% in the 400 mg mannitol group
versus 12% for 50 mg mannitol) due to adverse events and other
reasons, e.g. withdrawal of consent (Aitken 2012); and in a second
study 37% during 400 mgmannitol treatment and 28% in the 50
mgmannitol group, for which the authors of the study considered
one possible reason to be the high burden of treatment (Bilton
2011). Sensitivity analyses conducted by Pharmaxis (methods of
imputation of missing data for withdrawals) showed a consistent
treatment effect in favour of mannitol and no change to conclu-
sions. In the third study judged to have low risk of bias, results were
reported for all 22 randomised participants (Middleton 2015).
One study was judged to have unclear risk of bias; even though
reasons for withdrawal were clearly documented in a flow diagram
and primary and secondary efficacy endpoints were reported to
have been analysed on an intention-to-treat (ITT) basis, it is also
stated that missing data were imputed using ’last observation car-
ried forward’ (de Boeck 2017). Such a method does not capture
change over time, so may have introduced bias into results. How-
ever, it is not stated how much data have been imputed and for
how many participants, therefore the risk of bias is unclear.
The remaining two studies were judged to have a high risk of
bias for this domain (Jaques 2008; Minasian 2010). In the Jaques
study, three participants withdrew because of adverse effects and
there was also an unexplained withdrawal of participants by the
physician (Jaques 2008). It is unclear how many participants were
evaluated for outcomes and, in addition it is not stated why the
56-day follow-up data were not reported. In the Minasian study,
there were many dropouts during the study, but little information
was provided about why this occurred; eight participants with-
drew because of adverse events or treatment burden. Additionally,
Minasian only reported results for participants who completed all
three arms of the cross-over study (per protocol analysis) (Minasian
2010).
Selective reporting
Limited information regarding the outcomes considered in this
review was available in the publications for four included stud-
ies, particularly for HRQoL, for measures of lung function other
than FEV1 and for the review’s secondary outcomes (Aitken 2012;
Bilton 2011; Jaques 2008; Minasian 2010). However, for three
of the studies detailed additional information was provided on
request for all of the primary outcomes and the majority of the
secondary outcomes included in this review; for two studies infor-
mation was provided by Pharmaxis (Aitken 2012; Bilton 2011)
and for one study by the principle investigator (Minasian 2010).
Therefore these three studies were judged to be at low risk of bias.
Some additional information was also supplied by Pharmaxis for
the fourth study (Jaques 2008); however, as there was insufficient
detail to include data for many of the secondary outcomes of this
review, this study is judged to be at unclear risk of bias.
For the remaining two studies which were phase 2 and pilot stud-
ies respectively, examining efficacy and safety, all important out-
comes relating to efficacy and safety appear to have been reported,
therefore the two studies were judged to be at low risk of selective
reporting bias (de Boeck 2017; Middleton 2015).
Other potential sources of bias
We identified a number of other potential sources of bias in the
included studies and all studies are judged to be at high risk of
’other bias’.
As there is a risk of bronchoconstriction with mannitol, partici-
pants in all studies underwent a mannitol tolerance test at screen-
ing; those who failed the test or in whom the test was incomplete
did not enter the study. Thus, the participant population included
only those people with CF who passed the tolerance test and not
all potential participants with CF.
All studies were funded and sponsored by Pharmaxis, and the
manufacturer participated in the study design, data collection, data
analysis, data interpretation and writing of the reports for five of
the studies, therefore the risk of bias for all studies is high (Aitken
2012; Bilton 2011; de Boeck 2017; Jaques 2008;Minasian 2010).
Three studies had a cross-over design but two of these studies
reported little information on potential carry-over effects between
arms of the study (Jaques 2008; Minasian 2010).
One pilot study notes a relatively small sample size which pre-
vents “strong conclusions about clinical utility in this setting”
(Middleton 2015). The remaining five studies reported sample size
calculations and were reported to be powered to detect changes
in FEV1; however, one study did not manage to recruit a suffi-
cient number of participants and a priori and post-hoc power cal-
culations are based on different sizes of treatment difference (de
Boeck 2017); while a further study may have been underpowered
(Minasian 2010).
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Effects of interventions
See: Summary of findings for the main comparison Summary
of findings - 400 mg inhaled mannitol compared with 50
mg inhaled mannitol for cystic fibrosis; Summary of findings
2 Summary of findings - Inhaled mannitol compared with
control (non-respirable mannitol) for cystic fibrosis; Summary of
findings 3 Summary of findings - Inhaled mannitol compared
with control (non-respirable mannitol) for people with cystic
fibrosis, hospitalised due to pulmonary exacerbations; Summary
of findings 4 Summary of findings - Inhaled mannitol compared
with dornase alfa for cystic fibrosis; Summary of findings
5 Summary of findings - Inhaled mannitol plus dornase alfa
compared with dornase alfa for cystic fibrosis
Five studies comparedmannitol with control (Aitken 2012; Bilton
2011; de Boeck 2017; Jaques 2008; Middleton 2015). Two stud-
ies comparing mannitol to low-dose (sub-therapeutic) mannitol
had similar designs and homogeneous populations, so we were
able to pool the results analyse these for the time points up to
two months, up to four months and up to six months (Aitken
2012; Bilton 2011). Two studies were cross-over in design and of
shorter duration with different control treatments; therefore we
report these studies under a separate comparison (de Boeck 2017;
Jaques 2008). The fifth study comparing mannitol to low-dose
(sub-therapeutic) mannitol in individuals with CF who had been
hospitalised due to a pulmonary exacerbation was a pilot study
(Middleton 2015). Due to the difference in the population re-
cruited within this study (hospitalised patients) compared to the
other studies (outpatients); we report this study under a third sep-
arate comparison (Middleton 2015).
The final study included in the review compared mannitol to
mannitol plus dornase alfa and to dornase alfa alone; and the two
comparisons are reported separately below (Minasian 2010).
In summary, the following comparisons are presented in this re-
view.
• Mannitol compared with control - parallel studies of people
with CF
• Mannitol compared with control - cross-over studies of
people with CF
• Mannitol compared with control - parallel study of people
with CF hospitalised due to pulmonary exacerbations
• Mannitol compared with dornase alfa - cross-over study of
people with CF
• Mannitol plus dornase alfa compared with dornase alfa -
cross-over study of people with CF
For all comparisons, we have taken the results we present from the
final published papers, previously published abstracts and addi-
tional data provided by the manufacturer (Pharmaxis) and the au-
thors (DrMinasian). We note that where data have been converted
to another measure for entry into analysis (for example, MDs and
95% CIs converted into MDs and SEs to enter via generic inverse
variance), some conversions have lead to very slight differences (to
one or two decimal places) between results in published papers
and results in this review. We assume this is due to rounding of
numbers within the published papers and we note no differences
in statistical significance or conclusions between our analyses and
the published papers.
Mannitol compared with control - parallel studies of
individuals with cystic fibrosis
Two parallel studies with 600 participants in the ITT population
reported data for this comparison and additional data were pro-
vided by Pharmaxis (Aitken 2012; Bilton 2011). We refer to the
intervention as 400 mg mannitol and the control treatment (sub-
therapeutic mannitol) as 50 mgmannitol throughout this section.
Primary outcomes
1. HRQoL
Both studies measuredHRQoL using the age-appropriate versions
of the CFQ-R questionnaire and reported on differing numbers
of participants for different domains at different time points (for
exact numbers please see the graphs in Data and analyses) (Aitken
2012; Bilton 2011). Although ’Burden of treatment’ is part of
the QoL assessment, these results are presented under a separate
outcome below (secondary outcome 7). We note that results pre-
sented for the domains of respiratory, physical, emotion, eating,
social, body, weight and digestion are the pooled results for all indi-
viduals (results from age-appropriate version of the questionnaire
combined and such a combination of results across questionnaires
may not be valid (Quittner 2015 [pers comm]), therefore we en-
courage caution when interpreting the results from any of these
domains. The domains of vitality, health, role and weight were
assessed only in individuals over the age of 14 years. Furthermore,
we are aware that the HRQoL tool used in the studies was not
designed to be used to assess mucolytics and therefore the results
for some domains, e.g. mucus production, should be interpreted
in light of the mechanism of action of the drug.
In the publications, Bilton reported some limited data from the
respiratory domain and Aitken reported that there were no dif-
ferences between treatments for any of the QoL domains (Aitken
2012; Bilton 2011). Pharmaxis supplied additional data for the
respiratory domain for both studies. When data were combined
at the time points ’up to four months’ and ’up to six months’,
no statistically significant differences were observed (Analysis 1.1;
low-quality evidence). It should be noted that as part of its mech-
anism of action mannitol increases sputum production; however,
this has a negative result in the CFQ-R questionnaires.
Pharmaxis also supplied additional data for the change from base-
line for other domains of the CFQ-R for the Aitken and Bilton
studies at up to four months and up to six months. For domains
of physical, emotion, eating, health, social, body, role, weight and
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digestion, none of the results were statistically significant (Analysis
1.3; Analysis 1.4; Analysis 1.5; Analysis 1.6; Analysis 1.7; Analysis
1.8; Analysis 1.9; Analysis 1.10; Analysis 1.11), although the re-
sults favoured 400 mg mannitol for the vitality domain at six
months, MD 4.84 (95% CI 0.86 to 8.82; P = 0.02) (Analysis 1.2).
Some heterogeneity was observed between the two studies at six
months in the domains of respiratory, physical, social and role; for
all four domains the Aitken study showed an advantage to the 50
mg mannitol group and the Bilton study showed an advantage to
the 400 mg mannitol group (of varying magnitudes), but not sta-
tistically significant. Given the subjective nature of this outcome
and the limited number of studies included, we have not con-
ducted any subgroup analyses to explore this heterogeneity and
encourage caution when interpreting the numerical results from
these domains.
Subgroup analyses - dornase alfa use and age
Subgroup-specific data for HRQoL were not available for either
study (Aitken 2012; Bilton 2011).
2. Lung function
Pharmaxis provided additional lung function data from aMMRM
for the two studies (see Measures of treatment effect for further
information). The primary comparison in the original publica-
tions was on the average effect across the three time points up to
and including six months. However, the results at each time point
(which correspond to our analyses) were also presented.
No consistent heterogeneity was found for any of the outcomes at
any of the time points.
a. FEV1 (mL or % predicted)
Data were available for the absolute change from baseline in FEV1
(mL) at up to two, four and six months for 600 participants in the
ITT populations of both studies. We found a significant benefit
for 400 mg mannitol compared with 50 mg mannitol at: up to
two months, pooled MD 71.27 mL (95% CI 36.00 to 106.54,
P < 0.0001); up to four months, pooled MD 64.54 mL (95%
CI 26.65 to 102.42, P = 0.0008); and up to six months, pooled
MD 86.50 (95% CI 45.15 to 127.86, P < 0.0001) (Analysis 1.12,
moderate-quality evidence).
Data were also available for the relative change from baseline in
FEV1 % predicted at up to two, four and six months for 600
participants in the ITT populations of both studies (Aitken 2012;
Bilton 2011). Pooling these data, we found a significant benefit for
400 mg mannitol compared with 50 mg mannitol at: up to two
months, pooled MD 2.98% (95% CI 1.04 to 4.92, P = 0.003);
up to four months, pooled MD 3.26% (95% CI 1.16 to 5.35, P =
0.002); and up to six months, MD 3.89% (95% CI 1.69 to 6.08,
P = 0.0005) (Analysis 1.13, moderate-quality evidence).
b. FVC (mL or % predicted)
Data were available for the absolute change from baseline in FVC
(mL) at up to two, four and six months for 600 participants in
the ITT populations of both studies (Aitken 2012; Bilton 2011).
There was a statistically significant benefit for 400 mg mannitol
compared with 50 mg mannitol at all three time points; MD
87.81 mL (95% CI 41.96 to 133.66, P = 0.0002), MD 89.24
mL (95% CI 40.55 to 137.92, P = 0.0003) and MD 102.17 mL
(95% CI 48.40 to 155.94, P = 0.0002), respectively (Analysis
1.14, moderate-quality evidence).
FVC % predicted was not recorded in either of the studies.
c. FEF25−75 (mL/s or % predicted)
Data were available for the absolute change from baseline in
FEF25−75 (mL/s) at up to two, four and six months for 600 par-
ticipants in the ITT populations of both studies; there was no sta-
tistically significant difference between 400 mg mannitol and 50
mg mannitol at any time-point (Analysis 1.15, moderate-quality
evidence).
FEF25−75 % predicted was not recorded in either of the studies
(Aitken 2012; Bilton 2011).
Subgroup analysis - dornase alfa use
Subgroup data were available for the two studies for all measures
of lung function at all time points of interest in the review. For
brevity, the results of the subgroup analysis are summarised in the
additional tables (Table 1). As in the primary analysis above, gen-
erally the change from baseline of the measures of lung function
was significantly improved in the 400 mg mannitol group com-
pared to the 50 mg mannitol group in both subgroups (dornase
alfa users and non-users). The MD in the change from baseline
was larger in the non-user subgroup than the user subgroup for
the majority of measures and time points; however, there was no
significant difference between the subgroups for any of the mea-
sures (Table 1).
Subgroup analysis - age
Subgroup data were available for the two studies for all measures
of lung function at all time points of interest in the review. For
brevity, the results of the subgroup analysis are summarised in the
additional tables (Table 2). The statistically significant benefits for
400 mg mannitol compared to 50 mg mannitol shown in the pri-
mary analyses above were also shown in the adult subgroup; how-
ever, this was not shown in the subgroup of children. There were
no significant differences between the subgroups for the majority
of the measures at most time points (Table 2).
3. Adverse effects relating to treatment
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a. type and number of adverse events (defined as mild,
moderate or severe in this review)
Both studies used the following researcher-defined classification
when reporting adverse events: mild (awareness of sign or symp-
tombut easily tolerated);moderate (discomfort causes interference
with usual activity); and severe (incapacitating, or unable to do
usual activities) (Aitken 2012; Bilton 2011). Both studies further
defined serious adverse events as a reaction that results in death,
is life-threatening, requires hospitalisation or prolongation of ex-
isting hospitalisation, results in persistent or significant disability
or incapacity, or is a congenital anomaly or birth defect. We have
reported the classification applied in the Pharmaxis studies within
the framework of our outcomes (see Types of outcome measures
for review definitions of adverse event classifications). Aitken and
Bilton both considered that the reported adverse events presented
here were possibly or probably related to treatment. All data and
analyses relate to the ’up to six months’ time point; some data are
taken from the published papers and other data were supplied ad-
ditionally by Pharmaxis. A wide range of different adverse events
were reported by both Aitken and Bilton relating to respiratory,
gastrointestinal and musculoskeletal events, amongst others. We
report the number of participants experiencing one or more of
these events and the quality of the evidence for this outcome was
judged to be moderate.
i. mild
The most common ’mild’ adverse effects experienced by partici-
pants in both treatment arms were cough (3% of participants in
the 400 mgmannitol group and 1.7% of participants in the 50 mg
mannitol group), haemoptysis (1.7% of participants in the 400
mg mannitol group and 0.8% of participants in the 50 mg man-
nitol group) and pharyngolaryngeal pain (1.4% of participants in
the 400 mgmannitol group and 1.3% of participants in the 50 mg
mannitol group), with no clinically or statistically significant dif-
ference between the two study arms (Analysis 1.16). Three partic-
ipants in the 400 mgmannitol group (0.8%) and two participants
in the 50 mg mannitol group (0.8%) experienced an aggravation
of their condition. Most other side effects were only reported in
one or two participants per treatment arm. None of the results
for mild adverse effects were statistically significant, although they
may have clinical relevance for people with CF.
ii. moderate
Considering ’moderate’ adverse effects, 5.3% of participants in the
400 mg mannitol treatment group and 1.4% of participants in
the 50 mg mannitol group experienced cough. Also, more par-
ticipants experienced haemoptysis in the 400 mg mannitol group
compared with those in the 50 mg mannitol group (2.8% com-
pared to 0.4%). Pharyngolaryngeal pain was experienced in the
400 mg mannitol and 50 mg mannitol groups by 1.4% and 0.4%
of participants, respectively. A total of 11 participants (3.0%) in
the 400 mg mannitol group and four participants (1.7%) in the
50mgmannitol group experienced aggravation of their condition.
None of the results for moderate adverse effects were statistically
significant (Analysis 1.17), although they may have clinical rele-
vance for people with CF.
iii. severe
Combined data from the two studies showed that at least one
treatment-related adverse event (defined in the trials as serious and
presented in line with our definition of severe) occurred in 10 out
of 361 participants (2.8%) in the 400 mg mannitol group and
four out of 239 participants (1.7%) in the 50 mg mannitol group
(Aitken 2012; Bilton 2011).
The most common ’severe’ adverse effect was cough with 1.9%
of participants from the 400 mg mannitol group and 1.7% of
participants in the 50 mg mannitol group experiencing this; this
was not statistically significant (Analysis 1.18).One ormore report
of haemoptysis occurred in 0.8% and 0.4% participants in the
400 mg mannitol and 50 mg mannitol arms, respectively. There
were reports of pharyngolaryngeal pain in 1.1% of in the 400
mg mannitol group but in none of the participants in the 50 mg
mannitol group. An aggravation of CF was reported in 0.2% of
participants taking 400 mg mannitol and 0.4% of participants
taking 50 mg mannitol. None of these results were statistically
significant, although they may have clinical relevance for people
with CF.
iv. total
Considering all treatment-related adverse events from the two
studies (whether defined as mild, moderate or severe), the most
common adverse effects were cough (occurring 10% and 5% re-
spectively in the 400mgand50mgmannitol groups) andhaemop-
tysis (occurring 5% and 2% respectively in the 400 mg and 50 mg
mannitol groups). Other common adverse events were pharyngo-
laryngeal pain, occurring in 4% of the 400 mg mannitol group
compared to 2% of the 50 mgmannitol group, and aggravation of
condition, occurring in 4% of the 400 mg mannitol group com-
pared to 3% of the 50 mg mannitol group. Differences between
the rates of all adverse events, were not statistically significant;
however, such events may have clinical relevance for people with
CF and further long-term studies with post hoc monitoring are
required to determine the clinical importance of adverse effects
associated with inhaled mannitol (Analysis 1.19).
Subgroup analysis - dornase alfa use
Subgroup data were available for the two studies for all treatment-
related adverse events of interest in the review. For brevity, the
results of the subgroup analysis are summarised in the additional
tables (Table 3). As in the primary analysis, 99%CIs are used to al-
low for multiple testing of different adverse events of interest. The
most commonly occurring adverse events in the dornase alfa users
were cough, haemoptysis, aggravation of condition and infections
and infestations. The most commonly occurring adverse events
in the non dornase alfa users were cough, haemoptysis, pharyn-
golaryngeal pain and aggravation of condition. As in the primary
analysis, in the subgroups there were no significant differences be-
tween treatments in the rates of adverse events. There were also
no significant differences across the subgroups (Table 3).
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Subgroup analysis - age
Subgroup data were available for the two studies for all treatment-
related adverse events of interest in the review. For brevity, the
results of the subgroup analysis are summarised in the additional
tables (Table 4). As in the primary analysis, 99% CIs are used
to allow for multiple testing of different adverse events of inter-
est. The most commonly occurring adverse events in adults were
cough, haemoptysis, aggravation of condition and pharyngolaryn-
geal pain. The most commonly occurring adverse events in chil-
drenwere cough, pharyngolaryngeal pain, headache and infections
and infestations. As in the primary analysis, in the subgroups there
were no significant differences between treatments in the rates of
adverse events. There were also no significant differences across
the subgroups (Table 4).
b. number of participants who ceased inhalations because of poor
tolerability, e.g. cough or bronchoconstriction
Pharmaxis provided additional data on tolerability and in both
the Aitken and Bilton studies, respiratory and thoracic side ef-
fects were the most common treatment-related reasons for stop-
ping treatment. These side effects were asthma, bronchospasm,
cough, haemoptysis, hyperventilation, obstructive airways disor-
der, pharyngolaryngeal pain, productive cough, throat irritation
and wheezing. Our analysis showed no statistically significant dif-
ferences between the 400mgmannitol and50mgmannitol groups
(Analysis 1.20). However, we were not able to simply pool the data
to give a total as some participants ceased inhalations for multiple
reasons. Pharmaxis confirmed there were a total of 31 out of 361
(8.6%) participants who dropped out of the 400 mg mannitol
group and 7 out of 239 (2.9%) participants who dropped out of
the 50 mg mannitol group due to respiratory and thoracic side
effects. Pharmaxis also confirmed that a total of 37 out of 361
(10.2%) participants in the 400 mg mannitol group and eight out
of 239 (3.3%) participants in the 50 mg mannitol group discon-
tinued treatment due to any treatment-related adverse event.
Secondary outcomes
1. Pulmonary exacerbations
a. number of participants free of pulmonary exacerbations
Both studies included a pre-specified definition of a pulmonary
exacerbation (Aitken 2012; Bilton 2011). Investigators using the
criteria specified by Fuchs which define exacerbations as when
participants are treated with intravenous antibiotics for four or
more of the following signs or symptoms: change in sputum pro-
duction; dyspnoea; new or increased haemoptysis; malaise; fatigue
or lethargy; fever (38°C or above); anorexia or weight loss; sinus
pain or tenderness; change in sinus discharge; pulmonary function
decreased by at least 10% from previous recorded value; radio-
graphic signs indicative of pulmonary infection; increased cough;
or changes in physical auscultation of the chest (Fuchs 1994).
The number of participants who had at least one protocol-defined
pulmonary exacerbation (PDPE) at up to six months was reported
for both studies in the data from Pharmaxis. Combining data from
the two studies showed a statistically significant benefit with 400
mgmannitol compared to 50mgmannitol, pooled RR 0.71 (95%
CI 0.51 to 0.98, P = 0.04), but the CIs are wide due to the low
numbers of events, which shows that the average effect of 400 mg
mannitol may reduce the exacerbation risk by as much as 49% or
by as little as only 2% (Analysis 1.21). Hence, we are unsure of
the clinical relevance of this result.
Subgroup analysis - dornase alfa use
Subgroup data were available for the two studies for the number
of participants experiencing pulmonary exacerbations. For brevity,
the results of the subgroup analysis are summarised in the addi-
tional tables (Table 1). The statistically significant benefits for 400
mg mannitol compared to 50 mg mannitol shown in the primary
analyses above was also shown in participants who were not dor-
nase alfa users, but this was not the case for participants using dor-
nase alfa. There was, however, no significant difference between
the subgroups (Table 1).
Subgroup analysis - age
Subgroup data were available for the two studies for the number
of participants experiencing pulmonary exacerbations. For brevity,
the results of the subgroup analysis are summarised in the addi-
tional tables (Table 2). The statistically significant benefits for 400
mg mannitol compared to 50 mg mannitol shown in the primary
analyses above was not shown in either subgroup and there was
no significant difference between the subgroups (Table 2).
b. time to first exacerbation
Both studies showed a slight increase in the time to first PDPE in
the 400 mg mannitol group compared with the 50 mg mannitol
group. Combining data from the two studies showed a slight in-
crease in the time to first PDPE, but this increase was not statisti-
cally significant (Analysis 1.22)
2. Time off school or work
Neither study recorded time off school or work (Aitken 2012;
Bilton 2011).
3. Need for additional non-routine antibiotics
a. intravenous antibiotics
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In both studies, PDPEs included the requirement for intravenous
antibiotics (Analysis 1.21). Pharmaxis provided full data for intra-
venous antibiotic use for all pulmonary exacerbations (protocol-
defined or otherwise) at the ’up to six months’ time point for two
studies; significantly fewer participants in the 400 mg mannitol
groups compared to the 50 mg mannitol groups required addi-
tional intravenous antibiotics, pooled RR 0.81 (95% CI 0.70 to
0.95, P = 0.01) (Analysis 1.23). Additional information was also
provided for the Aitken study where a total of 377 courses of in-
travenous antibiotics were administered in 102 participants in the
400 mg mannitol group and 280 courses in 74 participants in the
50 mg mannitol group (Aitken 2012).
b. oral antibiotics
Neither study reported the use of additional oral antibiotics
(Aitken 2012; Bilton 2011).
c. inhaled antibiotics
Neither study reported the use of additional inhaled antibiotics
(Aitken 2012; Bilton 2011).
4. Hospitalisations
a. number of hospitalisations
Both Aitken and Bilton provided data for the need for hospitalisa-
tion due to both PDPE and all pulmonary exacerbations at the ’up
to six months’ time point. Although in both studies fewer partici-
pants receiving 400 mgmannitol were hospitalised for pulmonary
exacerbations and PDPEs compared with those in the 50mgman-
nitol group, there was no statistically significant difference in the
number of participants requiring hospitalisation due to PDPE or
all pulmonary exacerbations (Analysis 1.24).
b. duration of hospitalisation
Pharmaxis also provided data on the duration of hospitalisation for
both pulmonary exacerbations andPDPEs at the ’up to sixmonths’
time point for the two studies. For all pulmonary exacerbations and
PDPE, the mean duration of hospitalisation seemed to be slightly
reduced in the 400 mg mannitol compared to 50 mg mannitol
group, but no significant difference was seen between the groups
(Analysis 1.25).
5. Assessment of symptoms (including cough, sputum
volume, ease of expectoration and dyspnoea)
Results for respiratory domain of the CFQ-R are reported in the
HRQoL section above (Analysis 1.1).
a. sputum weight (g): post-treatment and change from baseline
Sputum was collected for 30 minutes after treatment administra-
tion at baseline and then again at 14 weeks for the assessment of
sputum weight.
At 14 weeks (post-treatment), one study showed no differences
between the treatment groups in terms of sputum weight (Aitken
2012) while the second study showed a significant difference be-
tween the groups with the 400 mg mannitol group producing
over twice as much sputum as the 50 mg mannitol group (Bilton
2011).When pooling the data from the two studies, the difference
between the 400 mg mannitol and 50 mg mannitol groups was
not significant and heterogeneity between the studies was high,
MD 1.02 (95% CI -0.10 to 2.14), I² = 65% (Analysis 1.26).
This heterogeneity may have originated from the differences in
sputum weight at ’baseline;’ we note that the ’baseline’ measure-
ment was taken after the first administration of the study drug
and therefore may have been influenced by treatment. The mean
’baseline’ sputum weights in the 400 mg mannitol and 50 mg
mannitol groups in the one study were 4.9 g and 3.5 g respec-
tively (Aitken 2012) and 6.28 g and 2.26 g respectively in the sec-
ond study (Bilton 2012). Therefore, we carried out an additional
analysis examining the change from baseline in sputum weight in
the two studies. Neither study showed a significant difference in
the change in sputum weight from baseline between the 400 mg
mannitol and 50 mg mannitol groups. The pooled analysis also
showed no significant difference between groups and no hetero-
geneity was present between studies in this analysis, MD -0.95
(95% CI -2.05 to 0.15), I² = 0% (Analysis 1.27).
6. Sputum microbiology (change in numbers of pathogens,
emergence of new pathogens)
Pharmaxis provided data for both studies on the pathogens
present at the ’up to six months’ time-point (Aitken 2012; Bilton
2011); the pathogens assessed were Pseudomonas aeruginosa (mu-
coid, non-mucoid and not specified), Pseudomonas spp (other),
Staphylococcus aureus and methicillin-resistant Staphylococcus au-
reus, Burkholderia cepacia, Aspergillus spp and Candida spp. There
were no statistically significant differences in the prevalence of any
pathogens isolated (Analysis 1.28).
7. Burden of treatment
Additional CFQ-R data (change from baseline and final scores)
on the burden of treatment domain were provided by Pharmaxis.
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When the data were pooled at the ’up to four months’ time-point,
therewas a larger decrease in the burdenof treatment in the 400mg
mannitol group compared with the 50 mg mannitol group, giving
a statistically significant result, MD -4.60 (95% CI -7.90 to -1.30,
P = 0.006); however, this effect was not sustained to six months
(Analysis 1.29). We note that due to the blinding procedures of
the two studies, participants in both 400 mg mannitol group and
50 mg mannitol group would have had the same number of ad-
ditional capsules, therefore results should be interpreted accord-
ingly. We further note that not all participants contributed data to
the burden of treatment domain at each time point, therefore we
recommend caution when interpreting results of these analyses.
At the ’up to six month’ time-point, one study assessed treatment
adherence by counting returned unused medication and blister
packaging and defined compliance as the use of 60% or more of
drug dispensed; 152 out of 184 participants (83%) were compli-
ant in the 400 mgmannitol group and 107 out of 121 participants
(88%) in the 50 mg mannitol group (Aitken 2012). The paper
reported compliance was good in both arms; in the 400 mg man-
nitol arm, mean (SD) use of drug dispensed was 85.2% (23.81%)
and in the 50 mg mannitol arm, mean (SD) 88.7% (17.66%).
At the same time-point, the second paper recorded adherence to
protocol of at least 60% for 111 out of 177 participants in the 400
mgmannitol group (62.7%) and 89 out of 118 participants in the
50 mg mannitol group (75.4%) (Bilton 2011). The paper used
the same definition of compliance and stated that the “median
compliance was 89% and 91% for 400 mg mannitol and 50 mg
mannitol groups, respectively.”
Pooling this data shows that significantly fewer participants were
compliant with 400 mg mannitol compared to 50 mg mannitol
treatment, pooled RR 0.89, (95% CI 0.82 to 0.97, P = 0.006)
(Analysis 1.30).
Mannitol versus control - cross-over studies of
individuals with cystic fibrosis
Two cross-over studies (n = 134) compared mannitol with control
treatments (de Boeck 2017; Jaques 2008).
In one of the studies (n = 95), each treatment arm of the study
lasted eight weeks separated by an eight-week washout period (de
Boeck 2017). The control arm of this study used 10 mg of non-
spray dried, non-respirable raw material mannitol which is differ-
ent to the low-dose of mannitol used in the two parallel studies
described above. This study adjusted for the cross-over design of
the study using an analysis of covariancemodel including terms for
participant, treatment period, treatment and adjusting for baseline
measurements (de Boeck 2017). Investigators presentedMDs and
95% CIs from this model for lung function outcomes and these
data are entered into the analysis in this review.
In the second study (n = 39), each treatment arm of the study lasted
two weeks separated by a two-week washout period (Jaques 2008).
The control arm in this study used non-respirablemannitol, which
is also different to the low-dose ofmannitol used in the two parallel
studies described above. Investigators stated that they adjusted for
the cross-over design of the study via a mixed model of analysis of
variance when analysing and presenting results, but the format of
the data presented in the paper, only allows us to present these data
as if this was a parallel study. Therefore we have not performed an
analysis of the difference between treatment groups and we have
instead presented results narratively or in additional tables (Table
5; Table 6; Table 7).
Primary outcomes
1. HRQoL
Only one study reported on HRQoL (Jaques 2008).
As stated above, it should be noted that while ’Burden of treat-
ment’ is part of the QoL assessment, these results are presented
under a separate outcome below (secondary outcome 7). Jacques
measured HRQoL using the age-appropriate CFQ-R; for partici-
pants aged six to 13 years, either the parent or child questionnaire
was completed as appropriate, and those participants aged 14 years
and over used the teen or adult questionnaire with a two-week re-
call period (Jaques 2008). The results (adjusted for the cross-over
design) as reported in the paper are presented in the additional
tables (Table 5).
At the end of the study there were no significant differences be-
tween mannitol and control for the respiratory, health, physical
and vitality domains (very low-quality evidence). As stated above,
mannitol may have a negative effect on QoL scores due to its
mechanism of action being to increase sputum production (scored
as a negative outcome in the respiratory domain). Furthermore,
we are aware that the HRQoL tool used in the studies was not
designed to be used to assess mucolytics.
2. Lung function
One study presented results (adjusted from cross-over design) for
absolute and relative change in FEV1, FVC and FEF25−75 (%
predicted) (de Boeck 2017). This study also presented results for
pre-planned subgroup analyses based on age and dornase alfa use.
The results are presented below for each lung function measure.
The results for lung function measures (adjusted for cross-over de-
sign) as reported in the second study (Jaques 2008) or provided by
Pharmaxis are presented in the additional tables and summarised
below (Table 6).
a. FEV1 (mL or % predicted)
Absolute change from baseline
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One study reported a statistically significant advantage for 400 mg
mannitol over control in terms of the absolute change from base-
line in FEV1 (% predicted), MD 3.42 (95% CI 1.13 to 5.71, P =
0.003) (Analysis 2.1) (low-quality evidence) (de Boeck 2017). The
second study recorded FEV1 as the absolute change from baseline
in mL and % predicted (Jaques 2008). A statistically significant
improvement in participants on mannitol compared to control
was observed for both measures; MD FEV1 119 mL, P value for
difference = 0.01 and MD FEV1 3.95% predicted, P value for
difference < 0.01 (Table 6, low-quality evidence).
Subgroup analysis - age (absolute change from baseline)
The de Boeck study also reported a statistically significant advan-
tage in the absolute change from baseline in FEV1 (% predicted)
for 400mgmannitol over control in both age subgroups (de Boeck
2017); aged 6 to 11 years, MD 3.78 (95% CI 0.13 to 7.43, P =
0.04) and aged 12 to 17 years, MD 3.35 (95% CI 0.14 to 6.56,
P = 0.04) (Analysis 2.2).
Subgroup analysis - dornase alfa use (absolute change from base-
line)
The de Boeck study also reported a statistically significant advan-
tage in the absolute change from baseline in FEV1 (% predicted)
for 400 mg mannitol over control in both dornase alfa subgroups
(de Boeck 2017); dornase alfa users, MD 3.29 (95% CI 0.28 to
6.30, P = 0.03) and dornase alfa non-users, MD 3.92 (95% CI
0.42 to 7.42, P = 0.03) (Analysis 2.3).
Relative change from baseline
One study reported a statistically significant advantage for 400
mg mannitol over control in terms of the relative change from
baseline in FEV1 (% predicted) (de Boeck 2017), MD 4.97%
(95% CI 1.52 to 8.42, P = 0.005) (Analysis 2.4) (low-quality
evidence). The study also reported that subgroup results (including
age and dornase alfa use) were consistent with the overall treatment
difference for this endpoint, but did not present numerical results
(de Boeck 2017).
b. FVC (mL or % predicted)
Absolute change from baseline
One study reported no statistically significant difference between
the treatment groups in terms of the absolute change frombaseline
in FVC (% predicted) (de Boeck 2017), MD 1.80% (95% CI -
0.72 to 4.32, P = 0.16) (Analysis 2.5) (low-quality evidence). Fur-
thermore, de Boeck also reported that subgroup results (including
age and dornase alfa use) were consistent with the overall treat-
ment difference for this endpoint, but did not present numerical
results (de Boeck 2017).
The second study found no statistically significant difference in
absolute change in FVC (mL) between mannitol and control (
Jaques 2008), MD 70 mL, P value for difference = 0.16 (Table 6)
(low-quality evidence).
Relative change from baseline
One study reported no statistically significant difference between
the treatment groups in terms of the relative change from baseline
in FVC (% predicted) (de Boeck 2017), MD 2.54% (95% CI
-0.72 to 5.80, P = 0.13) (Analysis 2.6) (low-quality evidence).
Investigators also reported that subgroup results (including age
and dornase alfa use) were consistent with the overall treatment
difference for this endpoint, but did not present numerical results
(de Boeck 2017).
c. FEF25−75 (mL/s or % predicted)
Absolute change from baseline
One study reported a statistically significant advantage in the ab-
solute change from baseline in FEF25−75 (% predicted) for 400
mg mannitol over control (de Boeck 2017), MD 5.75% (95%
CI 1.81 to 9.69, P = 0.004) (Analysis 2.7) (low-quality evidence).
Investigators also reported that subgroup results (including age
and dornase alfa use) were consistent with the overall treatment
difference for this endpoint, but did not present numerical results
(de Boeck 2017).
The second study reported a statistically significant improvement
in absolute FEF25−75 (mL/s) duringmannitol treatment compared
with control (Jaques 2008 ), MD 160 mL/s, P value for difference
= 0.03 (Table 6) (low-quality evidence).
Relative change from baseline
One study reported a statistically significant advantage for 400 mg
mannitol over control in terms of the relative change from baseline
in FEF25−75 (% predicted) (de Boeck 2017), MD 10.52% (95%
CI 2.31 to 18.73, P = 0.01) (Analysis 2.8) (low-quality evidence).
Investigators also reported that subgroup results (including age
and dornase alfa use) were consistent with the overall treatment
difference for this endpoint, but did not present numerical results
(de Boeck 2017).
3. Adverse events relating to treatment
Due to the cross-over designs of both of the studies, no data re-
garding adverse events is entered into analysis for either study (de
Boeck 2017; Jaques 2008). Adverse events are summarised narra-
tively in additional tables (Table 7; Table 8; Table 9) (low-quality
evidence).
a. type and number of adverse events defined as mild,
moderate or severe
The de Boeck study reported treatment-emergent adverse events
(TEAEs) and serious adverse events (SAEs) during the study period
(de Boeck 2017); there were similar rates in the 400 mg mannitol
and control groups, 62.1% versus 59.8% respectively for TEAEs
and 11.5% versus 14.9% respectively for SAEs (Table 8). Rates of
treatment-related adverse events during the study period were also
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similar in the 400 mg mannitol and control groups, 18.4% versus
12.6%respectively; and treatment-related SAEswere rare,only one
occurred in the control group (Table 8).
In terms of specific TEAEs, investigators reported on the ’most
common’ events which occurred in at least 5% of participants
in either treatment group (de Boeck 2017). Cough, headache,
nasopharyngitis and lung infections occurred in either equal or
greater frequency in the control arm compared to the 400 mg
mannitol arm (Table 9). Rates of pulmonary exacerbations are
discussed below in ’Secondary outcomes’.
Study investigators reported that the majority of adverse events
were mild or moderate with only four (4.6%) participants in the
mannitol arm and three (3.4%) participants in the placebo arm
experiencing severe adverse events (de Boeck 2017). The severe
events reported included abdominal pain, anal fistula, pyrexia,
tonsillitis, gingivitis, headache, migraine, cough and respiratory
distress. No instances of severe bronchospasm were reported and
haemoptysis was uncommon, occurring in three participants tak-
ing mannitol and two taking placebo. All haemoptysis events were
either scant or mild.
Jacques reported adverse events considered possibly or probably
related to treatment and classified in the published paper as severe
or not severe, but the classifications are not defined (Jaques 2008).
It was later confirmed by Pharmaxis that the definitions used in
this study were the same as in the two later parallel studies and as
detailed above (Aitken 2012; Bilton 2011). In the published paper,
a total of 19 adverse events were reported in 38 participants during
mannitol treatment, 17 of these were classed as not severe and two
as severe. A further 10 adverse events were reported in 36 partic-
ipants receiving the control treatment, eight of these were classed
as not severe and two as severe. The most common adverse events
measured across both groups were cough, haemoptysis, pharyngo-
laryngeal pain and chest discomfort (Table 7). During mannitol
treatment, cough was the most common adverse event and during
the control period haemoptysis was the most common. The pa-
per reported that seven serious adverse events occurred during the
study, but none were considered by the investigator to be related
to treatment and none resulted in death.
Pharmaxis further stated that a total of five (13.2%) participants
reported six severe adverse events (all adverse events - not just those
considered to be possibly or probably treatment-related and de-
fined as incapacitating or leading to participants being unable to
do usual activities) and two (5.6%) participants reported one se-
vere adverse event each in the control group. There were three par-
ticipants who withdrew due to adverse events; one each for lower
respiratory tract infection and liver transplant in the mannitol
group, and one in the control group due to their condition being
aggravated. Pharmaxis confirmed that there were no treatment-
related serious adverse events (defined as a reaction that results in
death, is life-threatening, requires hospitalisation or prolongation
of existing hospitalisation, results in persistent or significant dis-
ability or incapacity, or is a congenital anomaly or birth defect).
b. number of participants who ceased inhalations because of
poor tolerability, e.g. cough or bronchoconstriction
It was reported by de Boeck that three participants (two in the 400
mgmannitol group and one in the control group) withdrew due to
adverse events (de Boeck 2017); and that these adverse events were
treatment-related in the two participants in the 400 mg mannitol
group (see Table 8). Specifically, reasons listed for withdrawal from
the study were dizziness, cough and oropharyngeal pain (Table 9).
The published paper by Jacques states that none of the reasons
given for participants stopping treatment (a liver transplant and a
lower respiratory tract infection in the mannitol arm; and aggra-
vation of CF symptoms in the placebo arm) were considered to be
related to tolerability (Jaques 2008).
Secondary outcomes
1. Pulmonary exacerbations
One study reported on infective pulmonary exacerbations of CF
(de Boeck 2017); these occurred less frequently in the 400 mg
mannitol group (11.5%) compared to the control arm (16.1%)
(Table 9).
The second study did not report the occurrence of pulmonary
exacerbations, but the published paper did note the aggravation of
CF symptoms in three out of 38 (7.9%) participants being treated
with mannitol (none were considered related to treatment) and
no participants in the control treatment phase (Jaques 2008). No
additional data were available; however, in such a short study, it
would be unlikely that this outcome would be assessed.
2. Time off school or work
Neither study reported either time off work or school (de Boeck
2017; Jaques 2008).
3. Need for additional non-routine antibiotics
Neither study reported the need for additional intravenous, oral
or inhaled antibiotics (de Boeck 2017; Jaques 2008).
4. Hospitalisations
Neither study reported details of hospitalisations (de Boeck 2017;
Jaques 2008).
5. Assessment of symptoms
a. sputum weight
One study reported a statistically significant advantage for 400
mg mannitol over control in terms of sputum weight post-initial
treatment (de Boeck 2017), MD 1.33 g (95% CI 0.29 to 2.37, P
= 0.01) (Analysis 2.9).
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b. other measures
Results for respiratory domain of the CFQ-R from the Jacques
study are reported in the HRQoL section above (Jaques 2008).
Investigators assessed symptoms using a standard set of questions
(produced specifically for the study and not validated) (Jaques
2008). The questionnaire concentrated on participant-perceived
severity of respiratory symptoms (e.g. breathlessness, cough, mu-
cus production, congestion, fatigue and discomfort) using a two-
week recall period and also sinus and nasal symptoms (e.g. post-
nasal drip, sore throat, sinus headache and pressure, nasal itch,
nasal blockage, loss of smell, and mucus colour and production)
using a 24-hour recall period. Responses were obtained before and
after each treatment arm. The published paper stated that after ad-
justing for the cross-over design, the change in respiratory symp-
tom scores for mannitol was MD -0.91 (95% CI -2.1 to 0.2) and
for control it was MD 0.39 (95% CI -0.8 to 1.5) and that there
were no significant differences between treatment arms.
6. Sputum microbiology
Only one study reported on this outcome (Jaques 2008). Inves-
tigators noted that there was no difference from baseline in ei-
ther treatment arm after two weeks of treatment with regards to
the acquisition or loss of the following micro-organisms: Pseu-
domonas aeruginosa, Staphyloccocus aureus,Haemophilis influenzae,
Aspergillus spp, Candida albicans and Mycobacterium. There was
no increase or decrease in the qualitative bacterial growth of respi-
ratory isolates from baseline. Specific data per pathogen were not
recorded.
7. Burden of treatment
Neither study reported on burden of treatment according to a
validated measure (de Boeck 2017; Jaques 2008).
Only one study reported on adherence which was measured by
counting returned empty capsules and defined as more than 70%
of the maximum dose used during the two-week treatment period
(Jaques 2008). According to this definition, 37 out of 39 partici-
pants taking mannitol and 33 out of 39 taking the control treat-
ment were adherent to treatment. The median time to complete
treatment with either mannitol or control was five minutes (in-
terquartile range three to 10 minutes) (Jaques 2008).
Mannitol versus control - parallel study of individuals
with cystic fibrosis, hospitalised due to pulmonary
exacerbations
One parallel pilot study of 22 participants compared 400mgman-
nitol (twice daily) to a control treatment (very low-dose (50 mg)
non-respirable mannitol) (Middleton 2015). Treatment was ad-
ministered for 12 consecutive days and outcome measures were
reported at 14 days (hospital discharge) and at one month of fol-
low-up.
Primary outcomes
1. HRQoL
Investigators measured HRQoL using the Cystic Fibrosis Clini-
cal Score (CFCS) and the CFQ-R respiratory domain (Middleton
2015). There were no statistically significant differences between
the treatment groups in terms of CFCS total score at hospital dis-
charge, MD 1.10 (95% CI -0.50 to 2.70, P = 0.18) or at one
month follow-up, MD -1.00 (95% CI -4.10 to 2.10, P = 0.53)
(Analysis 3.1) (very low-quality evidence). There were also no sta-
tistically significant differences in the CFQ-R respiratory domain
at hospital discharge, MD 1.30 (95% CI -10.50 to 13.10, P =
0.83) or at one month follow-up, MD 3.50 (95% CI -10.70 to
17.70, P = 0.63) (Analysis 3.2) (very low-quality evidence).
2. Lung function
The only study in this comparison reported three measures of lung
function (% predicted) (Middleton 2015).
a. FEV1 (% predicted)
Therewere no statistically significant differences between the treat-
ment groups in terms of FEV1 % predicted at hospital discharge,
MD 4.60% predicted (95% CI -3.80 to 13.00, P = 0.28) or at one
month follow-up, MD 5.40% predicted (95% CI -2.70 to 13.50,
P = 0.19) (Analysis 3.3) (low-quality evidence).
b. FVC (mL or % predicted)
Therewere no statistically significant differences between the treat-
ment groups in FVC % predicted at hospital discharge, MD
2.80%predicted (95%CI -3.60 to 9.20, P = 0.39) or at onemonth
follow-up,MD1.70% predicted (95%CI -4.10 to 7.50, P = 0.57)
(Analysis 3.4) (low-quality evidence).
c. FEF25−75 (mL/s or % predicted)
Therewere no statistically significant differences between the treat-
ment groups in terms of FEF25−75 % predicted at hospital dis-
charge, MD 12.80% predicted (95% CI -3.30 to 28.90, P = 0.12)
or at one month follow-up,MD3.90% predicted (95%CI -10.70
to 18.50, P = 0.60) (Analysis 3.5) (low-quality evidence).
3. Adverse events relating to treatment
The included study reported that inhaled dry-powder mannitol
was well tolerated and that no serious adverse events occurred
(Middleton 2015).
The authors provided unpublished presentation slides of the study
which outline specific adverse events. Vomiting (mucous) occurred
in one participant in each treatment group, haemoptysis (flecks
only) and blurred vision each occurred in one participant in the
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control group and dizziness and headaches occurred in one par-
ticipant in the 400 mg mannitol group (low-quality evidence).
Due to the small number of adverse events and as we had no
information regarding the severity of these reported events and
whether the events could be related to treatment, we did not enter
these data into the analysis.
Secondary outcomes
1. Pulmonary exacerbations
The participants recruited into the study were hospitalised dur-
ing the first 14 days of the study due to pulmonary exacerbation
(Middleton 2015). It was not reported whether any further pul-
monary exacerbations occurred in any participants while in hos-
pital or during the one month follow-up.
2. Time off school or work
The included study did not report time off school or work
(Middleton 2015).
3. Need for additional non-routine antibiotics
The included study did not report the use of additional non-
routine antibiotics (Middleton 2015).
4. Hospitalisations
The participants recruited into the study were hospitalised during
the first 14 days of the trial due to pulmonary exacerbation and
investigators did not report if any participants were re-admitted
to hospital during the one month follow-up (Middleton 2015).
5. Assessment of symptoms (including cough, sputum
volume, ease of expectoration and dyspnoea)
The study did not report any measures of assessment of symptoms
(Middleton 2015).
6. Sputum microbiology (change in numbers of pathogens,
emergence of new pathogens)
The study did not report on sputum microbiology (Middleton
2015).
7. Burden of treatment
The study did not report on burden of treatment (Middleton
2015).
Mannitol versus dornase alfa - cross-over study of
individuals with cystic fibrosis
One cross-over study compared 400 mg mannitol (twice daily) to
2.5 mg dornase alfa (once daily) (Minasian 2010). This study also
had a third arm, described below, which compared mannitol plus
dornase alfa to dornase alfa alone. Each arm lasted 12 weeks.
Note: this was a per protocol analysis, 28 participants were ran-
domised to treatment and 20 completed all three treatment peri-
ods in the three-arm cross-over study.
Primary outcomes
1. HRQoL
Again, it should be noted that while ’Burden of treatment’ is part
of the QoL assessment, these results are presented under a separate
outcome below (Secondary outcome 7). As stated above, mannitol
has a negative effect on some QoL scores due to its mode of action
with regards to sputum production.
The included study measured this outcome using the CFQ-R, but
did not report results in the published paper (Minasian 2010).
Pharmaxis provided additional data on the respiratory domain for
the age-specific questionnaires: adolescent and adult; children 12
to 13 years; children six to 11 years; parents and caregivers; and
overall. However, these additional data did not allow any further
comparison between treatment arms (Table 10, very low-quality
evidence).
2. Lung function
We were only able to use the data on % change from baseline in
lung function from this study in our analysis (Minasian 2010).
We note there may be minor discrepancies between our results (no
difference in statistical significance) and the publication, these are
likely due to the analysis of FEV1 using a log scale. Please see the
additional tables for further absolute data provided by Pharmaxis
which could not be analysed in this review (Table 11).
a. FEV1 (mL or % predicted)
Using data reported in the published paper, our analysis found no
significant difference in themean%change inFEV1 (mL) between
the mannitol and dornase alfa groups at up to three months, MD
2.80 (95% CI -4.80 to 10.40, P = 0.47) (Analysis 4.1) (very low-
quality evidence); data for FEV1 % predicted were not available.
The published paper reported that mannitol was as effective as
dornase alfa (Minasian 2010).
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b. FVC (mL or % predicted)
Using data reported in the published paper, we found no signifi-
cant difference in the mean % change in FVC (mL) between the
mannitol and dornase alfa groups at up to three months, MD 0.14
(95% CI -0.02 to 0.30, P = 0.08) (Analysis 4.2) (very low-quality
evidence). Again, the published paper reported that mannitol was
as effective as dornase alfa (Minasian 2010).
c. FEF25−75 (mL/s or % predicted)
Using data reported in the published paper, we found no signif-
icant difference in the mean % change in FEF25−75 (mL/s) be-
tween the mannitol and dornase alfa groups at up to three months
(MD -0.01, 95% CI -0.23 to 0.21, P = 0.93) (Analysis 4.3) (very
low-quality evidence). The published paper reported that manni-
tol was as effective as dornase alfa (Minasian 2010).
3. Adverse events relating to treatment
a. type and number of adverse events defined as mild,
moderate or severe
The included study used the MedDRA classification of mild,
moderate and severe adverse events and considered that the re-
ported adverse events were possibly or probably related to treat-
ment (Minasian 2010). In the original publication, investigators
reported that six out of the eight participants who withdrew re-
ported a troublesome cough (three of these also had evidence of a
chest exacerbation) and one of the eight reported nausea (Minasian
2010).
Dr Minasian also provided some additional data, but in the form
of the total number of adverse events rather than the number of
participants experiencing an adverse event. Hence, we are unable
to present these data in the meta-analysis (Minasian 2010). How-
ever, we also received additional data on the number of events
from Pharmaxis which we have presented in the additional tables
(Table 12; Table 13, very low-quality evidence); we note that in
Table 13 for brevity some adverse effects are grouped into system
organ class definitions and therefore do not match exactly the def-
initions of individual adverse effects as described in Table 12. A
total of 12 out of 23 participants in the mannitol arm and one out
of 21 participants in the dornase alfa arm experienced a TEAE.
The most common treatment-related adverse events in the man-
nitol arm were cough and CF exacerbation (Table 12). Addition-
ally, Pharmaxis confirmed that most events were either mild or
moderate.
b. number of participants who ceased inhalations because of
poor tolerability, e.g. cough or bronchoconstriction
The flow diagram in the published papers states that eight partic-
ipants withdrew from the study, mainly because of troublesome
cough associatedwithmannitol treatment (Minasian 2010).How-
ever, the text of the paper states that eight participants withdrew
during the study; the primary reason cited for six participants was
troublesome cough (in three of these participants there was evi-
dence of a chest exacerbation at the time of withdrawal), in one
child the primary reason was nausea and in another child the pri-
mary reason was treatment burden. Furthermore, treatment bur-
den was reported as a contributory factor in two of the eight par-
ticipants in whom cough was the main problem. In contrast, the
additional information provided by Pharmaxis states that eight
participants withdrew from the study, six of whom cited trou-
blesome cough. Two participants withdrew before receiving ran-
domised treatment and of the remaining six participants, not all of
them recorded an adverse event which led to withdrawal. For these
participants withdrawal was described as “subject decision” and all
participants who stopped treatment withdrew from the study.
Secondary outcomes
1. Pulmonary exacerbations
The additional Pharmaxis data stated that by 12 weeks, three out
of 23 (13%) participants in the mannitol group and three out of
21 (14.3%) participants in the dornase alfa arm experienced an
exacerbation and that there was no significant difference between
mannitol and dornase alfa.We did not have sufficient information
to adjust for the cross-over design in our analysis.
2. Time off school or work
The study did not report time off school or work (Minasian 2010).
3. Need for additional non-routine antibiotics
a. intravenous antibiotics
The additional Pharmaxis data for pulmonary exacerbations (de-
fined as requiring treatment with intravenous antibiotics) suggests
that during the 12-week study period, three out of 23 (13.0%)
participants in the mannitol arm of the study and three out of 21
(14.3%) participants in the dornase alfa arm required additional
intravenous antibiotics. We did not have sufficient information to
adjust for the cross-over design in our analysis.
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b. oral antibiotics
The study did not report the use of additional oral antibiotics
(Minasian 2010).
c. inhaled antibiotics
The study did not report the use of additional inhaled antibiotics
(Minasian 2010).
4. Hospitalisations
a. number of hospitalisations
No data relating to the hospitalisation of participants were pub-
lished (Minasian 2010). From the additional Pharmaxis data, nine
out of 26 participants who received the study drug were hospi-
talised for CF exacerbations and treatment with intravenous an-
tibiotics, but it is not stated how these were distributed between
the groups.
b. duration of hospitalisation
Pharmaxis reported that the duration of hospitalisation for the
nine participants ranged from four to 21 days.
5. Assessment of symptoms (including cough, sputum
volume, ease of expectoration and dyspnoea)
Pharmaxis provided additional data from the study on the respi-
ratory domain for the following age-specific questionnaires: ado-
lescent and adult; children 12 to 13 years; children six to 11 years;
parents and caregivers; and overall (Minasian 2010). However,
these additional data did not allow any further analyses.
Symptomswere also assessed in a ’Respiratory SymptomandTreat-
ment Effects’ questionnaire devised by the investigators (a copy has
been provided to the authors of this review), but the results were
not published. Pharmaxis provided symptom scores for the Mi-
nasian study at 12 weeks and the net change from baseline (num-
ber improved minus number worsened) was determined. The net
change was in favour of mannitol for chest symptoms, tiredness,
amount of sputum and coughing. The net change was in favour
of the dornase alfa arm for breathlessness.
6. Sputum microbiology (change in numbers of pathogens,
emergence of new pathogens)
The Pharmaxis data reported “no notable changes”; further details
are presented in the additional tables (Table 14). We did not have
sufficient information to adjust for the cross-over design in our
analysis.
7. Burden of treatment
Burden of treatment would have been determined as part of the
CFQ-R in the Minasian study, but the results from this question-
naire were not reported (Minasian 2010). One participant with-
drew from the study because of the burden of treatment, but it is
not reported in the paper at which stage of study this occurred.
Adherence over the 12 weeks of treatment was estimated using re-
turned empty packs and vials.The published paper states that ad-
herence was greater than 70% in 14 out of 19 participants receiv-
ing mannitol and in 13 out of 19 participants receiving dornase
alfa; there was no significant difference between treatment arms.
One participant did not return the pack (Minasian 2010). We did
not have sufficient information to adjust for the cross-over design
in our analysis.
Mannitol plus dornase alfa compared with dornase
alfa - cross-over study of individuals with cystic fibrosis
The Minasian study also compared 400 mg of mannitol (twice
daily) plus 2.5 mg dornase alfa (once daily) with 2.5 mg dornase
alfa alone (once daily) as part of the same cross-over study with 12
weeks in each arm (Minasian 2010).
Note: this was a per protocol analysis, 28 participants were ran-
domised to treatment and 20 completed all three treatment peri-
ods in the three-arm cross-over study. We present data below for
the mannitol plus dornase alfa arm versus the dornase alfa arm.
Primary outcomes
1. HRQoL
Again, please note that while ’Burden of treatment’ is part of the
QoL assessment, these results are presented under a separate out-
come below (secondary outcome 7) and that as already statedman-
nitol has a negative effect on QoL scores due to its mode of action
with regards to sputum production.
Although investigators measured HRQoL using the CFQ-R, they
did not publish the results (Minasian 2010). Pharmaxis provided
additional data on the respiratory domain for age-specific ques-
tionnaires, but these did not allow any further comparison be-
tween treatment arms (Table 10; very low-quality evidence).
2. Lung function
Wewere only able to use the data reporting%change frombaseline
in lung function from this study in our analysis (Minasian 2010).
We note there may be minor discrepancies between our results (no
difference in statistical significance) and the publication, these are
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likely due to the analysis of FEV1 using a log scale. We present
the additional data provided by Pharmaxis which could not be
analysed in the additional tables (Table 11).
a. FEV1 (mL or % predicted)
Using data reported in the published paper, we found no signifi-
cant difference in the mean % change in FEV1 (mL) between the
mannitol plus dornase alfa group and the group receiving dornase
alfa alone, MD -4.30 (95% CI -14.10 to 5.50, P = 0.39) (Analysis
5.1) (very low-quality evidence).
b. FVC (mL or % predicted)
Using data reported in the published paper, we found no signifi-
cant difference in the mean % change in FVC (mL) between the
mannitol plus dornase alfa group and the group receiving dornase
alfa alone, MD -0.07 (95% CI -0.30 to 0.16, P = 0.55) (Analysis
5.2) (very low-quality evidence).
c. FEF25−75 (mL/s or % predicted)
Using data reported in the published paper, we found no signif-
icant difference in the mean % change in FEF25−75 (mL/s) be-
tween the mannitol plus dornase alfa group and the group receiv-
ing dornase alfa alone (MD 0.03, 95%CI -0.18 to 0.24, P = 0.78)
(Analysis 5.3) (very low-quality evidence).
3. Adverse events relating to treatment
a. type and number of adverse events defined as mild,
moderate or severe
The study used the MedDRA classification of mild, moderate and
severe adverse events and considered that the reported adverse
events were possibly or probably related to treatment (Minasian
2010). Pharmaxis provided additional data for the total number
of participants experiencing an adverse event for this study, which
we have presented in the additional tables (Table 12; Table 13)
(very low-quality evidence); we note that in Table 13 for brevity
some adverse effects are grouped into systemorgan class definitions
and therefore do not match exactly the definitions of individual
adverse effects as described in Table 12. A total of 14 out of 23
participants in the mannitol plus dornase alfa arm experienced
treatment-emergent adverse events and one out of 21 participants
in the dornase alfa alone arm (Table 12).
b. number of participants who ceased inhalations because of
poor tolerability, e.g. cough or bronchoconstriction
Eight participants withdrew from the study because of trouble-
some cough associated with mannitol treatment. However, the ad-
ditional data from Pharmaxis stated that while two participants
from the mannitol arm plus dornase alfa arm had adverse events
(one each of cough and gastrointestinal disorder) leading to with-
drawal, this was not the case for any participant in the dornase alfa
arm.
Secondary outcomes
1. Pulmonary exacerbations
Minasian recorded pulmonary exacerbations, but did not publish
these results in the paper (Minasian 2010). Additional data pro-
vided by Pharmaxis, stated that six out of 23 (26.1%) participants
in the mannitol plus dornase alfa arm experienced an exacerbation
compared with three out of 21 (14.3%) in the dornase alfa alone
arm and that there was no significant difference between mannitol
and dornase alfa. We did not have sufficient information to adjust
for the cross-over design in our analysis.
2. Time off school or work
The study did not report time off school or work (Minasian 2010).
3. Need for additional non-routine antibiotics
a. intravenous antibiotics
Investigators measured the need for additional antibiotics but did
not report any data (Minasian 2010). The additional Pharmaxis
data for pulmonary exacerbations (defined as requiring treatment
with intravenous antibiotics) suggests that three out of 23 partici-
pants (13.0%) in themannitol plus dornase alfa arm and three out
of 21 participants (14.3%) receiving dornase alfa alone required
additional antibiotics during the 12-week study. We did not have
sufficient information to adjust for the cross-over design in our
analysis.
b. oral antibiotics
The study did not report the use of additional oral antibiotics
(Minasian 2010).
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c. inhaled antibiotics
The study did not report the use of additional inhaled antibiotics
(Minasian 2010).
4. Hospitalisations
From the additional Pharmaxis data, nine of 26 participants who
received the study drug were hospitalised for a CF exacerbation
and treated with intravenous antibiotics, but it is not stated how
these cases were distributed between the groups. We did not have
sufficient information to adjust for the cross-over design in our
analysis.
5. Assessment of symptoms (including cough, sputum
volume, ease of expectoration and dyspnoea)
Symptoms were assessed in a ’Respiratory Symptom and Treat-
ment Effects’ questionnaire devised by the study investigators (a
copy has been provided to the authors of this review), but the
results were not reported (Minasian 2010). Pharmaxis provided
symptom scores at 12 weeks and the net change from baseline
(number improved minus number worsened) was determined.
This favouredmannitol plus dornase alfa for a reduction in cough-
ing, but favoured dornase alfa alone for a reduction in chest symp-
toms and tiredness.
6. Sputum microbiology (change in numbers of pathogens,
emergence of new pathogens)
Sputummicrobiology was measured, but not published (Minasian
2010); the additional data from Pharmaxis reported “no notable
changes”. Further details are presented in the additional tables
(Table 14), We did not have sufficient information to adjust for
the cross-over design in our analysis.
7. Burden of treatment
Burden of treatment would have been determined as part of the
CFQ-R, but the results from this questionnaire were not available (
Minasian 2010).One participantwithdrew from the study because
of the burden of treatment, but it is not reported at which stage of
study this occurred or which treatment arm this participant was
in or had completed. In addition, two participants who withdrew
from the study reported that although cough had been the main
problem, treatment burden was a contributory factor (treatment
arms ongoing or completed were not stated).
Adherence over 12 weeks of treatment was estimated using re-
turned empty packs and vials. The published paper reported that
adherence was greater than 70% in 17 out of 19 participants re-
ceiving mannitol plus dornase alfa and in 13 out of 19 participants
receiving dornase alfa alone (Minasian 2010). One participant did
not return the pack. We did not have sufficient information to
adjust for the cross-over design in our analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Inhaled mannitol compared with control (non- respirable mannitol) for CF
Patient or population: adults, children and young people with CF
Settings: outpat ients
Intervention: inhaled mannitol
Comparison: non-respirable mannitol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Non- respirable manni-
tol
Inhaled mannitol
HRQoL - all domains
(change from baseline)
Scale: age-appropriate
versions of the CFQ-R
quest ionnaire
Follow-up: 2 weeks
At the end of the study there were no signif -
icant dif f erences between mannitol and con-
trol for the respiratory, health, physical and
vitality domains
NA 391
1 cross-over study
⊕©©©
very low1,2,3
Lung function: FEV1mL
(absolute change from
baseline)
Follow-up: 2 weeks
A stat ist ically signif icant improvement on
mannitol compared to control was observed
NA 391
1 study
⊕⊕©©
low1,2
Lung function: FEV1
% predicted (change
from baseline)
Follow-up: 2 weeks to 8
weeks
One study showed a stat ist ically signif icant
improvement in absolute change f rom base-
line on mannitol compared to control at 2
weeks
The second study showed stat ist ically signif -
icant improvement in both absolute and rela-
t ive change f rom baseline on mannitol com-
pared to control at 8 weeks
NA. 1261
2 cross-over studies
⊕⊕©©
low1,2
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Lung function: FVC mL
or % predicted (change
from baseline)
Follow-up: 2 weeks to 8
weeks
No stat ist ically signif icant dif f erences in ab-
solute or relat ive change f rom baseline in FVC
(mL or %predicted) were found in either study
NA 1261
2 cross-over studies
⊕⊕©©
low1,2
Lung func-
tion: FEF25−75 mL/s or
% predicted (change
from baseline)
Follow-up: 2 weeks to 8
weeks
One study showed a stat ist ically signif icant
improvement in absolute change f rom base-
line in FEF25−75 (mL/ S) on mannitol compared
to control at 2 weeks.
The other study showed stat ist ically signif i-
cant improvement in both absolute and rela-
t ive change f rom baseline in in FEF25−75 (%
predicted) on mannitol compared to control
at 8 weeks.
NA 1261
2 cross-over studies
⊕⊕©©
low1,2
Adverse events relat-
ing to treatment
Scale: m ild, moderate,
severe and total
Follow-up: 2 weeks to 8
weeks
The most commonly reported adverse events
in both groups in the two studies were cough,
haemoptysis, headache, nasopharyngit is and
lung infect ions
NA 123-1254
2 cross-over studies
⊕⊕©©
low1,2
Frequencies of adverse
events according to
severity and associa-
t ion to treatment only
were reported, a stat ist i-
cal comparison was not
made in either study
* The basis of the assumed risk and the corresponding risk is described in the comments. The study authors adjusted for the cross-over design of the study via a mixed
model of analysis of variance when analysing and present ing results, however the format of the presented data does not allow us to perform analyses in this review. Published
results f rom the study paper are presented
CF: cyst ic f ibrosis;CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised version; CI: conf idence interval; FEF25−75: m id-expiratory f low; FEV1: f orced expiratory volume at one second;
FVC: f orced vital capacity; HRQoL: health-related quality of lif e; NA: not applicable.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1. In one of the studies it was stated that 39 part icipants were randomised, unclear how many were evaluated for each
outcome. In the other study, the study may have been underpowered and imputat ion of m issing data may have introduced
bias (evidence downgraded due to risk of bias of incomplete outcome data).
2. Evidence downgraded due to indirectness: the part icipant populat ion included only those with CF who passed the tolerance
test and not all potent ial part icipants with CF.
3. Evidence downgraded due to indirectness: the CFQ-R tool used in the studies was not designed to assess mucolyt ics. Also,
pooling of the age-appropriate tools may not be valid so results should be interpreted with caut ion.
4. One of the studies, adverse event data available for 38 and 36 part icipants in the mannitol and control groups respect ively.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Inhaled mannitol compared with control (non- respirable mannitol) for people with cystic fibrosis, hospitalised due to pulmonary exacerbations
Patient or population: children and young people with CF
Settings: children and young people hospitalised due to pulmonary exacerbat ions (14 days) and up to 1 month of outpat ient follow-up
Intervention: inhaled mannitol
Comparison: non-respirable mannitol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Non- respirable manni-
tol
Inhaled mannitol
HRQoL - change from
baseline in CFCS total
score and CFQ-R respi-
ratory domain
Follow-up: up to 1
month
There was no stat ist ically signif icant dif f erence
in the change f rom baseline in HRQoL (CFCS total
score or CFQ-R respiratory domain) at hospital
discharge or at 1 month follow-up
NA 22
1 study
⊕©©©
very low1,2,3
Lung function: FEV1
mL%predicted (change
from baseline)
Follow-up: NA
Outcome not reported. NA
Lung function: FEV1
% predicted (change
from baseline)
Follow-up: up to 1
month
The mean dif ference in the change f rom base-
line in FEV1 (% predicted in the mannitol group
compared to the control group was 4.60%higher
(3.80% lower to 13.00% higher) at hospital dis-
charge and 5.40%higher (2.70% lower to 13.50%
higher) af ter 1-month follow-up
NA 22
1 study
⊕⊕©©
low1,2
3
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Lung function: FVC
% predicted (change
from baseline)
Follow-up: up to 1
month
The mean dif ference in the change f rom baseline
in FVC (% predicted in the mannitol group com-
pared to the control group was 2.80% higher (3.
60% lower to 9.20%higher) at hospital discharge
and 1.70% higher (4.10% lower to 7.50% higher)
af ter 1-month follow-up
NA 22
1 study
⊕⊕©©
low1,2
Lung function:
FEF25−75 % predicted
(change from baseline)
Follow-up: up to 1
month
The mean dif ference in the change f rom baseline
in FEV1 (% predicted in the mannitol group com-
pared to the control group was 12.80% higher
(3.30% lower to 28.90% higher) at hospital dis-
charge and 3.90% higher (-10.70% lower to 18.
50% higher) af ter 1-month follow-up
NA 22
1 study
⊕⊕©©
low1,2
Adverse events relat-
ing to treatment
Follow-up: up to 1
month
Vomit-
ing (mucous) haemop-
tysis (f lecks only) and
blurred vision each oc-
curred in one part ic-
ipant in the control
group
Vomit-
ing (mucous), dizziness
and headaches each
occurred in one part ici-
pant in the 400mg man-
nitol group
NA 22
1 study
⊕⊕©©
low1,2
Also stated that no seri-
ous adverse events oc-
curred.
Severity and relat ion-
ship to treatment not
stated.
* The basis for the assumed risk is the range of mean values in the control group and the corresponding risk (and its 95% conf idence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervent ion (and its 95% CI).
CF: cyst ic f ibrosis; CFCS: Cyst ic Fibrosis Clinical Score;CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised version, CI: conf idence interval; FEF25−75: m id-expiratory f low; FEV1:
f orced expiratory volume at one second; FVC: f orced vital capacity; HRQoL: health-related quality of lif e; NA: not applicable.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. Evidence downgraded due to indirectness: the part icipant populat ion included only those with CF who passed the tolerance
test and not all potent ial part icipants with CF. The populat ion recruited into the study were hospitalised, so results may not
be applicable to all individuals with CF.
2. Evidence downgraded due to imprecision: small sample size and wide conf idence intervals around the ef fect size.3
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3. Evidence downgraded due to indirectness: the CFQ-R tool used in the studies was not designed to assess mucolyt ics. Also,
pooling of the age-appropriate tools may not be valid so results should be interpreted with caut ion.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Inhaled mannitol compared with dornase alfa for CF
Patient or population: children and young people with CF
Settings: outpat ients
Intervention: inhaled mannitol
Comparison: dornase alfa
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Dornase alfa Inhaled mannitol
HRQoL - all domains
(change from baseline)
Scale: age-appropriate
versions of the CFQ-R
quest ionnaire
Follow-up: up to 3
months
No signif icant dif f erences were found between
treatment groups for any domains of the CFQ-R
NA up to 231
1 cross-over study
⊕©©©
very low1,2,3
Lung function: FEV1mL
(percentage change
from baseline)
Follow-up: up to 3
months
Themean (SD) absolute
change f rom baseline in
the dornase alfa group
was 84 (273) mL
Themean (SD) absolute
change f rom baseline in
the mannitol group was
-1 (279) mL
MD 2.80%
(95% CI: -4.80% to 10.
40%).
up to 231
1 cross-over study
⊕©©©
very low1,2
Only the relat ive ef fect
of percentage change
f rom baseline could be
analysed*
Lung function: FEV1 %
predicted
Follow-up: NA
Outcome not reported. NA
Lung function: FVC mL
(percentage change
from baseline)
Follow-up: up to 3
months
Themean (SD) absolute
change f rom baseline in
the dornase alfa group
was 7 (415) mL
Themean (SD) absolute
change f rom baseline in
the mannitol group was
-58 (361) mL
MD 0.14%
(95% CI: -0.02% to 0.
30%).
up to 231
1 cross-over study
⊕©©©
very low1,2
Only the relat ive ef fect
of percentage change
f rom baseline could be
analysed*
3
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Lung
function: FEF25−75 mL/
s (percentage change
from baseline)
Follow-up: up to 3
months
Themean (SD) absolute
change f rom baseline in
the dornase alfa group
was 173 (310) mL/ s
The mean (SD) absolute
change f rom baseline in
the mannitol group was
55 (282) mL/ s
MD -0.01%
(95%CI: -0.23 to 0.21%)
.
up to 231
1 cross-over study
⊕©©©
very low1,2
Only the relat ive ef fect
of percentage change
f rom baseline could be
analysed*
Adverse events relat-
ing to treatment
Scale: m ild, moderate,
severe and total
Follow-up: up to 3
months
CF exacerbat ion was
the most commonly re-
ported adverse event
(5% of part icipants)
Cough and CF exacer-
bat ion were the most
commonly reported ad-
verse events (22% and
17% of part icipants re-
spect ively)
See comment. up to 231
1 cross-over study
⊕©©©
very low1,2
Frequencies of adverse
events according to
severity only were re-
ported, a stat ist ical
comparison was not
made
* The basis of the assumed risk and the corresponding risk is described in the comments. For lung funct ion outcomes, absolute data was not presented in a format which
could be analysed due to the cross-over design of the study, therefore only analyses of percentage change f rom baseline were included in this review
CF: cyst ic f ibrosis;CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised version, CI: conf idence interval; FEF25−75: m id-expiratory f low; FEV1: f orced expiratory volume at one second;
FVC: f orced vital capacity; HRQoL: health-related quality of lif e; MD: mean dif ference; NA: not applicable; SD: standard deviat ion.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Stated that 28 part icipants were randomised, unclear how many part icipants dropped out and how many were evaluated
for each outcome (evidence downgraded due to incomplete outcome data). Evidence also downgraded due to imprecision,
study is known to be underpowered.
2. Evidence downgraded due to indirectness: the part icipant populat ion included only those with CF who passed the tolerance
test and not all potent ial part icipants with CF.
3. Evidence downgraded due to indirectness: the CFQ-R tool used in the studies was not designed to assess mucolyt ics. Also,
pooling of the age-appropriate tools may not be valid so results should be interpreted with caut ion.
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Inhaled mannitol plus dornase alfa compared with dornase alfa for CF
Patient or population: children and young people with cyst ic f ibrosis
Settings: outpat ients
Intervention: inhaled mannitol plus dornase alfa
Comparison: dornase alfa
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Dornase alfa Inhaled mannitol plus
dornase alfa
HRQoL - all domains
(change from baseline)
Scale: age-appropriate
versions of the CFQ-R
quest ionnaire
Follow-up: up to 3
months
No signif icant dif f erences were found between
treatment groups for any domains of the CFQ-R
NA up to 231
1 cross-over study
⊕©©©
very low1,2,3
Lung function: FEV1mL
(percentage change
from baseline)
Follow-up: up to 3
months
Themean (SD) absolute
change f rom baseline in
the dornase alfa group
was 84 (273) mL
Themean (SD) absolute
change f rom baseline in
the mannitol group was
-31 (306) mL
MD -4.30%
(95% CI: -14.10% to 5.
50%).
up to 231
1 cross-over study
⊕©©©
very low1,2
Only the relat ive ef fect
of percentage change
f rom baseline could be
analysed*
Lung function: FEV1 %
predicted
Follow-up: NA
Outcome not reported. NA
Lung function: FVC mL
(percentage change
from baseline)
Follow-up: up to 3
Themean (SD) absolute
change f rom baseline in
the dornase alfa group
was 7 (415) mL
Themean (SD) absolute
change f rom baseline in
the mannitol group was
-103 (394) mL
MD -0.07%
(95% CI: -0.30% to 0.
16%).
up to 231
1 cross-over study
⊕©©©
very low1,2
Only the relat ive ef fect
of percentage change
f rom baseline could be
analysed*4
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months
Lung
function: FEF25−75 mL/
s (percentage change
from baseline)
Follow-up: up to 3
months
Themean (SD) absolute
change f rom baseline in
the dornase alfa group
was 173 (310) mL/ s
The mean absolute
change f rom baseline in
the mannitol group was
68 (489) mL/ s
MD -0.03%
(95%CI: -0.18 to 0.24%)
.
up to 231
1 cross-over study
⊕©©©
very low1,2
Only the relat ive ef fect
of percentage change
f rom baseline could be
analysed*
Adverse events relat-
ing to treatment
Scale: m ild, moderate,
severe and total
Follow-up: up to 3
months
CF exacerbat ion was
the most commonly re-
ported adverse event
(5% of part icipants)
Cough and CF exacer-
bat ion were the most
commonly reported ad-
verse events (9% and
30% of part icipants re-
spect ively)
See comment. up to 231
1 cross-over study
⊕©©©
very low1,2
Frequencies of adverse
events according to
severity only were re-
ported, a stat ist ical
comparison was not
made
* The basis of the assumed risk and the corresponding risk is described in the comments. For lung funct ion outcomes, absolute data was not presented in a format which
could be analysed due to the cross-over design of the study, therefore only analyses of percentage change f rom baseline were included in this review
CF: cyst ic f ibrosis;CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised version, CI: conf idence interval; FEF25−75: m id-expiratory f low; FEV1: f orced expiratory volume at one second;
FVC: f orced vital capacity; HRQoL: health-related quality of lif e; MD: mean dif ference; NA: not applicable; SD: standard deviat ion.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1 Stated that 28 part icipants were randomised, unclear how many part icipants dropped out and how many were evaluated
for each outcome (evidence downgraded due to incomplete outcome data). Evidence also downgraded due to imprecision,
study is known to be underpowered.
2. Evidence downgraded due to indirectness: the part icipant populat ion included only those with CF who passed the tolerance
test and not all potent ial part icipants with CF.
3. Evidence downgraded due to indirectness: the CFQ-R tool used in the studies was not designed to assess mucolyt ics. Also,
pooling of the age-appropriate tools may not be valid so results should be interpreted with caut ion.
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D I S C U S S I O N
Lung disease remains the most common cause of mortality and
morbidity in people with CF (Accurso 2007; Robinson 2001).
Currently, nebulised dornase alfa and hypertonic saline are the
main pharmacological treatments used to manage secretions.
However, both agents require nebulization and some participants
are unable to tolerate one or both, or find them unpleasant to
use. Potential alternatives or supplementary treatments should be
considered and investigated. Mannitol is one possible alternative
treatment.
Summary of main results
The key studies included in the review were two large randomised
controlled studies of similar parallel design comparing mannitol
with control in adults, children and young people and reporting
results at our specified time point “up to six months” (Aitken
2012; Bilton 2011). Additional data were provided by the manu-
facturer and study sponsor (Pharmaxis) and we were able to pool
data in our analyses. Below, we summarise the primary outcomes
’HRQoL’, ’lung function’ and ’adverse events’ and important sec-
ondary outcomes ’number of pulmonary exacerbations’ and ’spu-
tum microbiology’ for each of the comparisons made in this re-
view.
Mannitol versus control for individuals with cystic
fibrosis (parallel studies)
Pharmaxis provided additional information for HRQoL, one of
the primary outcomes in our review. In our pooled analyses of the
parallel studies, we found no consistent significant differences for
any domains of the CFQ-R at any of the time points for which
data were available (Analysis 1.1 to Analysis 1.11) (low-quality evi-
dence).We do note that results presented for many of theHRQoL
domains are taken from the pooled results for all individuals (re-
sults from age-appropriate version of the questionnaire combined)
and that such a combination of results across questionnaires may
not be valid, so encourage caution in the interpretation of these
results. Also, for the respiratory domain it should be noted that
as stated above, mannitol has a negative effect on HRQoL scores
due to its mode of action causing increased sputum production.
From the additional HRQoL information provided by Pharmaxis
which was pooled for the two parallel studies, we found a statis-
tically significant reduction in the burden of treatment compared
to baseline at four months in the mannitol group compared to
the control group, MD -4.60 (95% CI -7.90 to -1.30); however,
the difference between the groups was no longer significant by six
months,MD -2.12 (95%CI -5.70 to 1.46). Combining data from
the two parallel studies did show significantly fewer participants
to be adherent to treatment with mannitol (defined as more than
60%compliance) than to control, RR0.89 (95%CI 0.82 to 0.97),
but the data from the cross-over study (see below) showed that
more participants were adherent (defined as above 70% compli-
ance) to mannitol than to control. We do note that such measures
are subjective to participants and study personnel and therefore
encourage caution when interpreting numerical results.
Lung function was a further primary outcome of this review. Phar-
maxis provided data from their original analysis via a MMRM
model, appropriate for the longitudinal design of the studies and
adjusted for participant factors (see Measures of treatment effect
for further details). Our pooled analyses of the two parallel studies
showed moderate quality evidence of significant improvements in
lung function as measured by FEV1 (mL), FEV1 (% predicted)
and FVC (mL) for participants receiving mannitol compared to
those receiving control at up to two months, up to four months
and up to six months (Analysis 1.12; Analysis 1.13; Analysis 1.14).
Cough, haemoptysis, bronchospasm, pharyngolaryngeal pain and
post-tussive vomiting were the most commonly reported side ef-
fects (moderate-quality evidence). Haemoptysis, bronchospasm,
pharyngolaryngeal pain and coughwere themost common reasons
for stopping treatment. There was a small but significant reduction
in the incidence of PDPE, the need for additional antibiotics and
the number of hospitalisations in favour of mannitol compared
to control from pooling the two parallel studies (Analysis 1.21;
Analysis 1.23).
Considering subgroups of dornase alfa users and non-users and
adults and children, we found that benefits in terms of lung func-
tion and exacerbations of 400 mg mannitol compared to 50 mg
mannitol tend to be greater in adults and non dornase alfa users,
but that there was no significant differences between the subgroups
for any measures of lung function at any time point (Table 1; Table
2). We also found a similar distribution of adverse events across
the subgroups and no significant differences in rates of adverse
events between the subgroups (Table 3; Table 4).
No significant differences were found between mannitol and con-
trol in terms of assessment of symptoms of sputum microbiology.
Mannitol versus control for individuals with cystic
fibrosis (cross-over studies)
Two cross-over studies compared mannitol to control (non-res-
pirable mannitol) over two weeks treatment duration (Jaques
2008) and over eight weeks duration (de Boeck 2017).
There were no statistically significant differences in any HRQoL
domains in the two-week cross-over study of mannitol compared
to control (non-respirablemannitol) included in the review (Jaques
2008; Table 5). As for the previously mentioned parallel trials, we
are aware of issues (related to age of participants and the mech-
anism of action of mannitol) which should be considered when
interpreting the results presented in the review and we consider
this evidence to be of very low quality.
Analysis of absolute and relative change frombaseline in lung func-
tion in the two cross-over studies showed low-quality evidence of
a significant improvement in FEV1 (mL) and FEV1 (% predicted)
and FEF25−75 mL/s in favour of mannitol, but no statistically sig-
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nificant differences between the groups in terms of FVC (mL or
% predicted) (Table 6; Analysis 2.1 to Analysis 2.8).
The most commonly reported adverse events in both groups in
the two studies were cough, haemoptysis, headache, nasopharyn-
gitis and lung infections (Table 7; Table 8; Table 9) (low-qual-
ity evidence) and in the eight-week cross-over study, pulmonary
exacerbations were more commonly observed in the control arm
compared to the mannitol arm (Table 9).
Finally, as for the two afore-mentioned parallel studies, no sig-
nificant differences were found between mannitol and control in
terms of assessment of symptoms of sputum microbiology.
Mannitol versus control for individuals with cystic
fibrosis, hospitalised due to pulmonary exacerbations
(parallel study)
A parallel study recruiting children and young people hospitalised
due to pulmonary exacerbations compared mannitol to control
(low-dose non-respirable mannitol) for 12 consecutive days of
treatment and followed up for one month following hospital dis-
charge (Middleton 2015). It was not reported in the study whether
any further pulmonary exacerbations occurred in any participants
while in hospital or during the one month follow-up.
There were no statistically significant differences in any measure
of HRQoL at hospital discharge or after one month of follow-
up (Analysis 3.1; Analysis 3.2). As for the previously mentioned
parallel trials, we are aware of issues (related to age of participants
and the mechanism of action of mannitol) which should be con-
sidered when interpreting the results presented in the review and
we consider this evidence to be of very low quality.
In terms of lung function, the study provided low-quality evidence
demonstratingno statistically significant differences inFEV1, FVC
orFEF25−75 (%predicted) at hospital discharge or after onemonth
of follow-up (Analysis 3.3; Analysis 3.4; Analysis 3.5). No infor-
mation regarding sputum microbiology was reported.
Adverse events were uncommon and no serious adverse occurred,
however due to the small number of participants and limited du-
ration of follow-up, we consider this evidence to be of low quality.
Mannitol alone versus mannitol plus dornase alfa
versus dornase alfa alone (cross-over study)
Across-over study compared 12weeks of treatmentwithmannitol,
dornase alfa or mannitol plus dornase alfa in children and young
people (Minasian 2010). No significant differences were found in
the recorded domains of HRQoL or themeasures of lung function
(FEV1, FVC or FEF25−75 ) between the three treatment arms.
There seemed to be a higher rate of pulmonary exacerbations in the
mannitol plus dornase alfa arm compared with dornase alfa alone
(although this was not statistically significant) and this was the
most common reason for stopping treatment in this arm. Cough
was the most common side effect in the mannitol alone arm, but
there was no occurrence of cough in the dornase alfa alone arm.No
significant differences were found between mannitol and control
in terms of assessment of symptoms of sputum microbiology.
Overall completeness and applicability of
evidence
Applicability of interventions and controls
Two studies used sub-therapeutic doses of mannitol as the control
treatment (Aitken 2012; Bilton 2011), while the other studies
comparing mannitol to a control treatment used non-respirable
mannitol as the control treatment (de Boeck 2017; Jaques 2008;
Middleton 2015). Use of a sub-therapeutic dose of mannitol was
justified by citing a dose-escalation study which showed that 50
mg mannitol had no effect (Teper 2011). However, it was also
acknowledged that this dose may have had some degree of effect
as an improvement in FEV1 was noted in the control arm of one
study (Aitken 2012).
In three studies, between 44% and 75% of participants were also
using dornase alfa before randomisation and continued their treat-
ment regimen throughout the study (Aitken 2012; Bilton 2011;
de Boeck 2017; Jaques 2008; Middleton 2015). Comparing the
subgroups of dornase alfa users to non-users in the two large par-
allel studies, generally a beneficial effect in terms of lung function
was observed in both subgroups; however, the benefit seems to be
larger in non-dornase alfa users than users (Aitken 2012; Bilton
2011). Again, we note that these studies were not designed to test
subgroup differences and results do not show any significant ev-
idence of a difference between the subgroups. This suggests that
mannitol may be an effective treatment as single therapy or in
combination with dornase alfa.
One cross-over study compared mannitol with and without dor-
nase alfa with dornase alfa alone, but the study was underpowered
which prevents any conclusions being drawn (Minasian 2010).
The mechanism of action of dornase alfa is to cleave extracellular
DNA from inflammatory cells in the CF mucus, thus it works in
a quite different way to the rehydrating properties of mannitol. It,
therefore, seems reasonable to presume that people with CF may
benefit from the addition of mannitol to dornase alfa therapy, and
to include participants on dornase alfa in the study design.
While it is known that the addition of mannitol to an already
intense treatment regimenwill be time-consuming and could cause
problems with adherence, the studies collected little information
on the burden of treatment and adherence. Although the CFQ-R
was used in all studies, only the two longer-term studies reported
the results of the treatment burden domain (as would be expected)
(Aitken 2012; Bilton 2011). Four studies reported information on
adherence to treatment which was measured through pack counts;
the two larger studies used a threshold of at least 60% and the
smaller studies used a threshold of 70% (Jaques 2008; Minasian
2010).
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Adherence to other CF medications was not measured during any
of the studies and therefore the impact of an additional treatment
(i.e. mannitol or control) on the use of other CF medication is
unknown. In addition, it is accepted that participants in clini-
cal trials are usually more adherent to treatment regimens than
those receiving the same treatment but as part of usual care. In the
open study by Minasian, treatment burden was reported as a con-
tributory factor to withdrawal (Minasian 2010). Although adding
mannitol capsules for inhalation to current treatment regimens
appeared to have little long-term effect on the burden of treat-
ment or adherence throughout the studies, it is hard to compare
this fully as in the three studies comparing the active mannitol
treatment to a control treatment both were administered using the
same inhalers. An arm with no treatment is needed to determine
the additional size of the treatment burden.
Hypertonic saline acts as an airway rehydrating agent and therefore
people currently using hypertonic saline were excluded from five
out of six of these studies; in one included study, 14% of partici-
pants randomised in the study were reported to have been using
hypertonic saline in addition to their randomised treatment, but
the split by treatment group was not reported (Middleton 2015).
No studies compared the use of mannitol (alone) to the use of
hypertonic saline (alone) therefore this review does not inform
a comparison between these two treatments and future research
should address this.
Applicability of participant populations and study
design
As there is a risk of bronchoconstriction with mannitol, partici-
pants in all six included studies underwent a mannitol tolerance
test at screening; those who failed the test or in whom the test was
incomplete did not enter into the study. Approximately 12% of
individuals failed the test dose demonstrating that mannitol, even
if effective, will not be suitable for everyone with CF.
Three studies recruited a mixture of adults, children and young
people (Aitken 2012; Bilton 2011; Jaques 2008) and three re-
cruited only children and young people under the age of 18 (de
Boeck 2017; Middleton 2015; Minasian 2010). The mean age of
the two large studies was approximately 20 years of age, around
43% of participants were under 18 years of age and around 20%
of participants were under 12 years of age (Aitken 2012; Bilton
2011). The evidence from these studies in this review suggests a
significantly beneficial effect in terms of lung function for adults
treated with mannitol compared to control but this effect has not
been shown in children (Aitken 2012; Bilton 2011). We do note
that the studies included in the review were not designed to test
subgroup differences and the results in the subgroup of children
have wide confidence intervals which does not exclude the pres-
ence of a treatment effect.
The two large studies recruited participants with a range of lung
function (% predicted FEV1 between 30% and 90%) and mean
FEV1 was around 60% of predicted (Aitken 2012; Bilton 2011).
In the remaining three studies recruiting individuals with CF as
outpatients (two cross-over studies) participants had a baseline
meanFEV1%predicted rangingbetween64%and72%and itwas
stated that participantswere clinically stable at the start of the study
(de Boeck 2017; Jaques 2008; Minasian 2010). The final study
recruited participants with CF who were hospitalised with a pul-
monary exacerbation (Middleton 2015) and within this study, the
control group had a significantly lower FEV1 and FEF25−75 than
the mannitol group. For these reasons, results reported within this
study may not be applicable to all individuals with CF (Middleton
2015).
The randomised phases of the two large studies lasted for 26weeks;
and although they continued for a further 26 weeks, this phase
had an open design (Aitken 2012; Bilton 2011). The treatment
duration of the cross-over studies lasted two weeks (Jaques 2008),
eight weeks (de Boeck 2017) and 12 weeks (Minasian 2010); and
in the third parallel study participants were treated for only 12
days (Middleton 2015). In studies of people with chronic condi-
tions, it is important that the duration of the study is sufficient to
demonstrate differences in long-term outcome measures. Clearly
the smaller studies included in this review are likely of too short
a duration to adequately measure the effectiveness of mannitol
of too short a duration (de Boeck 2017; Jaques 2008; Middleton
2015; Minasian 2010).
The two longer studies incorporated an open-label phase as the
second six months of the total 12-month study (open-label results
not presented in this review), which makes the longer-term re-
porting of more subjective outcomes such as HRQoL and burden
of treatment less meaningful (Aitken 2012; Bilton 2011). How-
ever, it is of note that in the two longer studies, any improvements
shown in lung function were apparent at the six-week follow-up
visit and appeared to be maintained through to the 12-month fol-
low-up visit (Aitken 2012; Bilton 2011).
As stated above, one of the cross-over studies was underpowered
which prevents conclusions from being drawn (Minasian 2010).
In an additional study, the recruitment of participants was halted
early after potential candidate pools were exhausted and 95 out of a
target 160 participants had been recruited (de Boeck 2017). Post-
hoc power calculations were reported, but using a different sizes of
treatment difference (3% or 3.5% change in FEV1 % predicted),
therefore it is unclear whether this study was adequately powered
and whether conclusions can be drawn from these results.
Finally, although two of the studies had a similar design and re-
sults could be pooled, one was run in Europe (UK and Ireland),
Australia and New Zealand (Bilton 2011) while the other was run
in Europe (Germany, France, Belgium and the Netherlands) and
North and South America (Aitken 2012). It is possible that stan-
dard clinical practice may vary between these areas.
Quality of the evidence
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The quality of the evidence provided in this review ranges from
moderate quality to very low quality, varying by comparison and
by outcome (Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
findings 4; Summary of findings 5). The main issues influencing
the quality of the evidence within this review were that all six
studies included in the review were sponsored by themanufacturer
of mannitol (Pharmaxis); some study authors declared financial
interests. We also note that the study populations of all included
studies were somewhat selective; excluding participants who failed
amannitol tolerance test, therefore the individuals included in this
review may not represent the wider CF population.
Furthermore, we note that for the assessment of HRQoL, the
CFQ-R tool was frequently used and such a tool was not designed
to assess mucolytics. Also, where a range of age groups had been
included in studies and age appropriate tools had been used, pool-
ing the results across age-groups may be not be valid. Therefore
results for HRQoL are judged to be low to very low quality for all
comparisons of the review and should be interpreted with caution.
The two largest studies were of high methodological quality, gen-
erally low risk of bias and well-powered, each including approx-
imately 300 participants (Aitken 2012; Bilton 2011). Evidence
from these studies was consistent andmostly moderate quality (ex-
cept for HRQoL), with very little heterogeneity observed between
the study results (Summary of findings for the main comparison).
The remaining studies were smaller, randomising 95 participants
(de Boeck 2017), 39 participants (Jaques 2008), 28 participants
(Minasian 2010) and 22 participants (Middleton 2015); further-
more, in three of these studies, results were not reported for all
randomised individuals and the studies may be at risk of bias
due to incomplete outcome data (de Boeck 2017; Jaques 2008;
Minasian 2010). In addition, one study was open label with no
attempt at allocation concealment or blinding (Minasian 2010)
and other studies did not report clear information regarding ei-
ther randomisation or allocation concealment methods (de Boeck
2017; Jaques 2008; Middleton 2015). Evidence provided from
these studies was more limited and judged to be of low to very low
quality (Summary of findings 2; Summary of findings 3; Summary
of findings 4; Summary of findings 5).
Potential biases in the review process
We are grateful for the additional information provided to us by
Pharmaxis to supplement the information in the published papers.
We acknowledge that the studies were designed by Pharmaxis with
a primary outcome of change in FEV1 therefore may not be pow-
ered to detect a difference in our first primary outcome HRQoL,
an outcome we deemed to be the most important to people with
CF. Therefore an absence of evidence of a difference in HRQoL
found in this review does not rule out that mannitol may improve
HRQoL compared to control treatments including dornase alfa.
We also note that the combination of results across all ages for
HRQoL may not be valid; however, we were not able to separate
age groups in the analyses. Furthermore, we are aware that the
HRQoL tool used in the studies was not designed to be used to
assess mucolytics and therefore the results for some domains, e.g.
mucus production, should be interpreted in light of the mecha-
nism of action of the drug.
Given the complex structures of the studies included in this re-
view (two longitudinal studies, three cross-over studies and a pilot
study), in many instances we felt it would be more appropriate to
summarise results narratively rather than perform our own anal-
yses. We felt that the statistical methodology used originally was
the most appropriate for the design of the included studies and
attempting to adjust original results in order to perform meta-
analysis for this review would not have been appropriate.
Agreements and disagreements with other
studies or reviews
The Aitken and Bilton studies have been combined and their re-
sults published as a pooled analysis (Bilton 2013; Flume 2015). It
was possible to compare these results to the results of our pooled
analyses of these studies; we found that the results are numeri-
cally similar (we assumed that any minor differences are due to
this review pooling summary results from the statistical models,
while the pooled analyses combine data and then fit the statistical
models) and all conclusions are the same.
There are no other published systematic reviews of mannitol to
our knowledge. A technology appraisal of mannitol has been pub-
lished by the UK National Institute for Health and Care Excel-
lence (NICE) and recommends mannitol dry powder for inhala-
tion as an option for treating CF in adults fulfilling the following
criteria (NICE 2012):
• unable to use dornase alfa because of ineligibility,
intolerance or inadequate response to this agent; and
• rapid decline in lung function (FEV1 decline greater than
2% annually); and
• other osmotic agents not considered appropriate.
There are a few differences in approach between the NICE review
and our review. The NICE review considered only adults, whereas
we considered adults, children and young people. The NICE re-
view also considered the sub-populations of dornase alfa users and
non-users separately, whereas we have considered all participants
as a single group regardless of concomitant treatment in our pri-
mary analysis. Finally, the NICE review included an analysis of
cost-effectiveness.
We also identified an online publication by the European
Medicines Agency (EMA) which considered information submit-
ted by Pharmaxis on five phase I studies, three phase II studies and
two phase III studies. Two of the phase II studies (Jaques 2008;
Minasian 2010) and the phase III studies (Aitken 2012; Bilton
2011) are also included in this review; the third phase II dose-re-
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sponse study is listed in this review as excluded (Teper 2011). The
EMA report granted marketing authorisation for 400 mg manni-
tol inhalation powder for the treatment of CF in adults aged 18
years and above (EMA 2011). Similar to our review, this report
found small improvements in FEV1 % predicted and recognised
the difficulty in determining the clinical benefit while simultane-
ously acknowledging that even a small effect may be of relevance
given the deterioration of FEV1 seen in the progression of CF. The
report also agreed that the most commonly observed side effect
was cough, with other important adverse effects of mannitol being
bronchospasm and haemoptysis.
A document published by the Scottish Medicines Consortium
(SMC) agreed that using mannitol at a dose of 400 mg per day led
to superior lung function compared to control (sub-therapeutic
mannitol), but also found that there was an insufficiently robust
economic analysis to allow acceptance by the SMC (SMC 2013).
This Cochrane Review did not include an analysis of cost-effec-
tiveness.
A Dutch report undertook an indirect comparison with hyper-
tonic saline, which this review did not do. The report agreed that
there was an improvement in FEV1 with mannitol; however, it
judgedmannitol to have limited applicability and to bemore often
associated with adverse effects in comparison to nebulised hyper-
tonic saline (Zorginstituut 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In this review, wewere able to combine results from two large, well-
powered studies comparing 400 mg twice-daily inhaled mannitol
to low-dose, sub-therapeutic (50 mg inhaled mannitol) in people
with cystic fibrosis (CF) (Aitken 2012; Bilton 2011). Pooled evi-
dence from these studies demonstrates moderate quality evidence
of efficacy for 400 mg mannitol in terms of improved lung func-
tion (forced expiratory volume at one second (FEV1)), both mL
and % predicted) at two, four and six months. This efficacy is
shown in adults and both dornase alfa users and non-users.
We foundno clear evidence in this reviewof an associationbetween
health-related quality of life (HRQoL) and the use of inhaled
mannitol. We also found no consistent evidence of the association
between inhaled mannitol and adverse effects.
When compared to non-respirablemannitol as a control treatment
in four small studies of short duration, this review provides only
low- to very low-quality evidence regardingdifferences inHRQoL,
lung function and adverse events associated with treatment.
However, results of this review do not provide a definitive argu-
ment for the universal use of mannitol in all people with cystic
fibrosis (CF). This review provides limited information regarding
the effectiveness of inhaled mannitol in different severities of CF.
Stakeholders need to be aware of this evidence base when assessing
the use of inhaled mannitol for CF.
Implications for research
It is important that future studies collect, analyse and publish out-
comes to determine the long-termuse of inhaledmannitol in terms
of both efficacy and tolerability. It is essential that future studies
are powered to detect a difference in both efficacy outcomes and
clearly defined HRQoL outcomes, outcomes which are of great
importance to people with CF. Existing HRQoL tools used in CF
are not designed to assess mucolytics; it is important that tools
developed in future take into account the mechanism of action
of mucolytic drugs such as mannitol. Information on burden of
treatment is particularly important as the impact of adding a fur-
ther inhaled treatment to people’s current regimens is unclear. In
the two large studies, participants in the control arms received a
matched product administered using the same inhalers and taking
the same amount of time to administer; such study designs make
it difficult to determine the true size of any additional burden.
In addition, adherence to other medications for CF was not mea-
sured during any of the published studies; future research should
specifically examine this issue.
As it is accepted that participants in clinical trials are usually more
adherent to treatment regimens than people receiving usual care,
pragmatic studies may be more appropriate for examining burden
of treatment and adherence in real-life situations compared with
randomised controlled studies. The two large included studies in
this reviewhad a six-month open-label period after the randomised
period and data from these extension periods suggest that the gains
in lung function remain.However, some self-selection often occurs
with open-label extensions to studies, i.e. only participants who
perceive a benefit will continue to take the study treatment.
Future studies should be large enough to enable detailed analysis
of the effectiveness of mannitol in population subgroups such as
adults and children, varying severities of CF or concomitant use
of dornase alfa. Currently, data are pooled from study participants
treated across a range of countries and we have already commented
that routine clinical practice for treating CF may vary between
the different settings, so sufficient numbers of participants are
needed in each setting. Currently no studies compare mannitol to
treatment with hypertonic saline; future research should address
this.
Determination of resource use and the cost of mannitol treatment
are important and cost-effectiveness evaluations to relate these to
benefits in local settings are needed.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aitken 2012
Methods Double-blind, randomised parallel trial.
Duration: intervention for 26 weeks, followed by 26-week open-label treatment with
mannitol
Multicentre: 53 sites.
Location: USA, Canada, Argentina, Europe.
Participants 305 participants with CF: mannitol group (n = 184) and control group (n = 121)
Mean age: 20 years, range: 6 - 53 years, 154 aged < 18 years
Mannitol group: 19% aged 6 - 11 years; 30.4% aged 12 - 17 years.
Control group: 19.8% aged 6 - 11 years; 32.2% aged 12 - 17 years.
Gender split: 51.5% male, 48.5% female.
All participants clinically stable at start of study, mean (SD) baseline FEV1 % predicted
63.8 (15.9).
75.1% received concomitant dornase alfa.
Participants receiving hypertonic saline excluded.
Interventions Treatment: inhaled dry powder mannitol, 400 mg 2x daily, 10 x 40 mg capsules. Ad-
ministered using RS01 inhaler model 7, Plastiape, Italy
Control: subtherapeutic mannitol 50 mg 2x daily, 10 x 50 mg capsules. Administered
using RS01 inhaler model 7, Plastiape, Italy (same inhaler as for active intervention)
Outcomes Primary outcome: FEV1 (absolute value over the 26-week study).
Secondary outcomes: FEV1 % predicted at 26 weeks; FVC; FEF25−75; PDPE; sputum
weight; HRQoL (as assessed by CFQ-R, including burden of treatment and assessment
of symptoms provided by Pharmaxis)
Other outcome measures: adverse events and sputum microbiology (also additional
non-routine antibiotic use and hospitalisations provided by Pharmaxis)
Funding Source Supported by Pharmaxis Limited.
Conflicts of Interest No specific conflicts of interest of the authors of the manuscript reported
Stated that the study sponsor participated in the study design, data collection, data
analysis, data interpretation, and writing of the report. After completion of the trial, the
data were held and analysed by the sponsor
Notes Additional data supplied by manufacturer of mannitol (Pharmaxis) for the majority of
outcomes reported in this review. Pharmaxis stated that the lung function results in the
paperwere presented as per the primary analysismethod also described in the publication.
The FEV1 and FVC data were presented in full, however they acknowledged that in this
study the outcome FEF25−75 was mentioned in the methodology and not presented in
the results section
Risk of bias
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Aitken 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Further details were provided by Phar-
maxis: the master randomisation list, strat-
ified by country and dornase alfa user (yes/
no) for a parallel design was prepared us-
ing SAS Version 8.1 by an external com-
pany. 300 randomisation numbers (180 ac-
tive and 120 control) were generated for
each country and each dornase alfa user/
non-user group. Randomization blocking
by country was done in paired blocks of 5,
1 block for dornase alfa users and 1 block
for non-users
Allocation concealment (selection bias) Low risk Pharmaxis confirmed randomisation man-
aged via an IVRS, therefore the investiga-
tor was unaware prior to randomising the
participant which specific blinded pack of
treatment they would be allocated to. This
provided an extra level of security (over
and above the blinded nature of the study)
against selection bias
Blinding (performance bias and detection
bias)
Participants
Low risk Described as double blind - mannitol and
low-dose mannitol control administered as
capsules identical in taste and appearance
with identical methods of administration
Blinding (performance bias and detection
bias)
Clinicians
Low risk Described as double blind - mannitol and
low-dose mannitol control administered as
capsules identical in taste and appearance
and with identical methods of administra-
tion
Pharmaxis confirmed investigators and
study staff, including statisticians and all
outcome assessors at investigator sites e.g.
spirometry technicians were blinded
Both Bilton 2011 and Aitken 2012 used
the same low-dose mannitol control that
was identical in taste and appearance to the
400 mg mannitol active intervention
Blinding (performance bias and detection
bias)
Outcome assessors
Low risk Described as double blind - mannitol and
low-dose mannitol control administered as
capsules identical in taste and appearance
and with identical methods of administra-
tion. Pharmaxis confirmed blinding of in-
vestigators and study staff including statis-
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Aitken 2012 (Continued)
ticians and all outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Higher dropout rate with mannitol, 17%
versus 12% for control, for adverse events
and other reasons e.g. withdrawal of con-
sent. However, paper provides flow dia-
gram with timing and reasons for drop
out and which group the participants were
in. Sensitivity analyses conducted by Phar-
maxis (methods of imputation of missing
data for withdrawals) showed a consistent
treatment effect in favour of mannitol and
no change to conclusions
Selective reporting (reporting bias) Low risk Limited information was reported in the
study publication; particularly HRQoL
and lung function
Additional data were provided by Phar-
maxis on request for all primary outcomes
of this review and many secondary out-
comes
Other bias High risk Participants underwent a mannitol toler-
ance test at screening; those who failed the
test or in whom the test was incomplete
were not entered into the study and thus,
the participant population included only
those withCFwhopassed the tolerance test
and not all potential participants with CF
Sponsored by manufacturer of mannitol
(Pharmaxis); authors or study staff worked
for Pharmaxis or had financial interest
Bilton 2011
Methods Double-blind, randomised parallel trial, stratified according to concurrent dornase alfa
use
Duration: intervention for 26 weeks compared with control followed by optional 26-
week open-label phase
Multicentre.
Location: Australia, New Zealand, UK, Ireland.
Participants 295 participants with CF; mannitol group (n = 177), control group (n = 118)
Mean (SD) age: 23 (11.3) years.
Gender split: 55.3% male, 44.7% female.
All participants clinically stable at start of study, mean (SD) baseline FEV1 % predicted
62.0 (16.3).
55.3% received concomitant dornase alfa.
Participants receiving hypertonic saline excluded.
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Bilton 2011 (Continued)
Interventions Treatment: inhaled dry powder mannitol, 400 mg 2x daily administered using RS01
Monodose Inhaler model 7, Plastiape, Italy
Control: subtherapeutic mannitol (mannitol 50 mg), 2x daily administered using RS01
Monodose Inhaler model 7, Plastiape, Italy (same inhaler as for active intervention)
Outcomes Primary outcome: FEV1 (change over 26 weeks).
Secondary outcomes: % of responders to treatment at 26 weeks; FVC; FEF25−75;
PDPEs; PEs; rescue antibiotics;HRQoL scores (using age-appropriateCFQ-R, including
burden of treatment and assessment of symptoms provided by Pharmaxis)
Other outcomemeasures: adverse events; haematology; liver and renal function; sputum
microbiology (also additional non-routine antibiotic use and hospitalisations provided
by Pharmaxis)
Safety and efficacy endpoints were examined in cohorts according to dornase alfa use as
well as within total cohort
Funding Source This work was supported by the NIHR Respiratory Disease Biomedical Research Unit
at the Royal Brompton and Harefield NHS Foundation Trust, and Imperial College
London (London, UK)
The study was supported by Pharmaxis Limited.
Conflicts of Interest Conflicts of interest of the all authors of the manuscript are reported on the website of
the European Respiratory Journal
Stated that the study sponsor participated in the study design, data collection, data
analysis, data interpretation, and writing of the report. After completion of the trial, the
data were held and analysed by the sponsor
Notes Additional data supplied by manufacturer of mannitol (Pharmaxis) for the majority of
outcomes reported in this review
Pharmaxis stated that results for investigator-defined PEs were not reported in the paper;
however, the more appropriate PDPEs were included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised using 3:2 ratio
(mannitol versus control) and stratified ac-
cording to current dornase alfa use
Pharmaxis confirmed qualifying partici-
pants were randomised to a treatment arm
via an IVRS using the site-subject identi-
fication number, date of birth, initials and
dornase alfa use as requisites. A master ran-
domisation list, stratified by region (Aus-
tralia andEurope) anddornase alfa use (yes/
no), was prepared by an external company.
Randomisation numbers (for both manni-
tol and control) were generated for each
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Bilton 2011 (Continued)
stratum, in blocks of 5. The randomisation
number was assigned sequentially within
each stratum
Allocation concealment (selection bias) Low risk Pharmaxis confirmed randomisation was
managed via an IVRS, therefore the inves-
tigator was unaware prior to randomising
the participant which specific blinded pack
of treatment they would be allocated to
Blinding (performance bias and detection
bias)
Participants
Low risk Participants blinded to treatment alloca-
tion through using a subtherapeutic does
of mannitol and the same inhaler devices
were used for both treatment arms (not
specifically stated in the published paper
but Pharmaxis confirmed use of same in-
haler device with 10 capsules for both 400
mg mannitol and control (50 mg manni-
tol))
Blinding (performance bias and detection
bias)
Clinicians
Low risk Study personnel blinded to treatment allo-
cation. Pharmaxis confirmed that investi-
gators and study staff including statisticians
were blinded. Low-dose mannitol used as
control which was identical in taste and ap-
pearance to the 400 mg mannitol
Blinding (performance bias and detection
bias)
Outcome assessors
Low risk Pharmaxis confirmed investigators and
study staff, including statisticians and all
outcome assessors at investigator sites e.g.
spirometry technicians were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk High dropout rates in blinded phase of
study in both arms: 37% in mannitol arm
and 28% in control arm. However, sen-
sitivity analyses conducted by Pharmaxis
(methods of imputation of missing data
for withdrawals) showed a consistent treat-
ment effect in favour of mannitol and no
change to conclusions
Selective reporting (reporting bias) Low risk Limited information was reported in the
study publication; particularly HRQoL
and lung function
Additional data were provided by Phar-
maxis on request for all primary outcomes
of this review and many secondary out-
comes
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Bilton 2011 (Continued)
Other bias High risk Participants underwent a mannitol toler-
ance test at screening; those who failed the
test or in whom the test was incomplete
were not entered into the study and thus,
study population included only those with
CF who passed the tolerance test and not
all potential participants with CF
Sponsored by Pharmaxis; authors or study
staff worked for Pharmaxis or had financial
interest
de Boeck 2017
Methods Double-blind, randomised, phase 2, cross-over study.
Duration (total): 24weeks (2x 8-week cross-over periods, separated by an8-weekwashout
period)
Location: multicentre (39 centres) in UK, France, Belgium, Canada, Germany, Switzer-
land, Italy, Netherlands
Participants 95 children or adolescents aged 6 - 17 years with CF were randomised and 84 completed
the study
Inclusion criteria: aged between 6 and 18 years with a confirmed diagnosis of CF and
FEV1 (% predicted) between 30% and 90%.
Mean age (SD): 12.0 (3.0) years (reported for 92 children).
Gender split: 55 females (60%); 37 males (40%) (reported for 92 children)
Mean (SD) FEV1 (% predicted) at screening: 72.23 (11.6), range (38.3 to 89.9)
Use of dornase alfa andmaintenance antibiotics (if established 3months before screening)
were permitted during the study. 63 participants (68.5%) had previously used or were
using dornase alfa at screening
Other CF therapies except nebulised hypertonic saline were also permitted during the
study
Exclusion criteria: failing themannitol tolerance test, design to identify participants with
bronchial hyper-reactivity
Interventions Treatment: inhaled mannitol 400 mg 2x daily.
Control: 10 mg of non-spray dried, non-respirable raw material mannitol
Interventions administered 2x daily in a cross-over fashion.
Treatment duration: 8 weeks for each treatment arm, separated by an 8-week wash-out
period
Outcomes Primary outcome: FEV1 % predicted (absolute change from each treatment period
baseline)
Relative change from each treatment period baseline of FEV1 % predicted was also
measured.
Secondary outcomes: FVC % predicted (absolute and relative change from each treat-
ment period baseline); FEF25−75% predicted (absolute and relative change from each
treatment period baseline); safety (physical examination and adverse event data); sputum
weight
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de Boeck 2017 (Continued)
Funding Source The study was funded by Pharmaxis Limited and an employee of Pharmaxis was among
the authors
Pharmaxis participated in the study design, data collection, data interpretation and and
writing of the study report
Conflicts of Interest The authors declare that Pharmaxis provided travel support for investigator meetings,
but that no investigator received any personal funding to participate in the study
Notes The original planned sample size was 160 participants, calculated to have 90% power
of detecting a difference of 3% absolute change in FEV1 % predicted. Recruitment was
halted early after 95 participants were recruited (centres exhausted potential candidate
pools). Post hoc power calculations showed that the recruited sample size had 80% power
of detecting a difference of 3.5% absolute change in FEV1 % predicted.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was conducted in a 1:1 ra-
tio and stratified according to age (6 - 11
years or 12 - 17 years) and dornase alfa use
(user or non-user). No information given
of how random sequence was generated
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
Participants
Low risk Double-blind achieved with a placebo also
containing a low dose of mannitol
Blinding (performance bias and detection
bias)
Clinicians
Low risk Double-blind achieved with a placebo also
containing a low dose of mannitol
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk No information provided regarding blind-
ing of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 95 participants were randomised and 84
completed the study. Reasons for with-
drawal were clearly documented in a flow
diagram and primary and secondary effi-
cacy endpoints were analysed on an inten-
tion-to-treat basis
Missing data were imputed using ’last ob-
servation carried forward;’ such a method
does not capture change over time so may
have introduced bias into results. However,
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de Boeck 2017 (Continued)
it is not stated how much data has been
imputed and for how many participants,
therefore the risk of bias is unclear
Selective reporting (reporting bias) Low risk All important outcomes of the phase 2 ef-
ficacy and safety trial seem to be reported
Other bias High risk Participants underwent a mannitol toler-
ance test at screening; those who failed the
test or in whom the test was incomplete
were not entered into the study and thus,
study population included only those with
CF who passed the tolerance test and not
all potential participants with CF
Sponsored by Pharmaxis; authors or study
staff worked for Pharmaxis or had financial
interest
The study may be underpowered; a priori
and post-hoc power calculations are based
on different sizes of treatment difference
(3% or 3.5% change in FEV1 %predicted)
.
Jaques 2008
Methods Double-blind, randomised, cross-over study.
Duration (total): 6 weeks; each arm of cross-over study lasted 2 weeks with 2 week wash-
out period in between
Location: Australia, New Zealand. (Multicentre)
Participants 49 participants with CF, 39 randomised.
Mean age: 19.1 years, range 8 - 48 years.
Gender split: 41% male, 59% female.
All participants clinically stable at start of study, mean (SD) baseline FEV1 % predicted
64.9 (13.6) for the mannitol group and 64.4 (11.8) for the control group
46.2% received concomitant dornase alfa.
No hypertonic saline within 2 weeks of start of study.
Group A (received mannitol first, then control) and group B (received control first, then
mannitol)
Interventions Treatment: inhaled dry powder mannitol 420 mg 2x daily,14 x 30 mg capsules. Fine
particle fraction > 40%
Children < 12 years: administered via low resistance dry powder inhaler RS01 Plastiape,
Osnago, Italy
Children
>
= 12 years and adults: administered via higher resistance dry powder inhaler,
Inhalator, Boeringer-Ingelheim, Ingelheim, Germany
Control: non-respirable mannitol with a fine particle fraction < 2%. Identical in appear-
ance and taste to mannitol capsules. 14 capsules 2x daily using same inhaler devices as
for mannitol
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Jaques 2008 (Continued)
Outcomes Primary outcome: FEV1 (change over 2 weeks).
Secondary outcomes: FEF25−75; FVC; FEV1/FVC ratio and PEF;HRQoL scores (using
age appropriate CFQ-R, including burden of treatment); respiratory symptoms; sputum
microbiology and safety
Funding Source Supported by Pharmaxis Limited and and an employee of Pharmaxis was among the
authors
Conflicts of Interest Conflicts of interest of all authors outlined in the manuscript
Notes Some additional data supplied by Pharmaxis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation code externally generated
in small block design stratified to site and
dornase alfa
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
Participants
Low risk Described as double-blind; mannitol and
control capsules identical in taste and ap-
pearance. Same inhaler devices for manni-
tol and control
Blinding (performance bias and detection
bias)
Clinicians
Low risk Described as double-blind; mannitol and
control capsules identical in taste and ap-
pearance. Same inhaler devices for manni-
tol and control
Blinding (performance bias and detection
bias)
Outcome assessors
Low risk Described as double-blind, it was stated
that study staff and investigators were
blinded. Same inhaler devices for mannitol
and control
Pharmaxis confirmed the statistician is part
of the study staff and therefore was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 56 days follow-up data not reported.
4 participants withdrew and one of these
was due to ”Unexplained withdrawal“ by
physician
Unclear how many participants were eval-
uated for each outcome
Selective reporting (reporting bias) Unclear risk All outcomes specified were reported, but
little detail.
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Jaques 2008 (Continued)
Other bias High risk Participants underwent a mannitol toler-
ance test at screening; those who failed the
test or in whom the test was incomplete
were not entered into the study and thus,
the study population included only those
with CF who passed the tolerance test and
not all potential participants with CF
Sponsored by Pharmaxis; authors or study
staff worked for Pharmaxis or had financial
interest
Middleton 2015
Methods Randomised, double-blind, placebo-controlled, pilot study.
Parallel design.
Duration: 1 month.
Location: Australia.
Participants Inclusion criteria: young people hospitalised with a pulmonary exacerbation (defined by
Fuchs criteria)
Exclusion criteria: FEV1 on admission < 40%, oxygen requirement, oral corticosteroids,
recent commencement of mucolytic agents and failure to tolerate a test dose of the
randomised study drug
23 participants (8 - 18 years) recruited.
Both groups had 11 participants.
Mean (SD) age: mannitol group = 13.2 (3.7) years; control group = 14.4 (3.0) years
Gender split: mannitol group = 45% male, 55% female; control group = 36% male;
64% female.
Control group had lower mean (SD) admission FEV1 (58.0 (13.0)% versus 73.1 (15.
6)% predicted, P < 0.05) and mean (range) FEF25−75 (25.7 (20.1 - 71.8)% versus 44.1
(22.8 - 92.43)% predicted, P < 0.05) than the IDPM group
All other parameters were equivalent on admission.
Interventions Treatment: inhaled dry-powder mannitol (10x 40 mg capsules) 2x daily.
Control: very low-dose inhaled dry-powder mannitol (10x 5 mg non-respirable manni-
tol) 2x daily
Administered for 12 consecutive days prior to airway clearance treatments supervised by
a physiotherapist
Used as an adjunct to intravenous antibiotics.
Outcomes As this was a pilot study, primary and secondary outcomes were not specified, outcomes
measured were:
clinical status (CFCS and CFQ-R);
lung function and cardiopulmonary exercise parameters (peak oxygen consumption,
ventilation efficacy, carbon dioxide production)
Outcome parameters were assessed at day 7, day 14 (discharge from hospital) and 1
month (follow-up)
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Middleton 2015 (Continued)
Funding Source Funded by Pharmaxis Australia but all aspects of the research study, design and analysis
were conducted without input from Pharmaxis
Conflicts of Interest The study authors declare no conflicts of interest.
Notes Additional unpublished information and results provided from conference presentation
slides from the authors
A study-drug tolerance test was conducted and deemed acceptable if baseline FEV1
decreased by < 50% immediately or < 20% 15 min after the test dose, or if oxygen
saturation remained > 89%
Inhaled dry-powder mannitol was tolerated well with 22 participants completing the
study; 1 participant was excluded due to vomiting after the test dose
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blinded randomisation was performed (1:
1) ratio via random number generation
without stratification
Allocation concealment (selection bias) Unclear risk Randomisation was described as ’blinded’
but not discussed how this was achieved
Blinding (performance bias and detection
bias)
Participants
Unclear risk The study was described as ’double-blind’
but not discussed exactly who was blinded
and how the blind was achieved
Blinding (performance bias and detection
bias)
Clinicians
Unclear risk The study was described as ’double-blind’
but not discussed exactly who was blinded
and how the blind was achieved
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk The study was described as ’double-blind’
but not discussed exactly who was blinded
and how the blind was achieved
Incomplete outcome data (attrition bias)
All outcomes
Low risk 22 out of 23 participants completed the
study and contributed data to analysis. 1
participant failed the tolerance test and was
excluded
Selective reporting (reporting bias) Low risk All important outcomes of the pilot study
seem to be reported
Other bias High risk The authors note a relatively small sam-
ple size which prevents ’strong conclusions
about clinical utility in this setting
The study population included only those
with CF who passed the tolerance test and
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Middleton 2015 (Continued)
not all potential participants with CF
Minasian 2010
Methods Open-label, randomised, cross-over study.
Duration (total): 40 weeks; each arm of cross-over study lasted 12 weeks with a 2-week
wash-out period in between
Location: UK. (multicentre, two centres)
Participants 45 were recruited but only 28 were randomised, 8 participants withdrew. Considering
randomised participants (results different from those who completed treatment in all
arms and were analysed):
28 participants with CF:
Mean (SD) age: 13.3 (2.24) years.
Gender split: 36% male, 64% female.
All participants clinically stable at start of study.
Excluded participants using hypertonic saline
Characteristics of the 20 participants who completed treatment:
Mean (SD) age: 13.2 (2.4) years.
Gender split: 30% male, 70% female.
Mean (SD) baseline FEV1: 1.67 (0.50) litres, 64 (10)% of predicted FEV1.
Interventions Pre-treated with participant’s usual bronchodilator 15 minutes beforehand
Arm 1
Mannitol 400 mg 2x daily, 10 x 40 mg capsules. Manufacturer of mannitol not reported
but assumed to be Pharmaxis as study was sponsored by this company. Administered via
breath-actuated device Osmohaler, Plastiape, Osnago, Italy
Arm 2
Dornase alfa alone - 2.5 mg Pulmozyme® 2x daily via participant’s usual device
Arm 3
Mannitol (as above) plus dornase alfa (dose unclear).
Outcomes Primary outcome: FEV1.
Secondary outcomes: FVC; FEF25−75 ; frequency of pulmonary exacerbations; sputum
microbiology; exercise tolerance; HRQoL scores; respiratory symptom questionnaires;
and adverse events
Funding Source The study was funded by Pharmaxis Limited.
Conflicts of Interest No specific conflicts of interest are declared, other than the funding source of the study
Notes Pulmonary exacerbations, respiratory symptom and treatment effects questionnaire, spu-
tum microbiology and burden of treatment not reported in the publication, Pharmaxis
and primary investigator (Dr Minasian) supplied some additional information for most
outcomes included in this review
Risk of bias
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Minasian 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised, but details of
randomisation process not discussed in pa-
per. Dr Minasian provided additional in-
formation - participants were allocated a
unique randomisation number and treat-
ment schedule with equal probability for
assignment to treatment sequences. Ran-
domisation was carried out in balanced
blocks with separate schedules created for
each of the 2 recruiting centres
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
Participants
High risk Open study.
Blinding (performance bias and detection
bias)
Clinicians
High risk Open study.
Blinding (performance bias and detection
bias)
Outcome assessors
High risk Open study.
Incomplete outcome data (attrition bias)
All outcomes
High risk Results in the paper only reported for par-
ticipants who completed all 3 arms of the
study. The desired sample size was 48 par-
ticipants: 45 were recruited but only 28
were randomised and 8 participants with-
drew
Selective reporting (reporting bias) Low risk Limited information was reported in the
study publication regarding outcomes of
HRQoL, pulmonary exacerbations, spu-
tum microbiology and no information re-
ported on: time off work or school, non-
routine antibiotics, hospitalisations, toler-
ability or burden of treatment. Additional
data were provided by Pharmaxis and pri-
mary investigator Dr Minasian on request
for all primary outcomes of this review and
many secondary outcomes
Other bias High risk Participants underwent a mannitol toler-
ance test at screening; participants who
failed the test or in whom the test was in-
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Minasian 2010 (Continued)
complete were not entered into the study
and thus, the participant population in-
cluded only those participants with CF
who passed the tolerance test and not all
potential participants with CF
Underpowered study, many dropouts
(48% of required sample size were analysed
in the published analysis). Actual dropout
rate was 8/28 = 29% (as stated above)
Cross-over design - state that no carryover
effect observed, but more details needed
Sponsored by Pharmaxis; authors or study
staff worked for Pharmaxis or had financial
interest
CF: cystic fibrosis
CFCS: Cystic Fibrosis Clinical Score
CFQ-R: cystic fibrosis questionnaire (revised)
HRQoL: health-related quality of life
FEF25−75: mid-expiratory flow
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
IVRS: interactive voice response system
PDPE: protocol-defined pulmonary exacerbation
PE: pulmonary exacerbation
PEF: peak expiratory flow
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Robinson 1999 Single treatment study and examined effect on bronchial mucus clearance, not clinical
Teper 2011 Dose-response study and data on clinically-used dose cannot be incorporated
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Characteristics of ongoing studies [ordered by study ID]
NCT02134353
Trial name or title Long-Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult
Cystic Fibrosis Subjects
Methods Randomised, double-blind, parallel study.
Treatment duration: 26 weeks.
Multicentre in USA, Argentina, Australia, Belgium, Canada, Czech Republic, Hungary, Israel, Italy, Mexico,
New Zealand, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Participants Estimated enrolment: 440 adults with CF (18 years or older).
Interventions Inhaled mannitol 400 mg twice daily versus inhaled control twice daily for 26 weeks
Outcomes Primary outcome: FEV1 (mean absolute change in mL) over weeks 6, 14 and 26 with a REML-based repeated
measures approach
Secondary outcomes: FVC (mean change from baseline in mL); time to first pulmonary exacerbation; rate of
pulmonary exacerbations; number of days in hospital due to pulmonary exacerbation; incidence of pulmonary
exacerbations; days on antibiotics (oral, inhaled or IV) due to pulmonary exacerbation; ease of expectoration
measured using a visual analogue scale; CFQ-R respiratory domain score
Starting date October 2014.
Contact information April 2016 (March 2016 is final data collection date for primary outcome measure)
Notes Contact: Brett Charlton (brett.charlton@pharmaxis.com.au).
CF: cystic fibrosis
CFQ-R: cystic fibrosis questionnaire (revised)
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
IV: intravenous
REML: restricted maximum likelihood
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D A T A A N D A N A L Y S E S
Comparison 1. Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HRQoL - respiratory (change
from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Up to 4 months 2 507 Mean Difference (IV, Fixed, 95% CI) -1.54 [-4.69, 1.61]
1.2 Up to 6 months 2 465 Mean Difference (IV, Fixed, 95% CI) -0.99 [-4.50, 2.52]
2 HRQoL - vitality (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Up to 4 months 2 361 Mean Difference (IV, Fixed, 95% CI) 3.42 [-0.21, 7.04]
2.2 Up to 6 months 2 325 Mean Difference (IV, Fixed, 95% CI) 4.84 [0.86, 8.82]
3 HRQoL - physical (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Up to 4 months 2 505 Mean Difference (IV, Fixed, 95% CI) -1.80 [-4.72, 1.11]
3.2 Up to 6 months 2 465 Mean Difference (IV, Fixed, 95% CI) 0.52 [-2.75, 3.79]
4 HRQoL - emotion (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Up to 4 months 2 506 Mean Difference (IV, Fixed, 95% CI) -2.11 [-4.56, 0.34]
4.2 Up to 6 months 2 465 Mean Difference (IV, Fixed, 95% CI) -1.27 [-3.74, 1.20]
5 HRQoL - eating (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Up to 4 months 2 505 Mean Difference (IV, Fixed, 95% CI) 0.81 [-1.96, 3.58]
5.2 Up to 6 months 2 466 Mean Difference (IV, Fixed, 95% CI) 0.68 [-2.29, 3.65]
6 HRQoL - health (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Up to 4 months 2 360 Mean Difference (IV, Fixed, 95% CI) -0.43 [-4.18, 3.32]
6.2 Up to 6 months 2 325 Mean Difference (IV, Fixed, 95% CI) -0.21 [-4.14, 3.72]
7 HRQoL - social (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Up to 4 months 2 504 Mean Difference (IV, Fixed, 95% CI) -1.20 [-3.70, 1.30]
7.2 Up to 6 months 2 465 Mean Difference (IV, Fixed, 95% CI) -1.47 [-4.25, 1.32]
8 HRQoL - body (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Up to 4 months 2 500 Mean Difference (IV, Fixed, 95% CI) -3.10 [-6.49, 0.29]
8.2 Up to 6 months 2 461 Mean Difference (IV, Fixed, 95% CI) -1.19 [-4.51, 2.13]
9 HRQoL - role (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Up to 4 months 2 358 Mean Difference (IV, Fixed, 95% CI) 1.22 [-2.21, 4.66]
9.2 Up to 6 months 2 324 Mean Difference (IV, Fixed, 95% CI) -1.43 [-4.87, 2.00]
10 HRQoL - weight (change from
baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Up to 4 months 2 360 Mean Difference (IV, Fixed, 95% CI) -4.23 [-10.28, 1.83]
10.2 Up to 6 months 2 325 Mean Difference (IV, Fixed, 95% CI) -3.27 [-9.84, 3.31]
11 HRQoL - digestion (change
from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 Up to 4 months 2 505 Mean Difference (IV, Fixed, 95% CI) -1.49 [-4.77, 1.78]
69Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
11.2 Up to 6 months 2 465 Mean Difference (IV, Fixed, 95% CI) -1.07 [-5.04, 2.90]
12 FEV1 ml (repeated measures,
change from baseline)
2 Mean Difference (Fixed, 95% CI) Subtotals only
12.1 up to 2 months 2 600 Mean Difference (Fixed, 95% CI) 71.27 [36.00, 106.
54]
12.2 Up to 4 months 2 600 Mean Difference (Fixed, 95% CI) 64.54 [26.65, 102.
42]
12.3 Up to 6 months 2 600 Mean Difference (Fixed, 95% CI) 86.50 [45.15, 127.
86]
13 FEV1 % predicted (repeated
measures, change from
baseline)
2 Mean Difference (Fixed, 95% CI) Subtotals only
13.1 up to 2 months 2 600 Mean Difference (Fixed, 95% CI) 2.98 [1.04, 4.92]
13.2 up to 4 months 2 600 Mean Difference (Fixed, 95% CI) 3.26 [1.16, 5.35]
13.3 up to 6 months 2 600 Mean Difference (Fixed, 95% CI) 3.89 [1.69, 6.08]
14 FVC mL (repeated measures,
change from baseline)
2 Mean Difference (Fixed, 95% CI) Subtotals only
14.1 Up to 2 months 2 600 Mean Difference (Fixed, 95% CI) 87.81 [41.96, 133.
66]
14.2 Up to 4 months 2 600 Mean Difference (Fixed, 95% CI) 89.24 [40.55, 137.
92]
14.3 up to 6 months 2 600 Mean Difference (Fixed, 95% CI) 102.17 [48.40, 155.
94]
15 FEF25-75 mL/s (repeated
measures, change from
baseline)
2 Mean Difference (Fixed, 95% CI) Subtotals only
15.1 Up to 2 months 2 600 Mean Difference (Fixed, 95% CI) 47.53 [-16.42, 111.
48]
15.2 Up to 4 months 2 600 Mean Difference (Fixed, 95% CI) 31.30 [-34.78, 97.
37]
15.3 Up to 6 months 2 600 Mean Difference (Fixed, 95% CI) 42.67 [-28.07, 113.
42]
16 Adverse events at up to 6
months(mild)
2 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
16.1 Cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.82 [0.41, 8.07]
16.2 Haemoptysis 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.73 [0.26, 11.62]
16.3 Pharyngolaryngeal pain 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.04 [0.18, 5.97]
16.4 Throat irritation 2 600 Risk Ratio (M-H, Fixed, 99% CI) 3.30 [0.06, 176.31]
16.5 Productive cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.66 [0.15, 46.93]
16.6 Wheezing 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.66 [0.07, 6.59]
16.7 Asthma 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.22 [0.00, 14.79]
16.8 Bronchospasm 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
16.9 Condition aggravated 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.99 [0.10, 10.33]
16.10 Chest discomfort 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.40 [0.03, 5.66]
16.11 Chest pain 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.22 [0.00, 14.79]
16.12 Vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 3.99 [0.25, 63.83]
16.13 Post-tussive vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.99 [0.10, 38.69]
16.14 Headache 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.43 [0.23, 25.79]
16.15 Decreased appetite 1 295 Risk Ratio (M-H, Fixed, 99% CI) 3.34 [0.06, 178.67]
16.16 Infections and
infestations
2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.37 [0.05, 2.78]
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16.17 Musculoskeletal and
connective tissue disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.66 [0.15, 46.93]
16.18 Skin and subcutaneous
disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 3.33 [0.20, 55.34]
17 Adverse events at up to 6
months (moderate)
2 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
17.1 Cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 3.15 [0.78, 12.77]
17.2 Haemoptysis 2 600 Risk Ratio (M-H, Fixed, 99% CI) 4.66 [0.50, 43.49]
17.3 Pharyngolaryngeal pain 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.43 [0.23, 25.79]
17.4 Throat irritation 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.01 [0.03, 133.11]
17.5 Productive cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.66 [0.02, 24.81]
17.6 Wheezing 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.44 [0.04, 4.57]
17.7 Asthma 1 295 Risk Ratio (M-H, Fixed, 99% CI) 1.33 [0.06, 30.80]
17.8 Bronchospasm 1 295 Risk Ratio (M-H, Fixed, 99% CI) 2.01 [0.03, 133.11]
17.9 Condition aggravated 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.82 [0.41, 8.03]
17.10 Chest discomfort 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.99 [0.25, 16.10]
17.11 Chest pain 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.22 [0.00, 14.79]
17.12 Vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.13 [0.00, 7.15]
17.13 Post-tussive vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 4.62 [0.10, 224.14]
17.14 Headache 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.99 [0.18, 22.39]
17.15 Decreased appetite 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
17.16 Infections and
infestations
2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.04 [0.18, 5.95]
17.17 Musculoskeletal and
connective tissue disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.10 [0.08, 15.63]
17.18 Skin and subcutaneous
disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.22 [0.00, 14.59]
18 Adverse events at up to 6
months (severe)
2 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
18.1 Cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.17 [0.24, 5.69]
18.2 Haemoptysis 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.55 [0.13, 18.99]
18.3 Pharyngolaryngeal pain 2 600 Risk Ratio (M-H, Fixed, 99% CI) 3.33 [0.20, 55.34]
18.4 Throat irritation 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.66 [0.05, 8.70]
18.5 Productive cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.6 Wheezing 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.7 Asthma 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.8 Bronchospasm 1 295 Risk Ratio (M-H, Fixed, 99% CI) 2.01 [0.03, 133.11]
18.9 Condition aggravated 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.67 [0.02, 25.14]
18.10 Chest discomfort 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.11 Chest pain 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.12 Vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.13 Post-tussive vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.01 [0.03, 133.11]
18.14 Headache 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.98 [0.03, 131.35]
18.15 Decreased appetite 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.16 Infections and
infestations
2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.28 [0.02, 3.47]
18.17 Musculoskeletal and
connective tissue disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.0 [0.0, 0.0]
18.18 Skin and subcutaneous
tissue disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.01 [0.03, 133.11]
19 Adverse events at up to 6
months (total)
2 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
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19.1 Cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.05 [0.90, 4.67]
19.2 Haemoptysis 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.88 [0.77, 10.85]
19.3 Pharyngolaryngeal pain 2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.13 [0.54, 8.44]
19.4 Throat irritation 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.99 [0.18, 22.42]
19.5 Productive cough 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.99 [0.18, 22.30]
19.6 Wheezing 2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.53 [0.10, 2.95]
19.7 Asthma 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.67 [0.05, 8.60]
19.8 Bronchospasm 1 295 Risk Ratio (M-H, Fixed, 99% CI) 3.34 [0.06, 178.67]
19.9 Condition aggravated 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.42 [0.44, 4.52]
19.10 Chest discomfort 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.16 [0.23, 5.74]
19.11 Chest pain 1 295 Risk Ratio (M-H, Fixed, 99% CI) 0.13 [0.00, 7.15]
19.12 Vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 1.46 [0.21, 10.28]
19.13 Post-tussive vomiting 2 600 Risk Ratio (M-H, Fixed, 99% CI) 4.64 [0.30, 72.37]
19.14 Headache 2 600 Risk Ratio (M-H, Fixed, 99% CI) 3.31 [0.46, 24.06]
19.15 Decreased appetite 1 295 Risk Ratio (M-H, Fixed, 99% CI) 3.34 [0.06, 178.67]
19.16 Infections and
infestations
2 600 Risk Ratio (M-H, Fixed, 99% CI) 0.53 [0.16, 1.75]
19.17 Musculoskeletal and
connective tissue disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.43 [0.23, 25.79]
19.18 Skin and subcutaneous
tissues disorders
2 600 Risk Ratio (M-H, Fixed, 99% CI) 2.44 [0.23, 25.82]
20 Participants with
treatment-related respiratory
and thoracic adverse
events leading to study
discontinuation
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Asthma 2 600 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [0.08, 48.82]
20.2 Bronchospasm 2 600 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [0.08, 48.82]
20.3 Cough 2 600 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [0.85, 6.02]
20.4 Haemoptysis 2 600 Risk Ratio (M-H, Fixed, 95% CI) 3.33 [0.39, 28.25]
20.5 Hyperventilation 2 600 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.08, 48.17]
20.6 Obstructive airways
disorder
2 600 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.08, 48.17]
20.7 Pharynolaryngeal pain 2 600 Risk Ratio (M-H, Fixed, 95% CI) 2.66 [0.30, 23.62]
20.8 Productive cough 2 600 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.08, 48.17]
20.9 Throat irritation 2 600 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.09, 4.70]
20.10 Wheezing 2 600 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.76]
21 Number of patients with
protocol defined pulmonary
exacerbations
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 Up to 6 months 2 600 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.51, 0.98]
22 Time to first protocol defined
pulmonary exacerbation
(PDPE)
2 600 Hazard Ratio (Fixed, 95% CI) 0.70 [0.48, 1.02]
23 Number of patients needing
additional antibiotics
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 Intravenous 2 600 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.70, 0.95]
24 Number of participants
requiring hospitalisation
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
24.1 With pulmonary
exacerbation, up to 6 months
2 600 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.60, 1.15]
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24.2 With PDPE, up to 6
months
2 600 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.53, 1.15]
25 Duration of hospitalisation 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
25.1 Duration of
hospitalisation with pulmonary
exacerbation, up to 6 months
(days)
2 600 Mean Difference (IV, Fixed, 95% CI) -1.04 [-2.58, 0.50]
25.2 Duration of
hospitalisation with PDPE, up
to 6 months (days)
2 600 Mean Difference (IV, Fixed, 95% CI) -0.64 [-1.87, 0.60]
26 Sputum weight (g) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
26.1 at 14 weeks 2 460 Mean Difference (IV, Fixed, 95% CI) 1.02 [-0.10, 2.14]
27 Sputum weight (g) (change
from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
27.1 Up to 4 months 2 439 Mean Difference (IV, Fixed, 95% CI) -0.95 [-2.05, 0.15]
28 Microbiology: pathogens
present at end of study
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
28.1 Pseudomonas aeruginosa
(mucoid)
2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.69, 1.17]
28.2 Pseudomonas aeruginosa
(non-mucoid)
2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.53, 1.03]
28.3 Pseudomonas aeruginosa
(not specified)
2 461 Risk Ratio (M-H, Fixed, 95% CI) 3.80 [0.45, 31.97]
28.4 Pseudomonas spp (other) 2 461 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.42, 3.17]
28.5 Staphylococcus aureus 2 461 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.81, 1.28]
28.6 Methicillin-resistant
Staphylococcus aureus
1 263 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.58, 2.39]
28.7 Burkholderia cepacia
(cenocepacia)
2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.32, 1.48]
28.8 Aspergillus spp 2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.51, 1.30]
28.9 Candida spp 2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.49, 1.33]
29 Burden of treatment (change
from baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
29.1 Up to 4 months 2 505 Mean Difference (IV, Fixed, 95% CI) -4.6 [-7.90, -1.30]
29.2 Up to 6 months 2 465 Mean Difference (IV, Fixed, 95% CI) -2.12 [-5.70, 1.46]
30 Adherence ≥ 60% 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
30.1 Up to 6 months 2 600 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.82, 0.97]
Comparison 2. Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change from baseline)
1 174 Mean Difference (Fixed, 95% CI) 3.42 [1.13, 5.71]
2 FEV1 % predicted (absolute
change from baseline -
subgroup analysis by age)
1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 age 6 to 11 years 1 78 Mean Difference (Fixed, 95% CI) 3.78 [0.13, 7.43]
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2.2 age 12 to 17 years 1 106 Mean Difference (Fixed, 95% CI) 3.35 [0.14, 6.56]
3 FEV1 % predicted (absolute
change from baseline -
subgroup analysis by dornase
alfa use
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Dornase alfa user 1 126 Mean Difference (Fixed, 95% CI) 3.29 [0.28, 6.30]
3.2 Dornase alfa non-user 1 58 Mean Difference (Fixed, 95% CI) 3.92 [0.42, 7.42]
4 FEV1 % predicted (relative
change from baseline)
1 174 Mean Difference (Fixed, 95% CI) 4.97 [1.52, 8.42]
5 FVC % predicted (absolute
change from baseline)
1 174 Mean Difference (Fixed, 95% CI) 1.8 [-0.72, 4.32]
6 FVC % predicted (relative
change from baseline)
1 174 Mean Difference (Fixed, 95% CI) 2.54 [-0.72, 5.80]
7 FEF25-75 % predicted (absolute
change from baseline)
1 174 Mean Difference (Fixed, 95% CI) 5.75 [1.81, 9.69]
8 FEF25-75 % predicted (relative
change from baseline)
1 174 Mean Difference (Fixed, 95% CI) 10.52 [2.31, 18.73]
9 Sputum weight (grams)
(post-initial treatment)
1 174 Mean Difference (Fixed, 95% CI) 1.33 [0.29, 2.37]
Comparison 3. Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to
pulmonary exacerbations
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HRQoL - change from baseline
in CFCS total score
1 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 at hospital discharge (14
days)
1 22 Mean Difference (Fixed, 95% CI) 1.1 [-0.50, 2.70]
1.2 at 1 month follow-up 1 22 Mean Difference (Fixed, 95% CI) -1.0 [-4.10, 2.10]
2 HRQoL - change from baseline
in CFQ-R respiratory domain
1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 at hospital discharge (14
days)
1 22 Mean Difference (Fixed, 95% CI) 1.3 [-10.50, 13.10]
2.2 at 1 month follow-up 1 22 Mean Difference (Fixed, 95% CI) 3.5 [-10.70, 17.70]
3 FEV1 % predicted (change from
baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 at hospital discharge (14
days)
1 22 Mean Difference (Fixed, 95% CI) 4.6 [-3.80, 13.00]
3.2 at 1 month follow-up 1 22 Mean Difference (Fixed, 95% CI) 5.40 [-2.70, 13.50]
4 FVC % predicted (change from
baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
4.1 at hospital discharge (14
days)
1 22 Mean Difference (Fixed, 95% CI) 2.8 [-3.60, 9.20]
4.2 at 1 month follow-up 1 22 Mean Difference (Fixed, 95% CI) 1.7 [-4.10, 7.50]
5 FEF25-75 % predicted (change
from baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
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5.1 at hospital discharge (14
days)
1 22 Mean Difference (Fixed, 95% CI) 12.8 [-3.30, 28.90]
5.2 at 1 month follow-up 1 22 Mean Difference (Fixed, 95% CI) 3.9 [-10.70, 18.50]
Comparison 4. Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 (% change from baseline) 1 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 Up to 3 months 1 40 Mean Difference (Fixed, 95% CI) 2.8 [-4.80, 10.40]
2 FVC (% change from baseline) 1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 Up to 3 months 1 40 Mean Difference (Fixed, 95% CI) 0.14 [-0.02, 0.30]
3 FEF25-75 (% change from
baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Up to 3 months 1 40 Mean Difference (Fixed, 95% CI) -0.01 [-0.23, 0.21]
Comparison 5. Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 (% change from baseline) 1 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 Up to 3 months 1 40 Mean Difference (Fixed, 95% CI) -4.3 [-14.10, 5.50]
2 FVC (% change from baseline) 1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 Up to 3 months 1 40 Mean Difference (Fixed, 95% CI) -0.07 [-0.30, 0.16]
3 FEF25-75 (% change from
baseline)
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Up to 3 months 1 20 Mean Difference (Fixed, 95% CI) 0.03 [-0.18, 0.24]
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Analysis 1.1. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 1 HRQoL - respiratory (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 1 HRQoL - respiratory (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 -0.1 (17.58) 114 3.8 (21.89) 42.5 % -3.90 [ -8.74, 0.94 ]
Bilton 2011 128 0.3 (16.3) 101 0.1 (15.62) 57.5 % 0.20 [ -3.95, 4.35 ]
Subtotal (95% CI) 292 215 100.0 % -1.54 [ -4.69, 1.61 ]
Heterogeneity: Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Up to 6 months
Aitken 2012 154 -1.4 (20.16) 110 5.6 (22.51) 44.3 % -7.00 [ -12.28, -1.72 ]
Bilton 2011 114 1.3 (15.95) 87 -2.5 (17.55) 55.7 % 3.80 [ -0.91, 8.51 ]
Subtotal (95% CI) 268 197 100.0 % -0.99 [ -4.50, 2.52 ]
Heterogeneity: Chi2 = 8.96, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.55 (P = 0.58)
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Analysis 1.2. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 2 HRQoL - vitality (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 2 HRQoL - vitality (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 115 -1.9 (17.94) 80 -5.4 (15.81) 57.7 % 3.50 [ -1.27, 8.27 ]
Bilton 2011 92 -0.2 (17.56) 74 -3.5 (18.71) 42.3 % 3.30 [ -2.27, 8.87 ]
Subtotal (95% CI) 207 154 100.0 % 3.42 [ -0.21, 7.04 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.065)
2 Up to 6 months
Aitken 2012 107 -1.6 (20.48) 76 -4.2 (17.72) 51.2 % 2.60 [ -2.96, 8.16 ]
Bilton 2011 80 2.1 (15.88) 62 -5.1 (18.13) 48.8 % 7.20 [ 1.50, 12.90 ]
Subtotal (95% CI) 187 138 100.0 % 4.84 [ 0.86, 8.82 ]
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 2.39 (P = 0.017)
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Analysis 1.3. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 3 HRQoL - physical (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 3 HRQoL - physical (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 -0.1 (18.17) 114 2.3 (16.53) 50.2 % -2.40 [ -6.52, 1.72 ]
Bilton 2011 127 -2.7 (16.55) 100 -1.5 (15.1) 49.8 % -1.20 [ -5.33, 2.93 ]
Subtotal (95% CI) 291 214 100.0 % -1.80 [ -4.72, 1.11 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
2 Up to 6 months
Aitken 2012 155 -1.7 (18.85) 110 1.1 (18.2) 52.5 % -2.80 [ -7.31, 1.71 ]
Bilton 2011 113 -0.5 (16.22) 87 -4.7 (17.56) 47.5 % 4.20 [ -0.55, 8.95 ]
Subtotal (95% CI) 268 197 100.0 % 0.52 [ -2.75, 3.79 ]
Heterogeneity: Chi2 = 4.38, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.31 (P = 0.75)
-10 -5 0 5 10
Favours 50mg mannitol Favours 400mg mannitol
78Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 4 HRQoL - emotion (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 4 HRQoL - emotion (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 0.3 (14.35) 114 2.9 (12.64) 58.8 % -2.60 [ -5.79, 0.59 ]
Bilton 2011 128 -1.5 (15.4) 100 -0.1 (13.94) 41.2 % -1.40 [ -5.22, 2.42 ]
Subtotal (95% CI) 292 214 100.0 % -2.11 [ -4.56, 0.34 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
2 Up to 6 months
Aitken 2012 155 0.4 (15.34) 109 2.1 (12.84) 52.5 % -1.70 [ -5.11, 1.71 ]
Bilton 2011 114 -0.3 (11.7) 87 0.5 (13.66) 47.5 % -0.80 [ -4.38, 2.78 ]
Subtotal (95% CI) 269 196 100.0 % -1.27 [ -3.74, 1.20 ]
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
-4 -2 0 2 4
Favours 50mg mannitol Favours 400mg mannitol
79Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 5 HRQoL - eating (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 5 HRQoL - eating (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 -1.6 (17.29) 114 -3.3 (16.39) 47.8 % 1.70 [ -2.31, 5.71 ]
Bilton 2011 128 0.6 (15.1) 99 0.6 (14.23) 52.2 % 0.0 [ -3.83, 3.83 ]
Subtotal (95% CI) 292 213 100.0 % 0.81 [ -1.96, 3.58 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Up to 6 months
Aitken 2012 155 -0.4 (18.37) 110 -1.4 (17.3) 46.8 % 1.00 [ -3.34, 5.34 ]
Bilton 2011 114 2.3 (15.47) 87 1.9 (13.89) 53.2 % 0.40 [ -3.67, 4.47 ]
Subtotal (95% CI) 269 197 100.0 % 0.68 [ -2.29, 3.65 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
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Analysis 1.6. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 6 HRQoL - health (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 6 HRQoL - health (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 115 -0.1 (16.22) 80 -1 (17.52) 59.7 % 0.90 [ -3.95, 5.75 ]
Bilton 2011 93 -0.1 (18.45) 72 2.3 (19.73) 40.3 % -2.40 [ -8.30, 3.50 ]
Subtotal (95% CI) 208 152 100.0 % -0.43 [ -4.18, 3.32 ]
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Up to 6 months
Aitken 2012 107 -1.5 (17.61) 77 -0.9 (18) 56.6 % -0.60 [ -5.82, 4.62 ]
Bilton 2011 79 1.4 (17.47) 62 1.1 (18.3) 43.4 % 0.30 [ -5.67, 6.27 ]
Subtotal (95% CI) 186 139 100.0 % -0.21 [ -4.14, 3.72 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 1.7. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 7 HRQoL - social (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 7 HRQoL - social (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 -1.6 (13.66) 114 0.2 (15.55) 50.0 % -1.80 [ -5.34, 1.74 ]
Bilton 2011 128 -1.4 (15.6) 98 -0.8 (11.54) 50.0 % -0.60 [ -4.14, 2.94 ]
Subtotal (95% CI) 292 212 100.0 % -1.20 [ -3.70, 1.30 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Up to 6 months
Aitken 2012 155 -3.3 (16.99) 110 0.9 (16.23) 47.4 % -4.20 [ -8.24, -0.16 ]
Bilton 2011 113 0.3 (13.75) 87 -0.7 (13.74) 52.6 % 1.00 [ -2.84, 4.84 ]
Subtotal (95% CI) 268 197 100.0 % -1.47 [ -4.25, 1.32 ]
Heterogeneity: Chi2 = 3.34, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 1.8. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 8 HRQoL - body (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 8 HRQoL - body (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 -2 (21.75) 113 1.5 (21.39) 43.1 % -3.50 [ -8.66, 1.66 ]
Bilton 2011 126 -1.2 (16.94) 97 1.6 (16.97) 56.9 % -2.80 [ -7.29, 1.69 ]
Subtotal (95% CI) 290 210 100.0 % -3.10 [ -6.49, 0.29 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
2 Up to 6 months
Aitken 2012 155 0.4 (20.29) 109 2.9 (20.86) 43.2 % -2.50 [ -7.55, 2.55 ]
Bilton 2011 111 1.6 (16.26) 86 1.8 (15.14) 56.8 % -0.20 [ -4.60, 4.20 ]
Subtotal (95% CI) 266 195 100.0 % -1.19 [ -4.51, 2.13 ]
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 1.9. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 9 HRQoL - role (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 9 HRQoL - role (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 115 -0.9 (13.93) 79 -0.8 (17.33) 55.9 % -0.10 [ -4.69, 4.49 ]
Bilton 2011 92 0.5 (18.05) 72 -2.4 (15.66) 44.1 % 2.90 [ -2.27, 8.07 ]
Subtotal (95% CI) 207 151 100.0 % 1.22 [ -2.21, 4.66 ]
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Up to 6 months
Aitken 2012 106 -2.3 (17.35) 76 1.1 (13.83) 57.2 % -3.40 [ -7.94, 1.14 ]
Bilton 2011 80 -0.4 (16.66) 62 -1.6 (15.15) 42.8 % 1.20 [ -4.05, 6.45 ]
Subtotal (95% CI) 186 138 100.0 % -1.43 [ -4.87, 2.00 ]
Heterogeneity: Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 1.10. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 10 HRQoL - weight (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 10 HRQoL - weight (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 115 2 (32.23) 80 4.6 (27.94) 50.7 % -2.60 [ -11.10, 5.90 ]
Bilton 2011 92 1.4 (26.11) 73 7.3 (29.53) 49.3 % -5.90 [ -14.52, 2.72 ]
Subtotal (95% CI) 207 153 100.0 % -4.23 [ -10.28, 1.83 ]
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Up to 6 months
Aitken 2012 106 4.1 (33.71) 77 7.8 (29.07) 51.9 % -3.70 [ -12.83, 5.43 ]
Bilton 2011 80 3.7 (23.72) 62 6.5 (31.85) 48.1 % -2.80 [ -12.28, 6.68 ]
Subtotal (95% CI) 186 139 100.0 % -3.27 [ -9.84, 3.31 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 1.11. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 11 HRQoL - digestion (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 11 HRQoL - digestion (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 0.1 (16.58) 114 2.1 (21.36) 49.2 % -2.00 [ -6.67, 2.67 ]
Bilton 2011 128 -0.8 (17.2) 99 0.2 (17.75) 50.8 % -1.00 [ -5.59, 3.59 ]
Subtotal (95% CI) 292 213 100.0 % -1.49 [ -4.77, 1.78 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Up to 6 months
Aitken 2012 154 1.4 (20.47) 110 2.8 (23.48) 52.9 % -1.40 [ -6.85, 4.05 ]
Bilton 2011 114 -0.7 (19.46) 87 0 (21.63) 47.1 % -0.70 [ -6.48, 5.08 ]
Subtotal (95% CI) 268 197 100.0 % -1.07 [ -5.04, 2.90 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
-10 -5 0 5 10
Favours 50mg mannitol Favours 400mg mannitol
86Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.12. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 12 FEV1 ml (repeated measures, change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 12 FEV1 ml (repeated measures, change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to 2 months
Aitken 2012 184 121 59.52 (30.25) 35.4 % 59.52 [ 0.23, 118.81 ]
Bilton 2011 177 118 77.71 (22.387) 64.6 % 77.71 [ 33.83, 121.59 ]
Subtotal (95% CI) 361 239 100.0 % 71.27 [ 36.00, 106.54 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.96 (P = 0.000075)
2 Up to 4 months
Aitken 2012 184 121 30.71 (33.4) 33.5 % 30.71 [ -34.75, 96.17 ]
Bilton 2011 177 118 81.57 (23.7) 66.5 % 81.57 [ 35.12, 128.02 ]
Subtotal (95% CI) 361 239 100.0 % 64.54 [ 26.65, 102.42 ]
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 3.34 (P = 0.00084)
3 Up to 6 months
Aitken 2012 184 121 72.19 (38.01) 30.8 % 72.19 [ -2.31, 146.69 ]
Bilton 2011 177 118 92.88 (25.369) 69.2 % 92.88 [ 43.16, 142.60 ]
Subtotal (95% CI) 361 239 100.0 % 86.50 [ 45.15, 127.86 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.10 (P = 0.000041)
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Analysis 1.13. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 13 FEV1 % predicted (repeated measures, change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 13 FEV1 % predicted (repeated measures, change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to 2 months
Aitken 2012 184 121 3.89 (1.81) 30.0 % 3.89 [ 0.34, 7.44 ]
Bilton 2011 177 118 2.588 (1.184) 70.0 % 2.59 [ 0.27, 4.91 ]
Subtotal (95% CI) 361 239 100.0 % 2.98 [ 1.04, 4.92 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.01 (P = 0.0026)
2 up to 4 months
Aitken 2012 184 121 2.34 (2.04) 27.4 % 2.34 [ -1.66, 6.34 ]
Bilton 2011 177 118 3.602 (1.2534) 72.6 % 3.60 [ 1.15, 6.06 ]
Subtotal (95% CI) 361 239 100.0 % 3.26 [ 1.16, 5.35 ]
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.05 (P = 0.0023)
3 up to 6 months
Aitken 2012 184 121 4.55 (2.03) 30.4 % 4.55 [ 0.57, 8.53 ]
Bilton 2011 177 118 3.595 (1.3419) 69.6 % 3.60 [ 0.96, 6.23 ]
Subtotal (95% CI) 361 239 100.0 % 3.89 [ 1.69, 6.08 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00052)
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Analysis 1.14. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 14 FVC mL (repeated measures, change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 14 FVC mL (repeated measures, change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 2 months
Aitken 2012 184 121 78.17 (34.83) 45.1 % 78.17 [ 9.90, 146.44 ]
Bilton 2011 177 118 95.73 (31.572) 54.9 % 95.73 [ 33.85, 157.61 ]
Subtotal (95% CI) 361 239 100.0 % 87.81 [ 41.96, 133.66 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00017)
2 Up to 4 months
Aitken 2012 184 121 49.12 (37.1) 44.8 % 49.12 [ -23.59, 121.83 ]
Bilton 2011 177 118 121.83 (33.44) 55.2 % 121.83 [ 56.29, 187.37 ]
Subtotal (95% CI) 361 239 100.0 % 89.24 [ 40.55, 137.92 ]
Heterogeneity: Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 3.59 (P = 0.00033)
3 up to 6 months
Aitken 2012 184 121 86.77 (42.7) 41.3 % 86.77 [ 3.08, 170.46 ]
Bilton 2011 177 118 112.99 (35.8) 58.7 % 112.99 [ 42.82, 183.16 ]
Subtotal (95% CI) 361 239 100.0 % 102.17 [ 48.40, 155.94 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.72 (P = 0.00020)
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Analysis 1.15. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 15 FEF25-75 mL/s (repeated measures, change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 15 FEF25−75 mL/s (repeated measures, change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 2 months
Aitken 2012 184 121 36.64 (62.42) 27.3 % 36.64 [ -85.70, 158.98 ]
Bilton 2011 177 118 51.62 (38.273) 72.7 % 51.62 [ -23.39, 126.63 ]
Subtotal (95% CI) 361 239 100.0 % 47.53 [ -16.42, 111.48 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
2 Up to 4 months
Aitken 2012 184 121 11.89 (60.78) 30.8 % 11.89 [ -107.24, 131.02 ]
Bilton 2011 177 118 39.92 (40.514) 69.2 % 39.92 [ -39.49, 119.33 ]
Subtotal (95% CI) 361 239 100.0 % 31.30 [ -34.78, 97.37 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
3 Up to 6 months
Aitken 2012 184 121 54.48 (65.61) 30.3 % 54.48 [ -74.11, 183.07 ]
Bilton 2011 177 118 37.55 (43.228) 69.7 % 37.55 [ -47.18, 122.28 ]
Subtotal (95% CI) 361 239 100.0 % 42.67 [ -28.07, 113.42 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
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Analysis 1.16. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 16 Adverse events at up to 6 months(mild).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 16 Adverse events at up to 6 months(mild)
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Aitken 2012 4/184 3/121 75.1 % 0.88 [ 0.13, 6.13 ]
Bilton 2011 7/177 1/118 24.9 % 4.67 [ 0.30, 72.03 ]
Subtotal (99% CI) 361 239 100.0 % 1.82 [ 0.41, 8.07 ]
Total events: 11 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: Chi2 = 1.72, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Haemoptysis
Bilton 2011 3/177 2/118 79.9 % 1.00 [ 0.10, 10.29 ]
Aitken 2012 3/184 0/121 20.1 % 4.62 [ 0.10, 224.14 ]
Subtotal (99% CI) 361 239 100.0 % 1.73 [ 0.26, 11.62 ]
Total events: 6 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Pharyngolaryngeal pain
Aitken 2012 2/184 3/121 85.8 % 0.44 [ 0.04, 4.51 ]
Bilton 2011 3/177 0/118 14.2 % 4.68 [ 0.10, 227.14 ]
Subtotal (99% CI) 361 239 100.0 % 1.04 [ 0.18, 5.97 ]
Total events: 5 (400mg mannitol), 3 (50mg mannitol)
Heterogeneity: Chi2 = 1.91, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 0.06 (P = 0.95)
4 Throat irritation
Bilton 2011 0/177 0/118 Not estimable
Aitken 2012 2/184 0/121 100.0 % 3.30 [ 0.06, 176.31 ]
Subtotal (99% CI) 361 239 100.0 % 3.30 [ 0.06, 176.31 ]
Total events: 2 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
5 Productive cough
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 2/177 0/118 49.9 % 3.34 [ 0.06, 178.67 ]
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(. . . Continued)
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 361 239 100.0 % 2.66 [ 0.15, 46.93 ]
Total events: 3 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
6 Wheezing
Bilton 2011 0/177 1/118 59.8 % 0.22 [ 0.00, 14.79 ]
Aitken 2012 2/184 1/121 40.2 % 1.32 [ 0.06, 30.40 ]
Subtotal (99% CI) 361 239 100.0 % 0.66 [ 0.07, 6.59 ]
Total events: 2 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
7 Asthma
Bilton 2011 0/177 1/118 100.0 % 0.22 [ 0.00, 14.79 ]
Subtotal (99% CI) 177 118 100.0 % 0.22 [ 0.00, 14.79 ]
Total events: 0 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
8 Bronchospasm
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 177 118 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Condition aggravated
Bilton 2011 1/177 1/118 49.9 % 0.67 [ 0.02, 25.14 ]
Aitken 2012 2/184 1/121 50.1 % 1.32 [ 0.06, 30.40 ]
Subtotal (99% CI) 361 239 100.0 % 0.99 [ 0.10, 10.33 ]
Total events: 3 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
10 Chest discomfort
Bilton 2011 0/177 1/118 59.8 % 0.22 [ 0.00, 14.79 ]
Aitken 2012 1/184 1/121 40.2 % 0.66 [ 0.02, 24.81 ]
Subtotal (99% CI) 361 239 100.0 % 0.40 [ 0.03, 5.66 ]
Total events: 1 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
11 Chest pain
Bilton 2011 0/177 1/118 100.0 % 0.22 [ 0.00, 14.79 ]
Subtotal (99% CI) 177 118 100.0 % 0.22 [ 0.00, 14.79 ]
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 0 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
12 Vomiting
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 4/177 0/118 49.9 % 6.02 [ 0.13, 276.51 ]
Subtotal (99% CI) 361 239 100.0 % 3.99 [ 0.25, 63.83 ]
Total events: 5 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
13 Post-tussive vomiting
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 1/177 0/118 49.9 % 2.01 [ 0.03, 133.11 ]
Subtotal (99% CI) 361 239 100.0 % 1.99 [ 0.10, 38.69 ]
Total events: 2 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
14 Headache
Aitken 2012 2/184 1/121 66.8 % 1.32 [ 0.06, 30.40 ]
Bilton 2011 3/177 0/118 33.2 % 4.68 [ 0.10, 227.14 ]
Subtotal (99% CI) 361 239 100.0 % 2.43 [ 0.23, 25.79 ]
Total events: 5 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
15 Decreased appetite
Bilton 2011 2/177 0/118 100.0 % 3.34 [ 0.06, 178.67 ]
Subtotal (99% CI) 177 118 100.0 % 3.34 [ 0.06, 178.67 ]
Total events: 2 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
16 Infections and infestations
Bilton 2011 0/177 2/118 55.4 % 0.13 [ 0.00, 7.15 ]
Aitken 2012 2/184 2/121 44.6 % 0.66 [ 0.05, 8.49 ]
Subtotal (99% CI) 361 239 100.0 % 0.37 [ 0.05, 2.78 ]
Total events: 2 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
17 Musculoskeletal and connective tissue disorders
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 2/177 0/118 49.9 % 3.34 [ 0.06, 178.67 ]
Subtotal (99% CI) 361 239 100.0 % 2.66 [ 0.15, 46.93 ]
Total events: 3 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
18 Skin and subcutaneous disorders
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 3/177 0/118 49.9 % 4.68 [ 0.10, 227.14 ]
Subtotal (99% CI) 361 239 100.0 % 3.33 [ 0.20, 55.34 ]
Total events: 4 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 1.17. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 17 Adverse events at up to 6 months (moderate).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 17 Adverse events at up to 6 months (moderate)
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Aitken 2012 7/184 1/121 25.1 % 4.60 [ 0.30, 71.09 ]
Bilton 2011 12/177 3/118 74.9 % 2.67 [ 0.52, 13.67 ]
Subtotal (99% CI) 361 239 100.0 % 3.15 [ 0.78, 12.77 ]
Total events: 19 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.034)
2 Haemoptysis
Aitken 2012 1/184 0/121 33.4 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 9/177 1/118 66.6 % 6.00 [ 0.40, 89.09 ]
Subtotal (99% CI) 361 239 100.0 % 4.66 [ 0.50, 43.49 ]
Total events: 10 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
3 Pharyngolaryngeal pain
Aitken 2012 2/184 1/121 66.8 % 1.32 [ 0.06, 30.40 ]
Bilton 2011 3/177 0/118 33.2 % 4.68 [ 0.10, 227.14 ]
Subtotal (99% CI) 361 239 100.0 % 2.43 [ 0.23, 25.79 ]
Total events: 5 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
4 Throat irritation
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 1/177 0/118 100.0 % 2.01 [ 0.03, 133.11 ]
Subtotal (99% CI) 361 239 100.0 % 2.01 [ 0.03, 133.11 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
5 Productive cough
Aitken 2012 1/184 1/121 100.0 % 0.66 [ 0.02, 24.81 ]
Bilton 2011 0/177 0/118 Not estimable
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 361 239 100.0 % 0.66 [ 0.02, 24.81 ]
Total events: 1 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
6 Wheezing
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 2/177 3/118 100.0 % 0.44 [ 0.04, 4.57 ]
Subtotal (99% CI) 361 239 100.0 % 0.44 [ 0.04, 4.57 ]
Total events: 2 (400mg mannitol), 3 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
7 Asthma
Bilton 2011 2/177 1/118 100.0 % 1.33 [ 0.06, 30.80 ]
Subtotal (99% CI) 177 118 100.0 % 1.33 [ 0.06, 30.80 ]
Total events: 2 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
8 Bronchospasm
Bilton 2011 1/177 0/118 100.0 % 2.01 [ 0.03, 133.11 ]
Subtotal (99% CI) 177 118 100.0 % 2.01 [ 0.03, 133.11 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
9 Condition aggravated
Aitken 2012 7/184 3/121 75.1 % 1.53 [ 0.27, 8.85 ]
Bilton 2011 4/177 1/118 24.9 % 2.67 [ 0.15, 46.73 ]
Subtotal (99% CI) 361 239 100.0 % 1.82 [ 0.41, 8.03 ]
Total events: 11 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
10 Chest discomfort
Aitken 2012 1/184 1/121 50.1 % 0.66 [ 0.02, 24.81 ]
Bilton 2011 5/177 1/118 49.9 % 3.33 [ 0.20, 55.09 ]
Subtotal (99% CI) 361 239 100.0 % 1.99 [ 0.25, 16.10 ]
Total events: 6 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
11 Chest pain
Bilton 2011 0/177 1/118 100.0 % 0.22 [ 0.00, 14.79 ]
Subtotal (99% CI) 177 118 100.0 % 0.22 [ 0.00, 14.79 ]
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 0 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
12 Vomiting
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 0/177 2/118 100.0 % 0.13 [ 0.00, 7.15 ]
Subtotal (99% CI) 361 239 100.0 % 0.13 [ 0.00, 7.15 ]
Total events: 0 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
13 Post-tussive vomiting
Aitken 2012 3/184 0/121 100.0 % 4.62 [ 0.10, 224.14 ]
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 361 239 100.0 % 4.62 [ 0.10, 224.14 ]
Total events: 3 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
14 Headache
Aitken 2012 2/184 0/121 33.4 % 3.30 [ 0.06, 176.31 ]
Bilton 2011 2/177 1/118 66.6 % 1.33 [ 0.06, 30.80 ]
Subtotal (99% CI) 361 239 100.0 % 1.99 [ 0.18, 22.39 ]
Total events: 4 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
15 Decreased appetite
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 177 118 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
16 Infections and infestations
Aitken 2012 3/184 3/121 85.8 % 0.66 [ 0.08, 5.27 ]
Bilton 2011 2/177 0/118 14.2 % 3.34 [ 0.06, 178.67 ]
Subtotal (99% CI) 361 239 100.0 % 1.04 [ 0.18, 5.95 ]
Total events: 5 (400mg mannitol), 3 (50mg mannitol)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
17 Musculoskeletal and connective tissue disorders
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Aitken 2012 1/184 1/121 66.8 % 0.66 [ 0.02, 24.81 ]
Bilton 2011 1/177 0/118 33.2 % 2.01 [ 0.03, 133.11 ]
Subtotal (99% CI) 361 239 100.0 % 1.10 [ 0.08, 15.63 ]
Total events: 2 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
18 Skin and subcutaneous disorders
Aitken 2012 0/184 1/121 100.0 % 0.22 [ 0.00, 14.59 ]
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 361 239 100.0 % 0.22 [ 0.00, 14.59 ]
Total events: 0 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
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Analysis 1.18. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 18 Adverse events at up to 6 months (severe).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 18 Adverse events at up to 6 months (severe)
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 7/177 4/118 100.0 % 1.17 [ 0.24, 5.69 ]
Subtotal (99% CI) 361 239 100.0 % 1.17 [ 0.24, 5.69 ]
Total events: 7 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 Haemoptysis
Aitken 2012 2/184 0/121 33.4 % 3.30 [ 0.06, 176.31 ]
Bilton 2011 1/177 1/118 66.6 % 0.67 [ 0.02, 25.14 ]
Subtotal (99% CI) 361 239 100.0 % 1.55 [ 0.13, 18.99 ]
Total events: 3 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
3 Pharyngolaryngeal pain
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 3/177 0/118 49.9 % 4.68 [ 0.10, 227.14 ]
Subtotal (99% CI) 361 239 100.0 % 3.33 [ 0.20, 55.34 ]
Total events: 4 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
4 Throat irritation
Aitken 2012 1/184 0/121 25.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 0/177 1/118 74.9 % 0.22 [ 0.00, 14.79 ]
Subtotal (99% CI) 361 239 100.0 % 0.66 [ 0.05, 8.70 ]
Total events: 1 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
5 Productive cough
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 0/177 0/118 Not estimable
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 361 239 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Wheezing
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 361 239 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Asthma
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 177 118 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Bronchospasm
Bilton 2011 1/177 0/118 100.0 % 2.01 [ 0.03, 133.11 ]
Subtotal (99% CI) 177 118 100.0 % 2.01 [ 0.03, 133.11 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
9 Condition aggravated
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 1/177 1/118 100.0 % 0.67 [ 0.02, 25.14 ]
Subtotal (99% CI) 361 239 100.0 % 0.67 [ 0.02, 25.14 ]
Total events: 1 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
10 Chest discomfort
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 361 239 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Chest pain
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 177 118 Not estimable
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Vomiting
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 361 239 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
13 Post-tussive vomiting
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 1/177 0/118 100.0 % 2.01 [ 0.03, 133.11 ]
Subtotal (99% CI) 361 239 100.0 % 2.01 [ 0.03, 133.11 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
14 Headache
Aitken 2012 1/184 0/121 100.0 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 361 239 100.0 % 1.98 [ 0.03, 131.35 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
15 Decreased appetite
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 177 118 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
16 Infections and infestations
Aitken 2012 1/184 2/121 57.3 % 0.33 [ 0.01, 7.60 ]
Bilton 2011 0/177 1/118 42.7 % 0.22 [ 0.00, 14.79 ]
Subtotal (99% CI) 361 239 100.0 % 0.28 [ 0.02, 3.47 ]
Total events: 1 (400mg mannitol), 3 (50mg mannitol)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.20)
17 Musculoskeletal and connective tissue disorders
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 0/177 0/118 Not estimable
Subtotal (99% CI) 361 239 Not estimable
Total events: 0 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
18 Skin and subcutaneous tissue disorders
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 1/177 0/118 100.0 % 2.01 [ 0.03, 133.11 ]
Subtotal (99% CI) 361 239 100.0 % 2.01 [ 0.03, 133.11 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
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Analysis 1.19. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 19 Adverse events at up to 6 months (total).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 19 Adverse events at up to 6 months (total)
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cough
Aitken 2012 11/184 4/121 33.5 % 1.81 [ 0.41, 7.89 ]
Bilton 2011 26/177 8/118 66.5 % 2.17 [ 0.80, 5.86 ]
Subtotal (99% CI) 361 239 100.0 % 2.05 [ 0.90, 4.67 ]
Total events: 37 (400mg mannitol), 12 (50mg mannitol)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
2 Haemoptysis
Aitken 2012 6/184 0/121 11.2 % 8.57 [ 0.20, 371.27 ]
Bilton 2011 13/177 4/118 88.8 % 2.17 [ 0.51, 9.15 ]
Subtotal (99% CI) 361 239 100.0 % 2.88 [ 0.77, 10.85 ]
Total events: 19 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.040)
3 Pharyngolaryngeal pain
Aitken 2012 5/184 4/121 89.0 % 0.82 [ 0.15, 4.51 ]
Bilton 2011 9/177 0/118 11.0 % 12.70 [ 0.31, 526.75 ]
Subtotal (99% CI) 361 239 100.0 % 2.13 [ 0.54, 8.44 ]
Total events: 14 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: Chi2 = 3.61, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.42 (P = 0.16)
4 Throat irritation
Aitken 2012 3/184 0/121 33.4 % 4.62 [ 0.10, 224.14 ]
Bilton 2011 1/177 1/118 66.6 % 0.67 [ 0.02, 25.14 ]
Subtotal (99% CI) 361 239 100.0 % 1.99 [ 0.18, 22.42 ]
Total events: 4 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
5 Productive cough
Aitken 2012 2/184 1/121 66.8 % 1.32 [ 0.06, 30.40 ]
Bilton 2011 2/177 0/118 33.2 % 3.34 [ 0.06, 178.67 ]
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 361 239 100.0 % 1.99 [ 0.18, 22.30 ]
Total events: 4 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
6 Wheezing
Aitken 2012 2/184 1/121 20.1 % 1.32 [ 0.06, 30.40 ]
Bilton 2011 2/177 4/118 79.9 % 0.33 [ 0.04, 3.04 ]
Subtotal (99% CI) 361 239 100.0 % 0.53 [ 0.10, 2.95 ]
Total events: 4 (400mg mannitol), 5 (50mg mannitol)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
7 Asthma
Bilton 2011 2/177 2/118 100.0 % 0.67 [ 0.05, 8.60 ]
Subtotal (99% CI) 177 118 100.0 % 0.67 [ 0.05, 8.60 ]
Total events: 2 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
8 Bronchospasm
Bilton 2011 2/177 0/118 100.0 % 3.34 [ 0.06, 178.67 ]
Subtotal (99% CI) 177 118 100.0 % 3.34 [ 0.06, 178.67 ]
Total events: 2 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
9 Condition aggravated
Aitken 2012 9/184 4/121 57.3 % 1.48 [ 0.32, 6.75 ]
Bilton 2011 6/177 3/118 42.7 % 1.33 [ 0.22, 8.03 ]
Subtotal (99% CI) 361 239 100.0 % 1.42 [ 0.44, 4.52 ]
Total events: 15 (400mg mannitol), 7 (50mg mannitol)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
10 Chest discomfort
Aitken 2012 2/184 2/121 50.1 % 0.66 [ 0.05, 8.49 ]
Bilton 2011 5/177 2/118 49.9 % 1.67 [ 0.20, 14.07 ]
Subtotal (99% CI) 361 239 100.0 % 1.16 [ 0.23, 5.74 ]
Total events: 7 (400mg mannitol), 4 (50mg mannitol)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
11 Chest pain
Bilton 2011 0/177 2/118 100.0 % 0.13 [ 0.00, 7.15 ]
Subtotal (99% CI) 177 118 100.0 % 0.13 [ 0.00, 7.15 ]
0.002 0.1 1 10 500
Favours 400mg Mannitol Favours 50mg Mannitol
(Continued . . . )
104Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 0 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
12 Vomiting
Aitken 2012 1/184 0/121 20.1 % 1.98 [ 0.03, 131.35 ]
Bilton 2011 4/177 2/118 79.9 % 1.33 [ 0.15, 12.15 ]
Subtotal (99% CI) 361 239 100.0 % 1.46 [ 0.21, 10.28 ]
Total events: 5 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
13 Post-tussive vomiting
Aitken 2012 4/184 0/121 50.1 % 5.94 [ 0.13, 272.85 ]
Bilton 2011 2/177 0/118 49.9 % 3.34 [ 0.06, 178.67 ]
Subtotal (99% CI) 361 239 100.0 % 4.64 [ 0.30, 72.37 ]
Total events: 6 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
14 Headache
Aitken 2012 5/184 1/121 50.1 % 3.29 [ 0.20, 54.37 ]
Bilton 2011 5/177 1/118 49.9 % 3.33 [ 0.20, 55.09 ]
Subtotal (99% CI) 361 239 100.0 % 3.31 [ 0.46, 24.06 ]
Total events: 10 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
15 Decreased appetite
Bilton 2011 2/177 0/118 100.0 % 3.34 [ 0.06, 178.67 ]
Subtotal (99% CI) 177 118 100.0 % 3.34 [ 0.06, 178.67 ]
Total events: 2 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
16 Infections and infestations
Aitken 2012 6/184 7/121 70.1 % 0.56 [ 0.14, 2.29 ]
Bilton 2011 2/177 3/118 29.9 % 0.44 [ 0.04, 4.57 ]
Subtotal (99% CI) 361 239 100.0 % 0.53 [ 0.16, 1.75 ]
Total events: 8 (400mg mannitol), 10 (50mg mannitol)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
17 Musculoskeletal and connective tissue disorders
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Aitken 2012 2/184 1/121 66.8 % 1.32 [ 0.06, 30.40 ]
Bilton 2011 3/177 0/118 33.2 % 4.68 [ 0.10, 227.14 ]
Subtotal (99% CI) 361 239 100.0 % 2.43 [ 0.23, 25.79 ]
Total events: 5 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
18 Skin and subcutaneous tissues disorders
Aitken 2012 1/184 1/121 66.8 % 0.66 [ 0.02, 24.81 ]
Bilton 2011 4/177 0/118 33.2 % 6.02 [ 0.13, 276.51 ]
Subtotal (99% CI) 361 239 100.0 % 2.44 [ 0.23, 25.82 ]
Total events: 5 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 1.23, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 1.20. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 20 Participants with treatment-related respiratory and thoracic adverse events leading to study
discontinuation.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 20 Participants with treatment-related respiratory and thoracic adverse events leading to study discontinuation
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asthma
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 1/177 0/118 100.0 % 2.01 [ 0.08, 48.82 ]
Subtotal (95% CI) 361 239 100.0 % 2.01 [ 0.08, 48.82 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Bronchospasm
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 1/177 0/118 100.0 % 2.01 [ 0.08, 48.82 ]
Subtotal (95% CI) 361 239 100.0 % 2.01 [ 0.08, 48.82 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3 Cough
Aitken 2012 6/184 1/121 20.1 % 3.95 [ 0.48, 32.37 ]
Bilton 2011 11/177 4/118 79.9 % 1.83 [ 0.60, 5.62 ]
Subtotal (95% CI) 361 239 100.0 % 2.26 [ 0.85, 6.02 ]
Total events: 17 (400mg mannitol), 5 (50mg mannitol)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
4 Haemoptysis
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.08, 48.17 ]
Bilton 2011 3/177 0/118 49.9 % 4.68 [ 0.24, 89.78 ]
Subtotal (95% CI) 361 239 100.0 % 3.33 [ 0.39, 28.25 ]
Total events: 4 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
5 Hyperventilation
Aitken 2012 1/184 0/121 100.0 % 1.98 [ 0.08, 48.17 ]
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilton 2011 0/177 0/118 Not estimable
Subtotal (95% CI) 361 239 100.0 % 1.98 [ 0.08, 48.17 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
6 Obstructive airways disorder
Aitken 2012 1/184 0/121 100.0 % 1.98 [ 0.08, 48.17 ]
Bilton 2011 0/177 0/118 Not estimable
Subtotal (95% CI) 361 239 100.0 % 1.98 [ 0.08, 48.17 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
7 Pharynolaryngeal pain
Aitken 2012 1/184 0/121 50.1 % 1.98 [ 0.08, 48.17 ]
Bilton 2011 2/177 0/118 49.9 % 3.34 [ 0.16, 69.01 ]
Subtotal (95% CI) 361 239 100.0 % 2.66 [ 0.30, 23.62 ]
Total events: 3 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
8 Productive cough
Aitken 2012 1/184 0/121 100.0 % 1.98 [ 0.08, 48.17 ]
Bilton 2011 0/177 0/118 Not estimable
Subtotal (95% CI) 361 239 100.0 % 1.98 [ 0.08, 48.17 ]
Total events: 1 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
9 Throat irritation
Aitken 2012 1/184 0/121 25.1 % 1.98 [ 0.08, 48.17 ]
Bilton 2011 0/177 1/118 74.9 % 0.22 [ 0.01, 5.42 ]
Subtotal (95% CI) 361 239 100.0 % 0.66 [ 0.09, 4.70 ]
Total events: 1 (400mg mannitol), 1 (50mg mannitol)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
10 Wheezing
Aitken 2012 0/184 0/121 Not estimable
Bilton 2011 0/177 2/118 100.0 % 0.13 [ 0.01, 2.76 ]
Subtotal (95% CI) 361 239 100.0 % 0.13 [ 0.01, 2.76 ]
Total events: 0 (400mg mannitol), 2 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for subgroup differences: Chi2 = 4.49, df = 9 (P = 0.88), I2 =0.0%
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Analysis 1.21. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 21 Number of patients with protocol defined pulmonary exacerbations.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 21 Number of patients with protocol defined pulmonary exacerbations
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 6 months
Aitken 2012 28/184 23/121 41.2 % 0.80 [ 0.48, 1.32 ]
Bilton 2011 32/177 33/118 58.8 % 0.65 [ 0.42, 0.99 ]
Subtotal (95% CI) 361 239 100.0 % 0.71 [ 0.51, 0.98 ]
Total events: 60 (400mg mannitol), 56 (50mg mannitol)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.039)
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Analysis 1.22. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 22 Time to first protocol defined pulmonary exacerbation (PDPE).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 22 Time to first protocol defined pulmonary exacerbation (PDPE)
Study or subgroup 400mg mannitol 50mg mannitol log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Aitken 2012 184 121 -0.3011 (0.2953) 41.7 % 0.74 [ 0.41, 1.32 ]
Bilton 2011 177 118 -0.3857 (0.25) 58.3 % 0.68 [ 0.42, 1.11 ]
Total (95% CI) 361 239 100.0 % 0.70 [ 0.48, 1.02 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 23 Number of patients needing additional antibiotics.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 23 Number of patients needing additional antibiotics
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous
Aitken 2012 102/184 74/121 55.4 % 0.91 [ 0.75, 1.10 ]
Bilton 2011 63/177 60/118 44.6 % 0.70 [ 0.54, 0.91 ]
Subtotal (95% CI) 361 239 100.0 % 0.81 [ 0.70, 0.95 ]
Total events: 165 (400mg mannitol), 134 (50mg mannitol)
Heterogeneity: Chi2 = 2.44, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 2.56 (P = 0.010)
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Analysis 1.24. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 24 Number of participants requiring hospitalisation.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 24 Number of participants requiring hospitalisation
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 With pulmonary exacerbation, up to 6 months
Aitken 2012 28/184 24/121 46.3 % 0.77 [ 0.47, 1.26 ]
Bilton 2011 37/177 28/118 53.7 % 0.88 [ 0.57, 1.36 ]
Subtotal (95% CI) 361 239 100.0 % 0.83 [ 0.60, 1.15 ]
Total events: 65 (400mg mannitol), 52 (50mg mannitol)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
2 With PDPE, up to 6 months
Aitken 2012 22/184 19/121 47.6 % 0.76 [ 0.43, 1.35 ]
Bilton 2011 25/177 21/118 52.4 % 0.79 [ 0.47, 1.35 ]
Subtotal (95% CI) 361 239 100.0 % 0.78 [ 0.53, 1.15 ]
Total events: 47 (400mg mannitol), 40 (50mg mannitol)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
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Analysis 1.25. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 25 Duration of hospitalisation.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 25 Duration of hospitalisation
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Duration of hospitalisation with pulmonary exacerbation, up to 6 months (days)
Aitken 2012 184 1.99 (5.84) 121 3.26 (8.54) 78.5 % -1.27 [ -3.01, 0.47 ]
Bilton 2011 177 5.55 (12.94) 118 5.75 (15.08) 21.5 % -0.20 [ -3.52, 3.12 ]
Subtotal (95% CI) 361 239 100.0 % -1.04 [ -2.58, 0.50 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Duration of hospitalisation with PDPE, up to 6 months (days)
Aitken 2012 184 1.45 (4.76) 121 2.42 (6.87) 76.9 % -0.97 [ -2.37, 0.43 ]
Bilton 2011 177 4.03 (11.94) 118 3.55 (10.34) 23.1 % 0.48 [ -2.08, 3.04 ]
Subtotal (95% CI) 361 239 100.0 % -0.64 [ -1.87, 0.60 ]
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
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Analysis 1.26. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 26 Sputum weight (g).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 26 Sputum weight (g)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 14 weeks
Aitken 2012 155 3.8 (5.49) 107 3.5 (5.8) 64.2 % 0.30 [ -1.10, 1.70 ]
Bilton 2011 110 4.42 (8.601) 88 2.1 (4.58) 35.8 % 2.32 [ 0.45, 4.19 ]
Subtotal (95% CI) 265 195 100.0 % 1.02 [ -0.10, 2.14 ]
Heterogeneity: Chi2 = 2.87, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 1.79 (P = 0.073)
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Analysis 1.27. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 27 Sputum weight (g) (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 27 Sputum weight (g) (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 152 -1 (6.05) 103 0 (4.6) 71.0 % -1.00 [ -2.31, 0.31 ]
Bilton 2011 103 -1.19 (8.372) 81 -0.36 (5.79) 29.0 % -0.83 [ -2.88, 1.22 ]
Subtotal (95% CI) 255 184 100.0 % -0.95 [ -2.05, 0.15 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
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Analysis 1.28. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 28 Microbiology: pathogens present at end of study.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 28 Microbiology: pathogens present at end of study
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pseudomonas aeruginosa (mucoid)
Aitken 2012 44/153 36/110 53.1 % 0.88 [ 0.61, 1.27 ]
Bilton 2011 39/111 33/87 46.9 % 0.93 [ 0.64, 1.34 ]
Subtotal (95% CI) 264 197 100.0 % 0.90 [ 0.69, 1.17 ]
Total events: 83 (400mg mannitol), 69 (50mg mannitol)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Pseudomonas aeruginosa (non-mucoid)
Aitken 2012 26/153 30/110 57.5 % 0.62 [ 0.39, 0.99 ]
Bilton 2011 26/111 23/87 42.5 % 0.89 [ 0.55, 1.44 ]
Subtotal (95% CI) 264 197 100.0 % 0.73 [ 0.53, 1.03 ]
Total events: 52 (400mg mannitol), 53 (50mg mannitol)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 1.81 (P = 0.071)
3 Pseudomonas aeruginosa (not specified)
Aitken 2012 1/153 0/110 50.9 % 2.16 [ 0.09, 52.59 ]
Bilton 2011 3/111 0/87 49.1 % 5.50 [ 0.29, 105.08 ]
Subtotal (95% CI) 264 197 100.0 % 3.80 [ 0.45, 31.97 ]
Total events: 4 (400mg mannitol), 0 (50mg mannitol)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
4 Pseudomonas spp (other)
Aitken 2012 3/153 1/110 17.2 % 2.16 [ 0.23, 20.46 ]
Bilton 2011 6/111 5/87 82.8 % 0.94 [ 0.30, 2.98 ]
Subtotal (95% CI) 264 197 100.0 % 1.15 [ 0.42, 3.17 ]
Total events: 9 (400mg mannitol), 6 (50mg mannitol)
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Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
5 Staphylococcus aureus
Aitken 2012 75/153 55/110 76.0 % 0.98 [ 0.77, 1.26 ]
Bilton 2011 26/111 18/87 24.0 % 1.13 [ 0.67, 1.93 ]
Subtotal (95% CI) 264 197 100.0 % 1.02 [ 0.81, 1.28 ]
Total events: 101 (400mg mannitol), 73 (50mg mannitol)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
6 Methicillin-resistant Staphylococcus aureus
Aitken 2012 18/153 11/110 100.0 % 1.18 [ 0.58, 2.39 ]
Subtotal (95% CI) 153 110 100.0 % 1.18 [ 0.58, 2.39 ]
Total events: 18 (400mg mannitol), 11 (50mg mannitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
7 Burkholderia cepacia (cenocepacia)
Aitken 2012 5/153 8/110 62.4 % 0.45 [ 0.15, 1.34 ]
Bilton 2011 7/111 5/87 37.6 % 1.10 [ 0.36, 3.34 ]
Subtotal (95% CI) 264 197 100.0 % 0.69 [ 0.32, 1.48 ]
Total events: 12 (400mg mannitol), 13 (50mg mannitol)
Heterogeneity: Chi2 = 1.26, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.95 (P = 0.34)
8 Aspergillus spp
Aitken 2012 19/153 22/110 76.5 % 0.62 [ 0.35, 1.09 ]
Bilton 2011 13/111 7/87 23.5 % 1.46 [ 0.61, 3.49 ]
Subtotal (95% CI) 264 197 100.0 % 0.82 [ 0.51, 1.30 ]
Total events: 32 (400mg mannitol), 29 (50mg mannitol)
Heterogeneity: Chi2 = 2.59, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.85 (P = 0.39)
9 Candida spp
Aitken 2012 16/153 13/110 50.9 % 0.88 [ 0.44, 1.76 ]
Bilton 2011 12/111 13/87 49.1 % 0.72 [ 0.35, 1.51 ]
Subtotal (95% CI) 264 197 100.0 % 0.81 [ 0.49, 1.33 ]
Total events: 28 (400mg mannitol), 26 (50mg mannitol)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 5.84, df = 8 (P = 0.66), I2 =0.0%
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Analysis 1.29. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 29 Burden of treatment (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 29 Burden of treatment (change from baseline)
Study or subgroup 400mg mannitol 50mg mannitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 months
Aitken 2012 164 -1.7 (19.25) 114 2.9 (18.52) 53.7 % -4.60 [ -9.10, -0.10 ]
Bilton 2011 128 -4.4 (18.25) 99 0.2 (18.65) 46.3 % -4.60 [ -9.45, 0.25 ]
Subtotal (95% CI) 292 213 100.0 % -4.60 [ -7.90, -1.30 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0063)
2 Up to 6 months
Aitken 2012 155 0.4 (21.63) 110 3.1 (20.97) 47.6 % -2.70 [ -7.89, 2.49 ]
Bilton 2011 113 -1.5 (16.43) 87 0.1 (18.6) 52.4 % -1.60 [ -6.54, 3.34 ]
Subtotal (95% CI) 268 197 100.0 % -2.12 [ -5.70, 1.46 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
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Analysis 1.30. Comparison 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis,
Outcome 30 Adherence ≥ 60%.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 1 Mannitol versus control - parallel studies of individuals with cystic fibrosis
Outcome: 30 Adherence≥ 60%
Study or subgroup 400mg mannitol 50mg mannitol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 6 months
Aitken 2012 152/184 107/121 54.7 % 0.93 [ 0.85, 1.02 ]
Bilton 2011 111/177 89/118 45.3 % 0.83 [ 0.71, 0.97 ]
Subtotal (95% CI) 361 239 100.0 % 0.89 [ 0.82, 0.97 ]
Total events: 263 (400mg mannitol), 196 (50mg mannitol)
Heterogeneity: Chi2 = 1.87, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 2.75 (P = 0.0059)
0.5 0.7 1 1.5 2
Favours 50mg mannitol Favours 400mg mannitol
Analysis 2.1. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 1 FEV1 % predicted (absolute change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 1 FEV1 % predicted (absolute change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Boeck 2017 87 87 3.42 (1.1684) 100.0 % 3.42 [ 1.13, 5.71 ]
Total (95% CI) 87 87 100.0 % 3.42 [ 1.13, 5.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 2 FEV1 % predicted (absolute change from baseline - subgroup analysis by age).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 2 FEV1 % predicted (absolute change from baseline - subgroup analysis by age)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 age 6 to 11 years
de Boeck 2017 39 39 3.78 (1.8623) 100.0 % 3.78 [ 0.13, 7.43 ]
Subtotal (95% CI) 39 39 100.0 % 3.78 [ 0.13, 7.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
2 age 12 to 17 years
de Boeck 2017 53 53 3.35 (1.6378) 100.0 % 3.35 [ 0.14, 6.56 ]
Subtotal (95% CI) 53 53 100.0 % 3.35 [ 0.14, 6.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 2.3. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 3 FEV1 % predicted (absolute change from baseline - subgroup analysis by dornase alfa use.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 3 FEV1 % predicted (absolute change from baseline - subgroup analysis by dornase alfa use
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Dornase alfa user
de Boeck 2017 63 63 3.29 (1.5357) 100.0 % 3.29 [ 0.28, 6.30 ]
Subtotal (95% CI) 63 63 100.0 % 3.29 [ 0.28, 6.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
2 Dornase alfa non-user
de Boeck 2017 29 29 3.92 (1.7857) 100.0 % 3.92 [ 0.42, 7.42 ]
Subtotal (95% CI) 29 29 100.0 % 3.92 [ 0.42, 7.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 2.4. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 4 FEV1 % predicted (relative change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 4 FEV1 % predicted (relative change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Boeck 2017 87 87 4.97 (1.7602) 100.0 % 4.97 [ 1.52, 8.42 ]
Total (95% CI) 87 87 100.0 % 4.97 [ 1.52, 8.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0047)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 5 FVC % predicted (absolute change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 5 FVC % predicted (absolute change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Boeck 2017 87 87 1.8 (1.2857) 100.0 % 1.80 [ -0.72, 4.32 ]
Total (95% CI) 87 87 100.0 % 1.80 [ -0.72, 4.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 6 FVC % predicted (relative change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 6 FVC % predicted (relative change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Boeck 2017 87 87 2.54 (1.6633) 100.0 % 2.54 [ -0.72, 5.80 ]
Total (95% CI) 87 87 100.0 % 2.54 [ -0.72, 5.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 7 FEF25-75 % predicted (absolute change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 7 FEF25−75 % predicted (absolute change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Boeck 2017 87 87 5.75 (2.0102) 100.0 % 5.75 [ 1.81, 9.69 ]
Total (95% CI) 87 87 100.0 % 5.75 [ 1.81, 9.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 8 FEF25-75 % predicted (relative change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 8 FEF25−75 % predicted (relative change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Boeck 2017 87 87 10.52 (4.1889) 100.0 % 10.52 [ 2.31, 18.73 ]
Total (95% CI) 87 87 100.0 % 10.52 [ 2.31, 18.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis,
Outcome 9 Sputum weight (grams) (post-initial treatment).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 2 Mannitol versus control - cross-over studies of individuals with cystic fibrosis
Outcome: 9 Sputum weight (grams) (post-initial treatment)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Boeck 2017 87 87 1.33 (0.5306) 100.0 % 1.33 [ 0.29, 2.37 ]
Total (95% CI) 87 87 100.0 % 1.33 [ 0.29, 2.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis,
hospitalised due to pulmonary exacerbations, Outcome 1 HRQoL - change from baseline in CFCS total score.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to pulmonary exacerbations
Outcome: 1 HRQoL - change from baseline in CFCS total score
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at hospital discharge (14 days)
Middleton 2015 11 11 1.1 (0.8163) 100.0 % 1.10 [ -0.50, 2.70 ]
Subtotal (95% CI) 11 11 100.0 % 1.10 [ -0.50, 2.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
2 at 1 month follow-up
Middleton 2015 11 11 -1 (1.5817) 100.0 % -1.00 [ -4.10, 2.10 ]
Subtotal (95% CI) 11 11 100.0 % -1.00 [ -4.10, 2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 3.2. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis,
hospitalised due to pulmonary exacerbations, Outcome 2 HRQoL - change from baseline in CFQ-R
respiratory domain.
Review: Inhaled mannitol for cystic fibrosis
Comparison: 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to pulmonary exacerbations
Outcome: 2 HRQoL - change from baseline in CFQ-R respiratory domain
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at hospital discharge (14 days)
Middleton 2015 11 11 1.3 (6.0205) 100.0 % 1.30 [ -10.50, 13.10 ]
Subtotal (95% CI) 11 11 100.0 % 1.30 [ -10.50, 13.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
2 at 1 month follow-up
Middleton 2015 11 11 3.5 (7.245) 100.0 % 3.50 [ -10.70, 17.70 ]
Subtotal (95% CI) 11 11 100.0 % 3.50 [ -10.70, 17.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
-10 -5 0 5 10
Favours Control Favours 400mg mannitol
124Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis,
hospitalised due to pulmonary exacerbations, Outcome 3 FEV1 % predicted (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to pulmonary exacerbations
Outcome: 3 FEV1 % predicted (change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at hospital discharge (14 days)
Middleton 2015 11 11 4.6 (4.2858) 100.0 % 4.60 [ -3.80, 13.00 ]
Subtotal (95% CI) 11 11 100.0 % 4.60 [ -3.80, 13.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
2 at 1 month follow-up
Middleton 2015 11 11 5.4 (4.1327) 100.0 % 5.40 [ -2.70, 13.50 ]
Subtotal (95% CI) 11 11 100.0 % 5.40 [ -2.70, 13.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
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Analysis 3.4. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis,
hospitalised due to pulmonary exacerbations, Outcome 4 FVC % predicted (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to pulmonary exacerbations
Outcome: 4 FVC % predicted (change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at hospital discharge (14 days)
Middleton 2015 11 11 2.8 (3.2654) 100.0 % 2.80 [ -3.60, 9.20 ]
Subtotal (95% CI) 11 11 100.0 % 2.80 [ -3.60, 9.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
2 at 1 month follow-up
Middleton 2015 11 11 1.7 (2.9592) 100.0 % 1.70 [ -4.10, 7.50 ]
Subtotal (95% CI) 11 11 100.0 % 1.70 [ -4.10, 7.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
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Analysis 3.5. Comparison 3 Mannitol versus control - parallel study of individuals with cystic fibrosis,
hospitalised due to pulmonary exacerbations, Outcome 5 FEF25-75 % predicted (change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 3 Mannitol versus control - parallel study of individuals with cystic fibrosis, hospitalised due to pulmonary exacerbations
Outcome: 5 FEF25−75 % predicted (change from baseline)
Study or subgroup 400mg mannitol Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at hospital discharge (14 days)
Middleton 2015 11 11 12.8 (8.2144) 100.0 % 12.80 [ -3.30, 28.90 ]
Subtotal (95% CI) 11 11 100.0 % 12.80 [ -3.30, 28.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 at 1 month follow-up
Middleton 2015 11 11 3.9 (7.4491) 100.0 % 3.90 [ -10.70, 18.50 ]
Subtotal (95% CI) 11 11 100.0 % 3.90 [ -10.70, 18.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 4.1. Comparison 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis,
Outcome 1 FEV1 (% change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome: 1 FEV1 (% change from baseline)
Study or subgroup Mannitol Dornase alfa Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Minasian 2010 20 20 2.8 (3.88) 100.0 % 2.80 [ -4.80, 10.40 ]
Subtotal (95% CI) 20 20 100.0 % 2.80 [ -4.80, 10.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 4.2. Comparison 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis,
Outcome 2 FVC (% change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome: 2 FVC (% change from baseline)
Study or subgroup Mannitol Dornase alfa Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Minasian 2010 20 20 0.14 (0.08) 100.0 % 0.14 [ -0.02, 0.30 ]
Subtotal (95% CI) 20 20 100.0 % 0.14 [ -0.02, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
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Analysis 4.3. Comparison 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis,
Outcome 3 FEF25-75 (% change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 4 Mannitol versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome: 3 FEF25−75 (% change from baseline)
Study or subgroup Mannitol Dornase alfa Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Minasian 2010 20 20 -0.01 (0.11) 100.0 % -0.01 [ -0.23, 0.21 ]
Subtotal (95% CI) 20 20 100.0 % -0.01 [ -0.23, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
-0.5 -0.25 0 0.25 0.5
Favours dornase alfa Favours mannitol
Analysis 5.1. Comparison 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals
with cystic fibrosis, Outcome 1 FEV1 (% change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome: 1 FEV1 (% change from baseline)
Study or subgroup Dornase alfa
Mannitol/dornase
alfa Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Minasian 2010 20 20 -4.3 (5) 100.0 % -4.30 [ -14.10, 5.50 ]
Subtotal (95% CI) 20 20 100.0 % -4.30 [ -14.10, 5.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
-20 -10 0 10 20
Favours dornase alfa Favours mannitol/dornase
129Inhaled mannitol for cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.2. Comparison 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals
with cystic fibrosis, Outcome 2 FVC (% change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome: 2 FVC (% change from baseline)
Study or subgroup Mannitol/dornase alfa Dornase alfa Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Minasian 2010 20 20 -0.07 (0.117) 100.0 % -0.07 [ -0.30, 0.16 ]
Subtotal (95% CI) 20 20 100.0 % -0.07 [ -0.30, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
-0.5 -0.25 0 0.25 0.5
Favours dornase alfa Favours mannitol/dornase
Analysis 5.3. Comparison 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals
with cystic fibrosis, Outcome 3 FEF25-75 (% change from baseline).
Review: Inhaled mannitol for cystic fibrosis
Comparison: 5 Mannitol plus dornase alfa versus dornase alfa - cross-over study of individuals with cystic fibrosis
Outcome: 3 FEF25−75 (% change from baseline)
Study or subgroup Mannitol/dornase alfa Dornase alfa Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Minasian 2010 20 0 0.03 (0.107) 100.0 % 0.03 [ -0.18, 0.24 ]
Subtotal (95% CI) 20 0 100.0 % 0.03 [ -0.18, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
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A D D I T I O N A L T A B L E S
Table 1. Mannitol versus control - subgroup analysis by dornase alfa use (lung function)
Outcome Time point Dornase alfa users (n = 373)* Dornase alfa non users (n = 196)* P value for test of
subgroup differ-
ences
MD 95% CI P value MD 95% CI P value
FEV1 (mL) up to 2
months
54.13 6.67 to 101.
95
0.03 104.90 42.36 to 167.
44
0.001 0.21
up to 4
months
49.25 -5.87 to
104.37
0.08 82.77 8.38 to 157.
16
0.03 0.48
up to 6
months
90.76 28.32 to
153.19
0.004 103.22 19.82 to 186.
63
0.02 0.82
FEV1
(%
predicted)
up to 2
months
2.29 -0.49 to 5.
07
0.11 4.69 1.11 to 8.27 0.01 0.30
up to 4
months
2.05 -10.6 to 5.
17
0.20 4.49 0.44 to 8.54 0.03 0.35
up to 6
months
4.66 1.46 to 7.86 0.004 4.05 -0.11 to 8.21 0.06 0.82
FVC (mL) up to 2
months
70.99 9.98 to 132.
00
0.02 117.82 33.59 to 202.
05
0.01 0.38
up to 4
months
59.45 -8.08 to
126.99
0.08 127.34 31.20 to 223.
48
0.01 0.26
up to 6
months
114.56 38.30 to
190.82
0.003 121.93 15.76 to 228.
11
0.02 0.91
FEF25−75
(mL/s)
up to 2
months
22.59 -68.62 to
113.80
0.63 129.14 12.95 to 245.
33
0.03 0.16
up to 4
months
6.52 -87.14 to
100.18
0.89 99.17 -22.97 to
221.30
0.11 0.24
up to 6
months
47.83 -58.72 to
154.38
0.38 44.70 -97.52 to
186.92
0.54 0.97
Outcome Time point RR 95% CI p value RR 95% CI P value P value for test of
subgroup differ-
ences
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Table 1. Mannitol versus control - subgroup analysis by dornase alfa use (lung function) (Continued)
Exacerba-
tions*
up to 6
months
0.85 0.58 to 1.25 0.41 0.46 0.25 to 0.87 0.02 0.1
CI: confidence interval; FEF25−75 : mid-expiratory flow; FEV1: forced expiratory volume at one second; FVC: forced vital capacity;
MD: mean difference; RR: risk ratio.
MD and 95% CI for measures of lung function is change from baseline pooled across two studies (Aitken 2012; Bilton 2011).
RR and 95% CI represents the proportion of participants experiencing pulmonary exacerbations pooled across two studies (Aitken
2012; Bilton 2011).
* Intention-to-treat population analysed for lung function outcomes, all randomised participants were included for the outcome of
pulmonary exacerbations: dornase alfa users (n = 392) and non-users (n = 208).
Table 2. Mannitol versus control - subgroup analysis by age (lung function)
Outcome Time point Adults (n = 317) Children (n = 258) P value for test of
subgroup differ-
ences
MD 95% CI P value MD 95% CI P value
FEV1 (mL) up to 2
months
89.3 38.96 to
139.64
0.001 50.24 -7.82 to 108.
30
0.09 0.32
up to 4
months
87.83 29.08 to
146.58
0.003 25.89 -40.72 to 92.
50
0.45 0.17
up to 6
months
123.12 56.43 to
189.81
0.0001 62.52 -11.65 to
136.69
0.09 0.23
FEV1
(%
predicted)
up to 2
months
3.72 0.82 to 6.64 0.012 2.64 -0.73 to 6.02 0.13 0.63
up to 4
months
4.23 0.98 to 7.48 0.01 1.34 -2.42 to 5.10 0.49 0.25
up to 6
months
5.74 2.36 to 9.13 0.001 3.03 -0.78 to 6.84 0.12 0.30
FVC (mL) up to 2
months
101.66 35.15 to
168.16
0.003 69 -5.0 to 142.
99
0.07 0.52
up to 4
months
111.82 36.75 to
186.89
0.004 46.16 -35.53 to
127.84
0.27 0.25
up to 6
months
158.44 74.87 to
242.01
0.001 71.21 -19.1 to 161.
51
0.12 0.17
FEF25−75
(mL/s)
up to 2
months
95.09 0.56 to 189.
63
0.05 15.44 -95.62 to
126.51
0.79 0.28
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Table 2. Mannitol versus control - subgroup analysis by age (lung function) (Continued)
up to 4
months
108.42 10.23 to
206.63
0.03 -53.07 -165.97 to
59.84
0.36 0.03
up to 6
months
59.27 -55.59 to
174.12
0.31 31.29 -96.72 to
159.30
0.63 0.75
Outcome Time point RR 95% CI P value RR 95% CI P value P value for test of
subgroup differ-
ences
Exacerba-
tions
up to 6
months
0.76 0.52 to 1.13 0.18 0.62 0.35 to 1.09 0.10 0.55
CI: confidence interval; FEF25−75: mid-expiratory flow; FEV1: forced expiratory volume at one second; FVC: forced vital capacity;
MD: mean difference; RR: risk ratio.
MD and 95% CI for measures of lung function is change from baseline pooled across two studies (Aitken 2012; Bilton 2011).
RR and 95% CI represents the proportion of participants experiencing pulmonary exacerbations pooled across two studies (Aitken
2012; Bilton 2011).
* Intention-to-treat population analysed for lung function outcomes, all randomised participants were included for the outcome of
pulmonary exacerbations: adults (n = 341) and children (n = 259).
Table 3. Mannitol versus control - subgroup analysis by dornase alfa use (adverse events)
Adverse event Dornase alfa
users (n = 392)
Dornase alfa
non users (n = 208)
P value for test of
subgroup differences
RR 99% CI RR 99% CI
Cough 1.63 0.68 to 3.92 4.82 0.53 to 43.70 0.24
Haemoptysis 3.06 0.68 to 13.67 2.52 0.15 to 43.23 0.88
Pharyngolaryngeal
pain
1.66 0.33 to 8.33 2.71 0.27 to 27.12 0.65
Throat irritation 1.14 0.08 to 16.23 3.13 0.06 to 161.52 0.59
Productive cough 1.59 0.13 to 19.36 1.90 0.03 to 124.54 0.93
Wheezing 0.52 0.07 to 3.62 0.63 0.05 to 8.13 0.88
Asthma 1.40 0.06 to 31.86 0.21 0.00 to 13.84 0.35
Bronchospasm 2.10 0.03 to 138.37 1.90 0.03 to 124.54 0.97
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Table 3. Mannitol versus control - subgroup analysis by dornase alfa use (adverse events) (Continued)
Condition
aggravated
1.63 0.43 to 6.28 0.94 0.09 to 9.55 0.59
Chest discomfort 1.38 0.23 to 8.29 0.62 0.02 to 22.39 0.60
Chest pain 0.14 0.00 to 7.43 NA NA NA
Vomiting 0.69 0.07 to 6.84 4.44 0.09 to 212.27 0.29
Post-tussive vomit-
ing
4.72 0.10 to 228.19 2.52 0.15 to 43.83 0.74
Headache 3.87 0.40 to 37.22 1.26 0.06 to 28.54 0.45
Decreased appetite 2.10 0.03 to 138.37 1.90 0.03 to 124.54 0.97
Infections and infes-
tations
0.39 0.10 to 1.51 1.46 0.12 to 17.63 0.23
Musculos-
ketal and connective
tissue disorders
2.06 0.18 to 22.87 1.90 0.03 to 124.54 0.97
Skin and subcuta-
neous disorders
1.61 0.13 to 19.39 3.17 0.06 to 167.04 0.71
CI: confidence interval; NA: not estimable (no events reported in the subgroup); RR: risk ratio.
RR and 99% CI represents the proportion of participants experiencing pulmonary exacerbations pooled across two studies (Aitken
2012; Bilton 2011) (except asthma, bronchospasm, chest pain and decreased appetite reported in Bilton 2011 only).
Table 4. Mannitol versus control - subgroup analysis by age (adverse events)
Adverse event Adults (n = 341) Children (n = 259) P value for test of
subgroup differences
RR 99% CI RR 99% CI
Cough 2.05 0.75 to 5.57 2.03 0.48 to 8.67 0.99
Haemoptysis 1.83 0.46 to 7.28 5.48 0.36 to 82.41 0.35
Pharyngolaryngeal
pain
2.18 0.35 to 13.47 1.77 0.26 to 11.92 0.84
Throat irritation 0.97 0.09 to 10.24 2.05 0.11 to 39.42 0.61
Productive cough 0.65 0.08 to 5.16 3.48 0.07 to 183.99 0.33
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Table 4. Mannitol versus control - subgroup analysis by age (adverse events) (Continued)
Wheezing 0.32 0.04 to 3.00 1.13 0.08 to 15.79 0.35
Asthma 0.13 0.00 to 7.11 3.36 0.06 to 175.87 0.14
Bronchospasm 3.35 0.06 to 177.81 NA NA
Condition
aggravated
1.30 0.33 to 5.17 1.73 0.21 to 14.32 0.77
Chest discomfort 1.08 0.17 to 6.89 1.13 0.08 to 15.79 0.97
Chest pain NA 0.13 0.00 to 7.03 NA
Vomiting 0.67 0.05 to 8.52 2.73 0.16 to 47.76 0.34
Post-tussive vomit-
ing
4.39 0.09 to 210.79 2.73 0.16 to 47.76 0.80
Headache 3.90 0.25 to 61.93 1.70 0.20 to 14.30 0.54
Decreased appetite 3.35 0.06 to 177.81 NA NA
Infections and infes-
tations
0.43 0.08 to 2.21 0.69 0.12 to 4.07 0.61
Musculos-
ketal and connective
tissue disorders
3.24 0.20 to 53.67 0.68 0.05 to 8.93 0.29
Skin and subcuta-
neous disorders
1.31 0.15 to 11.79 2.05 0.11 to 39.42 0.75
CI: confidence interval; NA: not estimable (no events reported in the subgroup); RR: risk ratio.
RR and 99% CI represents the proportion of participants experiencing pulmonary exacerbations pooled across two studies (Aitken
2012; Bilton 2011) (except asthma, bronchospasm, chest pain and decreased appetite reported in Bilton 2011 only).
Table 5. Jaques 2008 - health-related quality of life (change from baseline at 2 weeks)
Domain Mannitol
(n = 35)
Control
(n = 34)
P value*
Mean SD Mean SD
Respiratory 4.7 19.62 -0.7 19.34 0.09
Health 5.2 17.20 0.6 16.96 0.25
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Table 5. Jaques 2008 - health-related quality of life (change from baseline at 2 weeks) (Continued)
Physical 3.2 27.76 -3.0 27.37 0.16
Vitality 2.7 18.71 0.5 18.74 0.54
SD: standard deviation.
Based on Table 3 of the primary publication (Jaques 2008).
P value for difference in means taken from F test of Least Squares Generalised mixed model (analysis of variance), see Jaques 2008 for
further details.
Table 6. Jaques 2008 - lung function data (change from baseline at 2 weeks)
Measure Mannitol
(n = 36)
Control
(n = 36)
P Value
Mean SD Mean SD
FEV1 (mL) 121 198 2 198 0.01
FEV1 (% predicted) 3.86 6.48 -0.09 6.48 <0.01
FVC (mL) 110 240 40 240 0.16
FEF25−75 (mL/s) 150 300 -10 300 0.03
FEF25−75: mid-expiratory flow; FEV1: forced expiratory volume at one second; FVC: forced vital capacity; mL: millilitres; mL/s:
millilitres per second; SD: standard deviation.
Based on additional data provided by Pharmaxis and the primary publication (Jaques 2008).
P value for difference in means taken from F test of Least Squares Generalised mixed model (analysis of variance), see Jaques 2008 for
further details.
Table 7. Jaques 2008 - adverse events at 2 weeks
Adverse event
(possibly or probably
related to treatment)
Mannitol group
(n = 38)
Control group
(n = 36)
Not severe Severe Not severe Severe
Upper respiratory tract
infection
1 0 1 0
Diarrhoea 0 0 0 1
Gastro-oesophageal re-
flux
0 0 1 0
Vomiting 2 0 0 0
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Table 7. Jaques 2008 - adverse events at 2 weeks (Continued)
Chest discomfort 2 0 1 0
Aggravation of CF
symptoms
1 0 0 0
Fatigue 1 0 0 0
Anorexia 1 0 0 0
Chest wall pain 2 0 0 0
Dysgeusia 0 0 0 1
Cough 2 2 0 0
Haemoptysis 2 0 2 0
Nasal congestion 0 0 1 0
Pharynolaryngeal pain 3 0 0 0
Respiratory tract conges-
tion
0 0 1 0
Wheeze 0 0 1 0
Total events 17 2 8 2
CF: cystic fibrosis
Study definition of ”severe“: incapacitating, or unable to do usual activities.
Table 8. de Boeck 2017 - participants with adverse events and serious adverse events
Event 400 mg mannitol (n = 87) Control (n = 87)
At least one treatment-emergent AE 54 (62.1%) 52 (59.8%)
At least one treatment-related AE 16 (18.4%) 11 (12.6%)
At least one SAE 10 (11.5%) 13 (14.9%)
At least one treatment-related SAE 0 (0%) 1 (1.1%)
AEs leading to withdrawal from the study 2 (2.3%) 1 (1.1%)
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Table 8. de Boeck 2017 - participants with adverse events and serious adverse events (Continued)
Treatment-related AEs leading to with-
drawal from the study
2 (2.3%) 0 (0%)
AE: adverse event; SAE :serious adverse event
Table 9. de Boeck 2017 - treatment-emergent and treatment-related adverse events
Event 400 mg mannitol (n = 87) Control (n = 87)
Treatment-emergent adverse events defined by MeDRa preferred term
Cough 14 (16.1%) 14 (16.1%)
Infective pulmonary exacerbation of cystic
fibrosis
10 (11.5%) 14 (16.1%)
Headache 6 (6.9%) 7 (8.0%)
Nasopharyngitis 6 (6.9%) 6 (6.9%)
Lung infection 2 (2.3%) 5 (5.7%)
Treatment related AEs leading to withdrawal from the study
Dizziness 1 (1.1%) 0 (0%)
Cough 2 (2.3%) 0 (0%)
Oropharnygeal pain 1 (1.1%) 0 (0%)
Total number of AEs 114 117
Treatment emergent adverse events reported in de Boeck 2017 occurring in at least 5% of participants on either treatment
Table 10. Minasian 2010 - quality of life questionnaire (respiratory domain): change from start of treatment at 2 weeks
(additional data from Pharmaxis)
Treatment arm Adolescent and
adult
Children 12 - 13
years
Children 6 - 11
years
Parents and care-
givers
Overall
Mannitol n = 7 n = 6 n = 4 n = 10 n = 27
Mean change 0.0 -5.6 0.0 -3.3 -2.5
Dornase alfa n = 4 n = 9 n = 3 n = 13 n = 29
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Table 10. Minasian 2010 - quality of life questionnaire (respiratory domain): change from start of treatment at 2 weeks
(additional data from Pharmaxis) (Continued)
Mean change 8.3 -3.7 13.9 0.4 1.6
Dornase alfa &
mannitol
n = 6 n = 5 n = 4 n = 9 n = 24
Mean change 1.9 -15.0 -10.4 -12.2 -9.0
Table 11. Minasian 2010 - lung function data: change from baseline at 12 weeks (additional data from Pharmaxis)
Measure Mannitol
(n = 23)
Dornase alfa
(n = 21)
Mannitol + dornase alfa
(n = 23)
Mean SD Mean SD Mean SD
FEV1 (mL) -1 279.2 84 237.3 -31 305.7
FVC (mL) -58 360.7 7 414.7 -103 393.8
FEF25−75 (mL/
s)
55 282.1 173 309.6 68 488.8
FEF25−75: mid-expiratory flow; FEV1: forced expiratory volume at one second; FVC: forced vital capacity; mL: millilitres; mL/s:
millilitres per second; SD: standard deviation.
Table 12. Minasian 2010 - treatment-emergent adverse events at 12 weeks
Adverse
event
Mannitol
(n = 23) n (%)
Dornase alfa
(n = 21) n (%)
Mannitol + dornase alfa
(n = 23) n (%)
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe
Number
of partici-
pants with
any
adverse
event
(some may
have more
than one
adverse
event)
4 (17.4) 6 (26.1) 2 (8.7) 0 0 1 (4.8) 5 (21.7) 5 (21.7) 4 (17.4)
CF exacer-
bation (CF
lung)
1 (4.3) 2 (8.7) 1 (4.3) 0 0 1 (4.8) 0 3 (13.0) 4 (17.4)
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Table 12. Minasian 2010 - treatment-emergent adverse events at 12 weeks (Continued)
Nausea 0 0 0 0 0 0 0 1 (4.3) 0
Ear infec-
tion
0 1 (4.3) 0 0 0 0 0 0 0
Pharyngi-
tis
0 1 (4.3) 0 0 0 0 0 0
Viral infec-
tion
1 (4.3) 0 0 0 0 0 0 0 0
Viral up-
per respi-
ratory tract
infection
0 0 0 0 0 0 1 (4.3) 0 0
Muscu-
loskeletal
pain
0 0 1 (4.3) 0 0 0 0 0 0
Headache 0 0 0 0 0 0 1 (4.3) 0 0
Cough 3 (13.0) 2 (8.7) 0 0 0 0 2 (8.7) 0 0
Productive
cough
0 1 (4.3) 0 0 0 0 0 0 0
Rash 0 0 0 0 0 0 1 (4.3) 0 0
CF: cystic fibrosis
Table 13. Minasian 2010 - all adverse events at 12 weeks
Adverse
event
Mannitol
(n = 23) n (%)
Dornase alfa
(n = 21) n (%)
Mannitol + dornase alfa
(n = 23) n (%)
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe
Number
of partici-
pants with
any
adverse
event
(some may
have more
than one
adverse
8 (34.9) 8 (34.9) 4 (17.4) 10 (47.6) 9 (42.9) 7 (33.3) 10 (43.4) 11 (47.8) 6 (26.1)
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Table 13. Minasian 2010 - all adverse events at 12 weeks (Continued)
event)
CF exacer-
bation (CF
lung)
1 (4.3) 4 (17.4) 3 (13.0) 1 (4.8) 2 (9.5) 5 (23.8) 0 7 (30.4) 5 (21.7)
Gastroin-
testinal
events
(nausea,
diarrhoea,
abdominal
pain, gas-
tritis)
0 0 0 0 3 (14.3) 0 1 (4.3) 2 (8.7) 0
Ear infec-
tion
0 1 (4.3) 0 0 0 0 0 0 0
Pharyngi-
tis
0 1 (4.3) 0 0 0 0 0 0 0
Infections
and infes-
tations
(ABPA, S
aureus, vi-
ral)
4 (17.4) 0 (4.3) 0 7 (33.3) 3 (14.3) 0 3 (13.0) 0 0
Injury,
poisoning,
procedure
(contu-
sion, wrist
fracture,
implant
site infec-
tion)
0 0 0 1 (4.8) 0 0 1 (4.3) 1 (4.3) 0
Muscu-
loskeletal
pain
0 0 1 (4.3) 0 1 (4.8) 0 0 0 0
Headache 0 0 0 2 (9.5) 0 0 2 (8.7) 0 0
Cough 3 (13.0) 2 (8.7) 0 4 (19.0) 0 0 2 (8.7) 1 (4.3) 0
Productive
cough
0 1 (4.3) 0 1 (4.8) 0 0 0 0 0
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Table 13. Minasian 2010 - all adverse events at 12 weeks (Continued)
Pharyngo-
laryngeal
pain
0 0 0 1 (4.8) 0 0 0 0 0
Rash 1 (4.3) 0 0 0 0 0 1 (4.3) 0 0
Immune
(anaphy-
lactic reac-
tion or hy-
persensi-
tivity)
0 0 0 0 1 (4.8) 2 (9.5) 0 0 0
CFRD 0 0 0 0 0 0 0 0 1 (4.3)
Surgical
and medi-
cal proce-
dures
(cen-
tral venous
catheteri-
zation)
0 0 0 0 0 0 0 0 1 (4.3)
ABPA: Allergic bronchopulmonary aspergillosis; CF: cystic fibrosis; CFRD: cystic fibrosis-related diabetes; S aureus: Staphylococcus
aureus.
Table 14. Minasian 2010 - sputum microbiology at 12 weeks (additional data from Pharmaxis)
Pathogen Mannitol
n (%)
Dornase alfa
n (%)
Mannitol + dornase alfa
n (%)
P aeruginosa non-mucoid 5 (33.3) 2 (16.7) 3 (25.0)
P aeruginosamucoid 1 (6.7) 5 (41.7) 6 (50.0)
Stenotrophomonas maltophilia 1 (6.7) 5 (41.7) 1 (8.3)
Aspergillus spp 4 (26.7) 5 (41.7) 6 (50.0)
Candida spp 3 (20.0) 5 (41.7) 4 (33.3)
Total number in each treatment group was not reported
P aeruginosa: Pseudomonas aeruginosa
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A P P E N D I C E S
Appendix 1. Glossary
Term Explanation
bronchiectasis a congenital or acquired disorder of the large bronchi of the lungs, characterized by permanent, abnormal
dilation and destruction of bronchial walls. In this condition some of the bronchi and bronchioles have
lost their elasticity and have expanded and filled with fluid. It may be caused by recurrent inflammation or
infection of the airways
ciliary beat frequency the rate at which the cilia beat (cilia are fine hair-like projections from certain kinds of cells; they line the
respiratory tract and move in rhythmic unison to ”sweep“ away fluids and particles within the lungs)
epithelial to do with the outside layer of cells that covers all the free, open surfaces of the body including the skin and
mucous membranes
hyperosmolar agents agents causing the abnormal increase in the concentration of a solution, especially a body fluid, as occurs in
dehydration
mucociliary clearance the movement of the mucous covering of the surface of the respiratory tract by the beating of cilia: rapid,
forward (effective) stroke and slow, return (recovery) stroke
mucolytic capable of dissolving, digesting, or liquefying mucus
WH A T ’ S N E W
Last assessed as up-to-date: 4 January 2018.
Date Event Description
4 January 2018 New citation required but conclusions have not changed Despite the inclusion of results from two studies (one
previously listed as ongoing and one as awaiting classifi-
cation), our conclusions remain the same
4 January 2018 New search has been performed A search of the Cystic Fibrosis and Genetic Disorders
Group’s Cystic Fibrosis Trials Register identified five new
references which were potentially eligible for inclusion in
this review. One reference was an additional reference to
an already excluded study (Teper 2011) and one was an
additional reference to an already included study (Aitken
2012). Three references were to a previously identified
ongoing study (de Boeck 2017) now included.
A study previously classified as awaiting classification is
now also included (Middleton 2015).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The initial inclusion criteria were for mannitol used as a single agent. We later changed the inclusion criteria for studies to include
mannitol used in conjunction with another agent (i.e. mannitol plus dornase alfa compared with dornase alfa alone) in the review as
this is most likely how it will be used in clinical practice.
We originally planned to report data at one month, three months and one year; however, in a post hoc change which grouped data into
more clinically appropriate time points, we reported data at time points of up to one month, up to two months, up to three months,
up to six months and up to one year. If any studies followed participants beyond this time, we also planned to report these data.
A post hoc change was made to ’Measures of Treatment effect’ to account for type I statistical errors when analysing number of
participants with any adverse events of interest, risk ratios and 99% confidence intervals were used.
The authors have moved the outcome ’Adverse events’ from the first secondary outcome to the third primary outcome and moved
’Pulmonary exacerbations’ from the third primary outcome to the first secondary outcome, in line with Cochrane guidance that adverse
events should be listed as one of the primary outcomes (maximum of three primary outcomes) in any review. This has also led to the
’Objectives’ being revised. The authors note that pulmonary exacerbations are still considered an important and relevant outcome to
individuals with CF and therefore have placed more emphasis on this secondary outcome than other secondary outcomes in the results,
discussion and conclusion.
In a post hoc change, in line with Cochrane guidance, the authors have presented five summary of findings tables; one for each
comparison including the primary outcomes of the review at the latest reported time point.
N O T E S
Sarah J Nolan (lead author of the 2015 version of the review) is now Sarah J Nevitt
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Cystic Fibrosis [∗drug therapy];Deoxyribonuclease I [administration&dosage];Mannitol [∗ administration
& dosage]; Mucociliary Clearance; Powders; Randomized Controlled Trials as Topic; Recombinant Proteins [administration & dosage]
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MeSH check words
Adult; Humans
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